Trinity Biotech (TRIB) 20-F 30 Apr 21 2020 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document And Entity Information
Entity Registrant Name	TRINITY BIOTECH PLC
Entity Central Index Key	0000888721
Document Type	20-F
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	83,606,810
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Entity Incorporation State Country Code	L2
Entity File Number	0-22320
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Revenues	$ 101,980	$ 90,435	$ 97,035
Cost of sales	(53,400)	(52,315)	(55,586)
Gross profit	48,580	38,120	41,449
Other operating income	1,860	91	102
Research and development expenses	(5,080)	(5,325)	(5,369)
Selling, general and administrative expenses	(26,390)	(27,661)	(29,477)
Selling, general and administrative expenses - recognition of contingent asset	1,316
Selling, general and administrative expenses - closure costs	(2,425)
Selling, general and administrative expenses - tax audit settlement		(5,042)
Impairment charges	(17,779)	(24,295)	(26,932)
Operating profit/(loss)	82	(24,112)	(20,227)
Financial income	36	697	2,124
Financial expenses	(6,751)	(6,582)	(5,080)
Net financing expense	(6,715)	(5,885)	(2,956)
Loss before tax	(6,633)	(29,997)	(23,183)
Total income tax credit	620	1,006	525
Loss for the year on continuing operations	(6,013)	(28,991)	(22,658)
(Loss)/Profit for the year on discontinued operations	(375)	77	568
Loss for the year (all attributable to owners of the parent)	$ (6,388)	$ (28,914)	$ (22,090)
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic loss per ADS (US Dollars) - continuing operations	$ (0.29)	$ (1.39)	$ (1.08)
Diluted loss per ADS (US Dollars) - continuing operations	(0.29)	(1.39)	(1.08)
Basic loss per ADS (US Dollars) - group	(0.31)	(1.38)	(1.06)
Diluted loss per ADS (US Dollars) - group	$ (0.31)	$ (1.38)	$ (1.06)
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
(Loss)/Profit for the year on discontinued operations	$ 375	$ 77	$ 568
Basic loss per ADS (US Dollars) - continuing operations	$ (0.07)	$ (0.35)	$ (0.27)
Diluted loss per ADS (US Dollars) - continuing operations	(0.07)	(0.35)	(0.27)
Basic loss per ADS (US Dollars) - group	(0.08)	(0.35)	(0.26)
Diluted loss per ADS (US Dollars) - group	$ (0.08)	$ (0.35)	$ (0.26)

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Consolidated Statement Of Comprehensive Income
Loss for the year	$ (6,388)	$ (28,914)	$ (22,090)
Other comprehensive loss
Foreign exchange translation differences	(1,360)	(167)	(520)
Other comprehensive loss	(1,360)	(167)	(520)
Total Comprehensive Loss (all attributable to owners of the parent)	$ (7,748)	$ (29,081)	$ (22,610)

CONSOLIDATED STATEMENT OF FINAN

CONSOLIDATED STATEMENT OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Non-current assets
Property, plant and equipment	$ 8,547	$ 9,290
Goodwill and intangible assets	33,860	43,654
Deferred tax assets	4,185	6,252
Derivative financial instruments	150
Other assets	355	485
Total non-current assets	47,097	59,681
Current assets
Inventories	30,219	32,021
Trade and other receivables	22,668	20,987
Income tax receivable	3,086	1,982
Cash and cash equivalents	27,327	15,231
Short term investments		1,169
Total current assets	83,300	71,390
TOTAL ASSETS	130,397	131,071
Equity attributable to the equity holders of the parent
Share capital	1,213	1,213
Share premium	16,187	16,187
Treasury shares	(24,922)	(24,922)
Accumulated surplus	10,573	16,145
Translation reserve	(5,293)	(3,933)
Other reserves	23	23
Total (deficit)/equity	(2,219)	4,713
Current liabilities
Income tax payable	154	48
Trade and other payables	24,335	16,947
Provisions	416	50
Lease liabilities	2,153	2,404
Total current liabilities	27,058	19,449
Non-current liabilities
Exchangeable notes and other borrowings	82,695	82,021
Derivative financial instruments	1,370	4
Lease liabilities	16,588	17,745
Deferred tax liabilities	4,905	7,139
Total non-current liabilities	105,558	106,909
TOTAL LIABILITIES	132,616	126,358
TOTAL EQUITY AND LIABILITIES	$ 130,397	$ 131,071

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY - USD ($) $ in Thousands	Share Capital 'A' Ordinary shares [Member]	Share premium [Member]	Treasury Shares [Member]	Translation reserve [Member]	Hedging reserves [Member]	Accumulated surplus [Member]	Total
Balance at Dec. 31, 2017	$ 1,213	$ 16,187	$ (24,783)	$ (3,246)	$ 23	$ 75,802	$ 65,196
Loss for the period						(22,090)	(22,090)
Other comprehensive income				(520)			(520)
Total comprehensive loss				(520)		(22,090)	(22,610)
Share-based payments (Note 22)						1,607	1,607
Shares purchased (Note 21)			(139)				(139)
Balance at Dec. 31, 2018	1,213	16,187	(24,922)	(3,766)	23	55,319	44,054
Loss for the period						(28,914)	(28,914)
Other comprehensive income				(167)			(167)
Total comprehensive loss				(167)		(28,914)	(29,081)
Share-based payments (Note 22)						839	839
Adjustment on transition to IFRS 16 (Note 13)						(11,099)	(11,099)
Balance at Dec. 31, 2019	1,213	16,187	(24,922)	(3,933)	23	16,145	4,713
Loss for the period						(6,388)	(6,388)
Other comprehensive income				(1,360)			(1,360)
Total comprehensive loss				(1,360)		(6,388)	(7,748)
Share-based payments (Note 22)						816	816
Balance at Dec. 31, 2020	$ 1,213	$ 16,187	$ (24,922)	$ (5,293)	$ 23	$ 10,573	$ (2,219)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Loss for the year	$ (6,388)	$ (28,914)	$ (22,090)
Adjustments to reconcile net loss to cash provided by operating activities:
Depreciation	1,674	2,526	1,296
Amortisation	1,403	2,368	2,825
Income tax credit	(182)	(1,006)	(1,115)
Financial income	(36)	(697)	(2,124)
Financial expense	6,751	6,582	5,080
Share-based payments (net of capitalized amounts)	792	758	1,369
Foreign exchange (gains)/losses on operating cash flows	(663)	(93)	311
Loss on disposal or retirement of property, plant and equipment	30	17	15
Movement in inventory provision	5,059	1,567	300
Impairment of prepayments	562	1,376	1,608
Impairment of property, plant and equipment	1,795	6,349	6,112
Impairment of intangible assets	15,422	16,570	19,212
Other non-cash items	(634)	835	570
Operating cash flows before changes in working capital	25,585	8,238	13,369
(Increase) / decrease in trade and other receivables	(2,489)	445	(5,960)
Increase) / decrease in inventories	(3,419)	(2,959)	1,988
Increase / (decrease) in trade and other payables	4,994	151	(3,419)
Cash generated from operations	24,671	5,875	5,978
Interest paid	(48)	(1,000)	(39)
Interest received	104	560	874
Income taxes (paid) / received	(972)	(18)	416
Net cash generated by operating activities	23,755	5,417	7,229
Cash flows from investing activities
Payments to acquire intangible assets	(6,990)	(9,718)	(9,863)
Acquisition of property, plant and equipment	(3,178)	(2,118)	(7,528)
Disposal of property, plant and equipment	(30)	(17)
Net cash used in investing activities	(10,198)	(11,853)	(17,391)
Cash flows from financing activities
Share buyback			(434)
Proceeds from Paycheck Protection loans	4,520
Interest payment on exchangeable notes	(3,996)	(3,996)	(4,503)
Purchase of exchangeable notes			(12,042)
Proceeds from sale & leaseback transactions			481
Payment of lease liabilities	(3,240)	(3,533)	(374)
Net cash used in financing activities	(2,716)	(7,529)	(16,872)
Increase/(Decrease) in cash and cash equivalents and short term investments	10,841	(13,965)	(27,034)
Effects of exchange rate movements on cash held	86	88	(296)
Cash and cash equivalents and short-term investments at beginning of year	16,400	30,277	57,607
Cash and cash equivalents and short term investments at end of year	$ 27,327	$ 16,400	$ 30,277

BASIS OF PREPARATION AND SIGNIF

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
Disclosure of basis of preparation and significant accounting policies [Abstract]
BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES	1. BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES The principal accounting policies adopted by Trinity Biotech plc (“the Company”) and its subsidiaries (together the (“the Group”) are set out below. i) General information Trinity Biotech develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech is a significant provider of raw materials to the life sciences and research industries globally. Trinity Biotech also operates a licenced reference laboratory that specializes in diagnostics for autoimmune diseases. ii) Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) both as issued by the International Accounting Standards Board (“IASB”) and as subsequently adopted by the European Union (“EU”) (together “IFRS”). The IFRS applied are those effective for accounting periods beginning January 1, 2020. Consolidated financial statements are required by Irish law to comply with IFRS as adopted by the EU which differ in certain respects from IFRS as issued by the IASB. These differences predominantly relate to the timing of adoption of new standards by the EU. However, in relation to the 2020 consolidated financial statements there are no differences regarding the effective date of new IFRS relevant to Trinity Biotech as issued by the IASB and as adopted by the EU. In relation to prior periods presented, none of the differences are relevant in the context of Trinity Biotech and the consolidated financial statements comply with IFRS both as issued by the IASB and as adopted by the EU. iii) Basis of preparation The consolidated financial statements have been prepared in United States Dollars (US$), rounded to the nearest thousand, under the historical cost basis of accounting, except for derivative financial instruments, certain balances arising on acquisition of subsidiary entities and share-based payments which are initially recorded at fair value. Derivative financial instruments are also subsequently revalued and carried at fair value. The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Judgements made by management that have a significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in Note 32. The directors have considered the Group’s current financial position and cash flow projections, taking into account all known events and developments including the Covid-19 pandemic. The directors believe that the Group will be able to continue its operations for at least the next 12 months from the date of this report and that it is appropriate to continue to prepare the consolidated financial statements on a going concern basis. In making this assessment, the directors have considered the potential repayment in April 2022 of part or all of the US$99.9m exchangeable notes under the terms of the indenture for such exchangeable notes. The directors have considered the various financing options expected to be available to the Group to assist it in meeting any repayment obligations under the exchangeable notes over the next 12 months, to the extent such obligations cannot be met from cash on hand, including refinancing the debt, repaying the debt with the proceeds from equity or debt offerings and the sale of assets. As with all such potential transactions, there are risks to successfully implement such transactions and the directors have considered these risks when considering the financing options and the appropriateness of adopting a going concern basis of accounting. The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. The accounting policies have been applied consistently by all Group entities. iv) Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and reporting policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Transactions eliminated on consolidation Intra-group balances and any unrealised gains or losses or income and expenses arising from intra-group transactions are eliminated in preparing the consolidated financial statements. v) Property, plant and equipment Owned assets Items of property, plant and equipment are stated at cost less any accumulated depreciation and any impairment losses (see Note 1(viii)). The cost of self-constructed assets includes the cost of materials, direct labour and attributable overheads. It is not Group policy to revalue any items of property, plant and equipment. Depreciation is charged to the statement of operations on a straight-line basis to write-off the cost of the assets over their expected useful lives as follows: • Leasehold improvements 5-15 years • Buildings 50 years • Office equipment and fittings 10 years • Computer equipment 3-5 years • Plant and equipment 2-15 years Land is not depreciated. The residual values, if not insignificant, useful lives and depreciation methods of property, plant and equipment are reviewed and adjusted if appropriate on a prospective basis, at each balance sheet date. There were no changes to useful lives in the year. Leased assets - as lessee The Group has applied IFRS 16, Leases, using the modified retrospective approach and therefore comparative information has not been restated. Accounting policy applicable from 1 January 2019 For any new contracts entered into on or after 1 January 2019, the Group considers whether a contract is, or contains a lease. A lease is defined as ‘a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration’. To apply this definition the Group assesses whether the contract meets three key evaluations which are whether: • the contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group • the Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract • the Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct ‘how and for what purpose’ the asset is used throughout the period of use. At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group’s incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero. The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included in property, plant and equipment and lease liabilities have been included in separate lines within the current liabilities and non-current liabilities sections. Leased assets - as lessor The Group’s accounting policy under IFRS 16 has not changed from the comparative period. As a lessor, the Group classifies its leases as either operating or finance leases. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of the underlying asset, and classified as an operating lease if it does not. Accounting policy applicable before 1 January 2019 Leased assets – as lessee Leases under terms of which the Group assumes substantially all the risks and rewards of ownership are classified as finance leases. Property, plant and equipment acquired by way of finance lease is stated at an amount equal to the lower of its fair value and present value of the minimum lease payments at inception of the lease, less accumulated depreciation and any impairment losses. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in financial expenses in the statement of operations. Depreciation is calculated in order to write-off the amounts capitalised over the estimated useful lives of the assets, or the lease term if shorter, by equal annual instalments. The excess of the total rentals under a lease over the amount capitalised is treated as interest, which is charged to the statement of operations in proportion to the amount outstanding under the lease. Leased assets are reviewed for impairment (see Note 1(viii)). Leases other than finance leases are classified as “operating leases”, and the rentals thereunder are charged to the statement of operations on a straight-line basis over the period of the leases. Lease incentives are recognised in the statement of operations on a straight-line basis over the lease term . Leased assets – as lessor Leases where the Group substantially transfers the risks and benefits of ownership of the asset to the customer are classified as finance leases within finance lease receivables. The Group recognises the amount receivable from assets leased under finance leases at an amount equal to the net investment in the lease. Finance lease income is recognised as revenue in the statement of operations reflecting a constant periodic rate of return on the Group’s net investment in the lease. Assets provided to customers under leases other than finance leases are classified as operating leases and carried in property, plant and equipment at cost and are depreciated on a straight-line basis over the useful life of the asset or the lease term, if shorter. Subsequent costs The Group recognises in the carrying amount of an item of property, plant and equipment the cost of replacing part of such an item when that cost is incurred if it is probable that the future economic benefits embodied within the item will flow to the Group and the cost of the replaced item can be measured reliably. All other costs are recognised in the statement of operations as an expense as incurred. vi) Goodwill In respect of business combinations that have occurred since January 1, 2004 (being the transition date to IFRS), goodwill represents the difference between the cost of the acquisition and the fair value of the net identifiable assets acquired. In respect of acquisitions prior to this date, goodwill is included on the basis of its deemed cost, which represents the amount recorded under the old basis of accounting, Irish GAAP, (“Previous GAAP”). Save for retrospective restatement of deferred tax as an adjustment to retained earnings in accordance with IAS 12, Income Taxes, To the extent that the Group’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities acquired exceeds the cost of a business combination, the identification and measurement of the related assets, liabilities and contingent liabilities are revisited accompanied by a reassessment of the cost of the transaction, and any remaining balance is immediately recognised in the statement of operations. At the acquisition date, any goodwill is allocated to each of the cash generating units expected to benefit from the combination’s synergies. Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 1(viii)). vii) Intangibles, including research and development (other than goodwill) An intangible asset, which is an identifiable non-monetary asset without physical substance, is recognised to the extent that it is probable that the expected future economic benefits attributable to the asset will flow to the Group and that its cost can be measured reliably. The asset is deemed to be identifiable when it is separable (that is, capable of being divided from the entity and sold, transferred, licenced, rented or exchanged, either individually or together with a related contract, asset or liability) or when it arises from contractual or other legal rights, regardless of whether those rights are transferable or separable from the Group or from other rights and obligations. Intangible assets acquired as part of a business combination are capitalised separately from goodwill if the intangible asset meets the definition of an asset and the fair value can be reliably measured on initial recognition. Subsequent to initial recognition, these intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Intangible assets with definite useful lives are reviewed for indicators of impairment annually while intangible assets with indefinite useful lives and those not yet brought into use are tested for impairment annually, either individually or at the cash generating unit level. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalised if the product or process is technically and commercially feasible and the Group has sufficient resources to complete the development. The expenditure capitalised includes the cost of materials, direct labour and attributable overheads and third party costs. Subsequent expenditure on capitalised intangible assets is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. The technical feasibility of a new product is determined by a specific feasibility study undertaken at the first stage of any development project. The majority of our new product developments involve the transfer of existing product know-how to a new application. Since the technology is already proven in an existing product which is being used by customers, this facilitates the proving of the technical feasibility of that same technology in a new product. The results of the feasibility study are reviewed by a design review committee comprising senior managers. The feasibility study occurs in the initial research phase of a project and costs in this phase are not capitalised. The commercial feasibility of a new product is determined by preparing a discounted cash flow projection. This projection compares the discounted sales revenues for future periods with the relevant costs. As part of preparing the cash flow projection, the size of the relevant market is determined, feedback is sought from customers and the strength of the proposed new product is assessed against competitors’ offerings. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. All other development expenditure is expensed as incurred. Subsequent to initial recognition, the capitalised development expenditure is carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the statement of operations as an expense as incurred. Expenditure on internally generated goodwill and brands is recognised in the statement of operations as an expense as incurred. Amortisation Amortisation is charged to the statement of operations on a straight-line basis over the estimated useful lives of intangible assets, unless such lives are indefinite. Intangible assets are amortised from the date they are available for use in its intended market. The estimated useful lives are as follows: • Capitalised development costs 15 years • Patents and licences 6-15 years • Other (including acquired customer and supplier lists) 6-15 years The Group uses a useful economic life of 15 years for capitalised development costs. This is a conservative estimate of the likely life of the products. The Group is confident that products have a minimum of 15 years life given the inertia that characterizes the medical diagnostics industry and the barriers to enter into the industry. The following factors have been considered in estimating the useful life of developed products: (a) once a diagnostic test becomes established, customers are reluctant to change to new technology until it is fully proven, thus resulting in relatively long product life cycles. There is also reluctance in customers to change to a new product as it can be costly both in terms of the initial changeover cost and as new technology is typically more expensive. (b) demand for the diagnostic tests is enduring and robust within a wide geographic base. The diseases that the products diagnose are widely prevalent (HIV, Diabetes and Chlamydia being just three examples) in many countries. There is a general consensus that these diseases will continue to be widely prevalent in the future. (c) there are significant barriers to new entrants in this industry. Patents and/or licences are in place for many of our products, though this is not the only barrier to entry. There is a significant cost and time to develop new products, it is necessary to obtain regulatory approval and tests are protected by proprietary know-how, manufacturing techniques and trade secrets. Certain trade names acquired are deemed to have an indefinite useful life as there is no foreseeable limit to the period over which these assets are expected to generate cash inflows for the Group. Where amortisation is charged on assets with finite lives, this expense is taken to the statement of operations through the ‘selling, general and administrative expenses’ line. Useful lives are examined on an annual basis and adjustments, where applicable, are made on a prospective basis. viii) Impairment The carrying amount of the Group’s assets, other than inventories, accounts receivable, cash and cash equivalents, short-term investments and deferred tax assets, are reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the asset’s recoverable amount (being the greater of fair value less costs to sell and value in use) is assessed at each balance sheet date. Fair value less costs to sell is defined as the amount obtainable from the sale of an asset or cash-generating unit in an arm’s length transaction between knowledgeable and willing parties, less the costs that would be incurred on disposal. Value in use is defined as the present value of the future cash flows expected to be derived through the continued use of an asset or cash-generating unit. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the future cash flow estimates have not yet been adjusted. The estimates of future cash flows exclude cash inflows or outflows attributable to financing activities. For an asset that does not generate largely independent cash flows, the recoverable amount is determined by reference to the cash generating unit to which the asset belongs. For goodwill, assets that have an indefinite useful life and intangible assets that are not yet available for use, the recoverable amount is estimated at each balance sheet date at the cash generating unit level. The goodwill and indefinite-lived assets were reviewed for impairment at December 31, 2019 and December 31, 2020. See Note 14. In-process research and development (IPR&D) is tested for impairment on an annual basis, in the fourth quarter, or more frequently if impairment indicators are present, using projected discounted cash flow models. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to its revised fair value with the related impairment charge recognised in the period in which the impairment occurs. If the fair value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs. The valuation techniques utilized in performing impairment tests incorporate significant assumptions and judgments to estimate the fair value, as described above. The use of different valuation techniques or different assumptions could result in materially different fair value estimates. An impairment loss is recognised whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in the statement of operations. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to cash-generating units and then to reduce the carrying amount of other assets in the cash-generating units on a pro-rata basis. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. An impairment loss in respect of goodwill is not reversed. Following recognition of any impairment loss (and on recognition of an impairment loss reversal), the depreciation or amortisation charge applicable to the asset or cash generating unit is adjusted prospectively with the objective of systematically allocating the revised carrying amount, net of any residual value, over the remaining useful life. ix) Inventories Inventories are stated at the lower of cost and net realisable value. Cost is based on the first-in, first-out principle and includes all expenditure which has been incurred in bringing the products to their present location and condition, and includes an appropriate allocation of manufacturing overhead based on the normal level of operating capacity. Net realisable value is the estimated selling price of inventory on hand in the ordinary course of business less all further costs to completion and costs expected to be incurred in selling these products. The Group provides for inventory, based on estimates of the expected realisability. The estimated realisability is evaluated on a case-by-case basis and any inventory that is approaching its “use-by” date and for which no further re-processing can be performed is written off. Any reversal of an inventory provision is recognised in the statement of operations in the year in which the reversal occurs. x) Trade and other receivables Trade receivables are amounts due from customers for products sold or services provided in the ordinary course of business. Trade and other receivables are stated at their amortised cost less impairment losses incurred. Cost approximates fair value given the short term nature of these assets. The Group records the loss allowance as lifetime expected credit losses. These are the expected shortfalls in contractual cash flows, considering the potential for default at any point during the life of the financial instrument. Expected credit losses are recorded on all of trade receivables based on an assessment of each individual debtor taking into account the probability of default or delinquency in payments and the probability that debtor will enter into financial difficulties or bankruptcy. xi) Trade and other payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business. Trade and other payables are stated at cost. Cost approximates fair value given the short term nature of these liabilities. xii) Cash and cash equivalents Cash and cash equivalents comprise cash balances and short-term deposits which are readily available at year-end. Deposits with maturities less than six months as at the year-end date are recognised as cash and cash equivalents and are carried at fair value when there is no expected loss in value on early termination. The Group has no short-term bank overdraft facilities. Where restrictions are imposed by third parties, such as lending institutions, on cash balances held by the Group these are treated as financial assets in the financial statements. xiii) Short-term investments Short-term investments comprise short-term bank deposits which have maturities greater than six months as at the year-end date. Short-term deposits made for varying periods depending on the immediate cash requirements of the Group and earn interest at the respective deposit rates in place. Where restrictions are imposed by third parties, such as lending institutions, on short-term deposits held by the Group these are treated as financial assets in the financial statements. xiv) Share-based payments For equity-settled share-based payments (share options), the Group measures the services received and the corresponding increase in equity at fair value at the measurement date (which is the grant date) using a trinomial model. Given that the share options granted do not vest until the completion of a specified period of service, the fair value, which is assessed at the grant date, is recognised on the basis that the services to be rendered by employees as consideration for the granting of share options will be received over the vesting period. The share options issued by the Group are not subject to market-based vesting conditions as defined in IFRS 2, Share-based Payment The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. The Group does not operate any cash-settled share-based payment schemes or share-based payment transactions with cash alternatives as defined in IFRS 2. xv) Government grants and financial support The Group has received government-backed Covid-19 financial supports in the form of forgivable loans. Under IAS 20, Accounting for Government Grants Grants that compensate the Group for expenses incurred such as research and development, employment and training are recognised as income in the statement of operations on a systematic basis in the same periods in which the expenses are incurred. Grants that compensate the Group for the cost of an asset are recognised in the statement of operations as other operating income on a systematic basis over the useful life of the asset. xvi) Revenue recognition Goods sold and services rendered The Group recognises revenue when it transfers control over a good or service to a customer. Revenue is recognised to the extent that it is probable that economic benefit will flow to the Group and the revenue can be measured. No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction. Revenue, including any amounts invoiced for shipping and handling costs, represents the value of goods and services supplied to external customers, net of discounts and rebates and excluding sales taxes. Revenue from products is generally recorded as of the date of shipment, consistent with typical ex-works shipment terms. Where the shipment terms do not permit revenue to be recognised as of the date of shipment, revenue is recognised when the Group has satisfied all of its performance obligations to the customer in accordance with the shipping terms. Some contracts oblige the Group to ship product to the customer ahead of the agreed payment schedule. For these shipments, a contract asset is recognised when control over the goods has transferred to the customer. The financing component is insignificant as invoicing for these shipments occurs within a short period of time after shipment has occurred and standard 30 day credit terms apply. The Group operates a licenced referenced laboratory in the US, which provides testing services to institutional customers and insurance companies. In the US, there are rules requiring all insurance companies to be billed the same amount per test. However, the amount that each insurance company pays for a particular test varies according to their own internal policies and this can typically be considerably less than the amount invoiced. We recognise lab services revenue for insurance companies by taking the invoiced amount and reducing it by an estimated percentage based on historical payment data. We review the percentage reduction annually based on the latest data. As a practical expedient, and in accordance with IFRS, we apply a portfolio approach to the insurance companies as they have similar characteristics. We judge that the effect on the financial statements of using a portfolio approach for the insurance companies will not differ materially from applying IFRS 15 to the individual contracts within that portfolio. Revenue from services rendered is recognised in the statement of operations in proportion to the stage of completion of the transaction at the balance sheet date. The Group leases instruments to customers typically as part of a bundled package. Where a contract has multiple performance obligations and its duration is greater than one year, the transaction price is allocated to the performance obligations in the contract by reference to their relative standalone selling prices. For contracts where control of the instrument is transferred to the customer, t

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2020
Disclosure of operating segments [abstract]
SEGMENT INFORMATION	2. SEGMENT INFORMATION Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing the performance of the operating segments, has been identified as the Board of Directors. Management has determined the operating segments based on the reports reviewed by the Board of Directors, which are used to make strategic decisions. The Board considers the business from a geographic perspective based on the Group’s management and internal reporting structure. Sales of product between companies in the Group are made on commercial terms which reflect the nature of the relationship between the relevant companies. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise interest-bearing loans, borrowings and expenses and corporate expenses. Segment capital expenditure is the total cost during the year to acquire segment plant, property and equipment and intangible assets that are expected to be used for more than one period, whether acquired on acquisition of a business combination or through acquisitions as part of the current operations. The Group comprises two main geographical segments (i) the Americas and (ii) Rest of World. The Group’s geographical segments are determined by the location of the Group’s assets and operations. The Group has also presented a geographical analysis of the segmental data for Ireland as is consistent with the information used by the Board of Directors. The reportable operating segments derive their revenue primarily from one source (i.e. the market for diagnostic tests for a range of diseases and other medical conditions). In determining the nature of its segmentation, the Group has considered the nature of the products, their risks and rewards, the nature of the production base, the customer base and the nature of the regulatory environment. The Group acquires, manufactures and markets a range of diagnostic products. The Group’s products are sold to a similar customer base and the main body whose regulation the Group’s products must comply with is the Food and Drug Administration (“FDA”) in the US. The following presents revenue and profit information and certain asset and liability information regarding the Group’s geographical segments. i) The distribution of revenue by geographical area based on location of assets was as follows: Rest of World Revenue Americas Ireland Other Eliminations Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 77,688 24,292 - - 101,980 Inter-segment revenue 59,304 1,095 - (60,399 ) - Total revenue 136,992 25,387 - (60,399 ) 101,980 Rest of World Revenue Americas Ireland Other Eliminations Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 64,045 26,390 - - 90,435 Inter-segment revenue 39,563 1,629 - (41,192 ) - Total revenue 103,608 28,019 - (41,192 ) 90,435 Rest of World Americas Ireland Other Eliminations Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 65,863 31,172 - - 97,035 Inter-segment revenue 38,665 2,899 - (41,564 ) - Total revenue 104,528 34,071 - (41,564 ) 97,035 ii) The distribution of revenue by customers’ geographical area was as follows: Revenue December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Americas 70,408 52,183 57,559 Asia / Africa 22,567 27,686 29,466 Europe (including Ireland) * 9,005 10,566 10,010 101,980 90,435 97,035 * Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues. iii) The distribution of revenue by major product group was as follows: Revenue December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Clinical laboratory goods 84,280 68,127 71,618 Clinical laboratory services 8,485 10,915 10,581 Point-of-Care 9,215 11,393 14,836 101,980 90,435 97,035 iv) The group has recognised the following amounts relating to revenue in the consolidated statement of operations: Revenue December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Revenue from contracts with customers (a) 101,980 90,435 97,035 Revenue from other sources - - - 101,980 90,435 97,035 (a) Disaggregation of revenue from contracts with customers: The Group derives revenue from the transfer of goods and services over time and at a point in time in the following geographical areas: Timing of revenue recognition Americas Ireland Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 77,060 24,292 — 101,352 Over time 628 — — 628 Total 77,688 24,292 — 101,980 Timing of revenue recognition Americas Ireland Other Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 63,300 26,390 — 89,690 Over time 745 — — 745 Total 64,045 26,390 — 90,435 Timing of revenue recognition Americas Ireland Other Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 64,941 31,172 — 96,113 Over time 922 — — 922 Total 65,863 31,172 — 97,035 (b) The Group derives revenue from the transfer of goods and services over time and at a point in time based on customers’ geographical area as follows: Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 69,780 22,567 9,005 101,352 Over time 628 — — 628 Total 70,408 22,567 9,005 101,980 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 51,438 27,686 10,566 89,690 Over time 745 — — 745 Total 52,183 27,686 10,566 90,435 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 56,637 29,466 10,010 96,113 Over time 922 — — 922 Total 57,559 29,466 10,010 97,035 v) The distribution of segment results by geographical area was as follows: Rest of World Americas Ireland Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 14,495 4,264 (71 ) 18,688 Impairment (17,779 ) - — (17,779 ) Result after impairment (3,284 ) 4,264 (71 ) 909 Unallocated expenses * (827 ) Operating profit 82 Net financing expense (Note 8) (6,715 ) Loss before tax (6,633 ) Income tax credit (Note 9) 620 Loss for the year on continuing operations (6,013 ) Loss for the year on discontinued operations (Note 10) (375 ) Loss for the year (6,388 ) Rest of World Americas Ireland Other Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 5,239 (4,334 ) (108 ) 797 Impairment (14,562 ) (9,733 ) — (24,295 ) Result after impairment (9,323 ) (14,067 ) (108 ) (23,498 ) Unallocated expenses * (614 ) Operating loss (24,112 ) Net financing expense (Note 8) (5,885 ) Loss before tax (29,997 ) Income tax credit (Note 9) 1,006 Loss for the year on continuing operations (28,991 ) Profit for the year on discontinued operations (Note 10) 77 Loss for the year (28,914 ) Rest of World Americas Ireland Other Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 5,514 1,900 (44 ) 7,370 Impairment (19,095 ) (7,837 ) — (26,932 ) Result after impairment (13,581 ) (5,937 ) (44 ) (19,562 ) Unallocated expenses * (665 ) Operating loss (20,227 ) Net financing expense (Note 8) (2,956 ) Loss before tax (23,183 ) Income tax credit (Note 9) 525 Loss for the year on continuing operations (22,658 ) Loss for the year on discontinued operations (Note 10) 568 Loss for the year (22,090 ) * Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area. vi) The distribution of segment assets and segment liabilities by geographical area was as follows: Rest of World Americas Ireland Other Total As at December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 58,164 37,632 3 95,799 Unallocated assets: Income tax assets (current and deferred) 7,271 Cash and cash equivalents and short-term investments 27,327 Total assets as reported in the Group balance sheet 130,397 Segment liabilities 20,431 107,080 46 127,557 Unallocated liabilities: Income tax liabilities (current and deferred) 5,059 Total liabilities as reported in the Group balance sheet 132,616 Rest of World Americas Ireland Other Total As at December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 69,224 37,212 1 106,437 Unallocated assets: Income tax assets (current and deferred) 8,234 Cash and cash equivalents and short-term investments 16,400 Total assets as reported in the Group balance sheet 131,071 Segment liabilities 14,575 104,396 200 119,171 Unallocated liabilities: Income tax liabilities (current and deferred) 7,187 Total liabilities as reported in the Group balance sheet 126,358 vii) The distribution of long-lived assets, which are property, plant and equipment, goodwill and intangible assets and other non-current assets (excluding deferred tax assets and derivative financial instruments), by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 Rest of World – Ireland 19,927 14,626 Americas 22,835 38,803 42,762 53,429 viii) The distribution of depreciation and amortisation by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Depreciation: Rest of World – Ireland 127 322 74 Americas 1,587 2,208 1,301 1,714 2,530 1,375 Rest of World – Ireland 32 642 655 Americas 1,371 1,726 2,170 1,403 2,368 2,825 ix) The distribution of share-based payment expense by geographical area was as follows: December 31, 2020 December 31, 2019 December 31, 2018 Rest of World – Ireland 722 659 1,265 Americas 70 99 104 792 758 1,369 See Note 22 for further information on share-based payments. x) The distribution of interest income and interest expense by geographical area was as follows: Interest Income Year ended December 31, 2020 Americas US$‘000 Ireland US$‘000 Rest of world Other US$‘000 Eliminations US$‘000 Total US$‘000 Interest income earned 9 27 — — 36 Inter-segment interest income — 3,656 4,853 (8,509 ) — Total 9 3,683 4,853 (8,509 ) 36 Interest Expense Year ended December 31, 2020 Americas US$‘000 Ireland US$‘000 Rest of World US$‘000 Eliminations US$‘000 Total US$’000 Interest on finance leases 290 606 — — 896 Cash interest on exchangeable notes — 3,996 — — 3,996 Non-cash interest on exchangeable notes ( Note 25) — 643 — — 643 Non-cash financial expense — 1,216 — — 1,216 Inter-segment interest expense 6,668 363 1,478 (8,509 ) — Total 6,958 6,824 1,478 (8,509 ) 6,751 Rest of world Interest Income Year ended December 31, 2019 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$‘000 Total US$‘000 Interest income earned 47 417 — — 464 Non-cash financial income — 233 — — 233 Inter-segment interest income — — 4,853 (4,853 ) — Total 47 650 4,853 (4,853 ) 697 Rest of World Interest Expense Year ended December 31, 2019 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$‘000 Total US$’000 Interest on finance leases 294 653 — — 947 Interest on tax audit settlement (Note 6) — 1,000 — — 1,000 Cash interest on exchangeable notes — 3,996 — — 3,996 Non-cash interest on exchangeable notes ( Note 25) — 639 — — 639 Inter-segment interest expense 4,853 — — (4,853 ) — Total 5,147 6,288 — (4,853 ) 6,582 Rest of world Interest Income Year ended December 31, 2018 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$’000 Total US$‘000 Interest income earned 32 704 — — 736 Non-cash financial income — 1,388 — — 1,388 Inter-segment interest income — — 4,853 (4,853 ) — Total 32 2,092 4,853 (4,853 ) 2,124 Rest of world Interest Income Year ended December 31, 2018 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$’000 Total US$‘000 Interest on finance leases 7 32 — — 39 Cash interest on exchangeable notes — 4,352 — — 4,352 Non-cash interest on exchangeable notes ( Note 25) — 689 — — 689 Inter-segment interest expense 4,853 — — (4,853 ) — Total 4,860 5,073 — (4,853 ) 5,080 xi) The distribution of taxation (expense)/credit by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Rest of World – Ireland 293 831 (59 ) Rest of World – Other (8 ) — (3 ) Americas 335 175 587 620 1,006 525 xii) During 2020, 2019 and 2018 there were no customers generating 10% or more of total revenues. xiii) The distribution of capital expenditure by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 Rest of World – Ireland 5,609 20,758 Rest of World – Other - - Americas 4,317 12,863 9,926 33,621

EMPLOYMENT

EMPLOYMENT	12 Months Ended
	Dec. 31, 2020
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
EMPLOYMENT	3. EMPLOYMENT The average number of persons employed by the Group is as follows: December 31, 2020 December 31, 2019 December 31, 2018 Research and development 52 57 59 Administration and sales 148 159 163 Manufacturing and quality 343 363 353 543 579 575 Employment costs charged in the Consolidated Income Statement for continuing operations are analysed as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Wages and salaries 26,187 25,885 26,475 Social welfare costs 2,195 2,538 2,585 Pension costs 447 503 490 Tax settlement (Note 6) — 5,094 — Share-based payments 792 758 1,369 Restructuring Cost 388 - - Recognition of contingent asset (Note 27) (1,316 ) 28,693 34,778 30,919 Employment costs are shown net of capitalisations and Irish government wage subsidies. Total employment costs, inclusive of amounts capitalised for wages and salaries, social welfare costs and pension costs, for the year ended December 31, 2020 amounted to US$33,347,000 (2019: US$36,288,000) (2018: US$38,002,000). Total share based payments, inclusive of amounts capitalised in the balance sheet, amounted to US$816,000 for the year ended December 31, 2020 (2019: US$838,000) (2018: US$1,607,000). See Note 22 for further details. Restructuring costs for the year ended December 31, 2020 were US$388,000 relating to termination payments associated with the closure of a manufacturing facility in California. Credit of US$1,316,000 relates to the recognition of a previously unrecognised contingent asset – refer to Note 27 for more information. The Group operates defined contribution pension schemes for certain of its full time employees. The benefits under these schemes are financed by both Group and employee contributions. Total contributions made by the Group in the financial year and charged against income amounted to US$447,000 (2019: US$503,000) (2018: US$490,000). The pension accrual for the Group at December 31, 2020 was US$47,000 (2019: US$43,000), (2018: US$45,000).

OTHER OPERATING INCOME

OTHER OPERATING INCOME	12 Months Ended
	Dec. 31, 2020
Disclosure of other operating income [Abstract]
OTHER OPERATING INCOME	4. OTHER OPERATING INCOME December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Government supports - COVID-19 1,840 - - Other income 17 88 99 Rental income from premises 3 3 3 1,860 91 102 Government supports - COVID-19 comprises funding received under the U.S. government’s Cares Act, specifically its Paycheck Protection Program and its Provider Relief Fund. Two out of six Paycheck Protection Program (“PPP”) loans received by the Company, amounting to US$1,615,000, were forgiven during the year. The four loans which remained unforgiven at year end, totaling US$2,905,000, are treated as short term liabilities at December 31, 2020. Three of these loans were 100% forgiven in early 2021 and we are in the process of seeking forgiveness for the final remaining PPP loan which amounts to US$244,000. These four remaining loans are treated as short term liabilities at December 31, 2020 (refer to Note 23). In addition, the company received US$225,000 under the Provider Relief Fund. Other income comprises US$17,000 (2019: US$88,000) for provision of canteen services to third parties in Ireland. Due to COVID-19 restrictions, these services were suspended in the second quarter of 2020.

SELLING, GENERAL AND ADMINISTRA

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES - CLOSURE COSTS	12 Months Ended
	Dec. 31, 2020
Analysis of income and expense [abstract]
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES - CLOSURE COSTS	5. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES – CLOSURE COSTS In early 2020, management decided to close a production facility in Carlsbad, California facility which specialised in Western Blot manufacturing. The last number of years had seen a steady migration of customers away from using the Western Blot testing format for diagnosing Lyme in favour of alternative testing platforms. Production volumes declined steadily at the plant to the extent that it no longer made economic sense to continue. The plant was closed on June 30, 2020. Production of remaining products was transferred to other locations in the Group. The charge for closing the facility was US$2.4 million which comprised redundancy costs, the write-off of inventory, the cost of exiting lease obligations and other costs associated with the closure of the facility.

SELLING, GENERAL AND ADMINIST_2

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES - TAX AUDIT SETTLEMENT	12 Months Ended
	Dec. 31, 2020
Selling General And Administrative Expenses - Tax Audit Settlement
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES - TAX AUDIT SETTLEMENT	6. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES – TAX AUDIT SETTLEMENT In the year ended December 31, 2019, the Company reached a tax settlement of US$6,442,000 arising out of a tax audit in one of the jurisdictions in which the company operates. The settlement consisted of US$3,863,000 in relation to a patent dividend scheme, which had operated via Rayville Limited from 1995 to 2010, US$1,231,000 in relation to payments for CEO Services made to Darnick Company (a company controlled by the family of Ronan O’Caoimh) and US$75,000 in relation to R&D tax credits. Penalties were US$273,000. Interest was US$1,000,000 and this is shown as a financial expense. The total settlement excluding interest of US$5,442,000 was partially offset by a provision of US$400,000, resulting in an expense of US$5,042,000 in the year ended December 31, 2019, which is shown as Selling, general and administrative expenses – tax audit settlement. Darnick Company agreed to contribute US$1,231,000 to the above settlement and this amount was outstanding at December 31, 2019 and was treated as a contingent asset and not recognised in the 2019 financial statements. This balance was settled in the year ended December 31, 2020 and has been credited to the Statement of Operations within Selling, General and Administrative Expenses. The underlying amount was denominated in Euro. Due to a depreciation in the US Dollar since 2019, the US Dollar equivalent amount increased from US$1,231,000 to US$1,316,000. The settlement amount received by the Company was US$177,000 more than the balance owed and this overpayment is recorded as a related party current liability for the benefit of Ronan O’Caoimh as at December 31, 2020. The amount was settled by the Group in January 2021.

IMPAIRMENT CHARGES

IMPAIRMENT CHARGES	12 Months Ended
	Dec. 31, 2020
Disclosure of impairment charges and inventory provisioning [Abstract]
IMPAIRMENT CHARGES	7. IMPAIRMENT CHARGES In accordance with IAS 36, Impairment of Assets The impact of the above items on the statement of operations for the year ended December 31, 2020, December 31, 2019 and December 31, 2018 was as follows: December December December 31, 2020 31, 2019 31, 2018 US$’000 US$’000 US$’000 Selling, general & administration expenses Impairment of PP&E (Note 13) 1,795 6,349 6,112 Impairment of goodwill and other intangible assets (Note 14) 15,422 16,570 19,212 Impairment of prepayments (Note 18) 562 1,376 1,608 Total impairment loss 17,779 24,295 26,932 Income tax impact of impairment loss 0 148 (1,752 ) Total impairment loss after tax 17,779 24,443 25,180

FINANCIAL INCOME AND EXPENSES

FINANCIAL INCOME AND EXPENSES	12 Months Ended
	Dec. 31, 2020
Disclosure of financial income and expenses [Abstract]
FINANCIAL INCOME AND EXPENSES	8. FINANCIAL INCOME AND EXPENSES December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Financial income: Non-cash financial income - 233 1,388 Interest income 36 464 736 36 697 2,124 Financial expense: Interest on leases (896 ) (947 ) (39 ) Interest on tax audit settlement (Note 6) - (1,000 ) - Cash interest on exchangeable notes (3,996 ) (3,996 ) (4,352 ) Non-cash interest on exchangeable notes (Note 25) (643 ) (639 ) (689 ) Non-cash financial expense (1,216 ) - - (6,751 ) (6,582 ) (5,080 ) Net Financing Expense (6,715 ) (5,885 ) (2,956 ) Exchangeable note interest expense and non-cash financial income and expense relate to the exchangeable senior notes issued in 2015. For further information, refer to Note 25.

INCOME TAX CREDIT

INCOME TAX CREDIT	12 Months Ended
	Dec. 31, 2020
Disclosure of income tax credit [Abstract]
INCOME TAX CREDIT	9. INCOME TAX CREDIT The tax credit based on the loss comprises: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Current tax (credit)/expense Irish Corporation tax (480 ) (312 ) (258 ) Foreign taxes (a) 179 197 195 Adjustment in respect of prior years (152 ) (50 ) (56 ) Total current tax credit (453 ) (165 ) (119 ) Deferred tax credit Origination and reversal of temporary differences (see Note 15) 48 (625 ) (2,031 ) Origination and reversal of net operating losses (see Note 15) (215 ) (216 ) 1,625 Total deferred tax credit (167 ) (841 ) (406 ) Total income tax credit on continuing operations in statement of operations (620 ) (1,006 ) (525 ) Tax charge / (credit) on discontinued operations (see Note 10) 438 - (590 ) 00 Total tax credit (182 ) (1,006 ) (1,115 ) (a) In 2020, the foreign taxes relate primarily to Canada. (b) In 2020, there was a deferred tax charge of US$53,000 (2019: credit of US$444,000; 2018: charge of US$369,000) recognised in respect of Ireland and a deferred tax credit of US$220,000 (2019: credit of US$397,000; 2018: credit of US$775,000) recognised in respect of overseas tax jurisdictions. Effective tax rate December 31, 2020 December 31, 2019 December 31, 2018 Loss before taxation – continuing operations (US$‘000) (6,633 ) (29,997 ) (23,183 ) As a percentage of loss before tax: Current tax % (6.83 )% (0.55 )% (0.51 )% Total (current and deferred) % (9.35 )% (3.36 )% (2.26 )% The following table reconciles the applicable Republic of Ireland statutory tax rate to the effective total tax rate for the Group: December 31, 2020 December 31, 2019 December 31, 2018 Irish corporation tax (12.5 )% (12.5 )% (12.5 )% Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised (a) 24.13 % 13.21 % 15.76 % Effect of tax rates on overseas earnings (9.92 )% (3.05 )% (6.10 )% Effect of Irish income taxable at higher tax rate 5.92 % 0.04 % 0.05 % Adjustments in respect of prior years (10.66 )% (0.17 )% 0.94 % R&D tax credits (11.00 )% (2.69 )% (1.70 )% Other items (c) 4.68 % 1.80 % 1.29 % Effective tax rate (9.35 )% (3.36 )% (2.26 )% (a) The effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised is analyzed further in the table below (see also Note 15). No deferred tax asset was recognised because there was no reversing deferred tax liability in the same jurisdiction reversing in the same period and no future taxable income in the same jurisdiction. (b) Other items comprise items not chargeable to tax/expenses not deductible for tax purposes. In 2020, this mainly comprises the movement in the exchangeable notes’ embedded derivatives value and the accretion of notional interest on the Loan Note’s host contract, both of which are exempt from deferred taxation recognition under IAS 12, Income Taxes. In 2019, other items mainly comprise the tax audit settlement recorded in Selling, General and Administrative expenses (see also Note 6), which is not deductible for tax and the movement in the exchangeable notes’ embedded derivatives value and the accretion of notional interest. Unrecognised deferred tax assets – continuing operations Effect in 2020 US$’000 Percentage effect in 2020 Effect in 2019 US$’000 Percentage effect in 2019 Increase in net operating losses arising in US 1,105 16.66 % 1,117 3.72 % Temporary differences arising in US - - 129 0.43 % (Decrease)/increase in net operating losses arising in Brazil (502 ) (7.57 )% 608 2.03 % Increase in net operating losses arising in Luxembourg 544 8.20 % - - Increase in net operating losses arising in UK 2 0.03 % - - Increase in net operating losses arising in Ireland 452 6.81 % 2,110 7.03 % 1,601 24.13 % 3,964 13.21 % The distribution of loss before taxes by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Rest of World – Ireland 296 (20,318 ) (9,590 ) Rest of World – Other 3,304 4,760 4,809 Americas (10,233 ) (14,439 ) (18,402 ) (6,633 ) (29,997 ) (23,183 ) At December 31, 2020, the Group had unutilised net operating losses for continuing operations as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Ireland 78,700 73,754 60,629 USA - 1,034 2,382 Luxembourg 2,175 - - UK 10 - - Brazil 4,313 5,789 4,001 85,198 80,577 67,012 At December 31, 2020, the Group had unrecognised deferred tax assets in respect of unused tax losses and unused tax credits as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Ireland – unused tax losses 12,514 12,062 9,953 US – unused tax losses - 3,291 2,174 US – unused tax credits 2,862 493 364 Luxembourg – unused tax losses 544 - - UK – unused tax losses 2 - - Brazil – unused tax losses 1,466 1,968 1,360 18,810 Unrecognised deferred tax asset 17,388 17,814 13,851 The accounting policy for deferred tax is to calculate the deferred tax asset that is deemed recoverable, considering all sources for future taxable profits. The deferred tax assets in the above table have not been recognised due to uncertainty regarding the full utilization of these losses in the related tax jurisdiction in future periods. Only when it is probable that future profits will be available to utilize the forward losses or temporary differences is a deferred tax asset recognised. When there is a reversing deferred tax liability in that jurisdiction that reverses in the same period, the deferred tax asset is restricted so that it equals the reversing deferred tax liability.

(LOSS)_PROFIT FOR THE YEAR ON D

(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION	12 Months Ended
	Dec. 31, 2020
Disclosure of loss on discontinued operation [Abstract]
(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION	10 . (LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION In 2016, management decided to cease the development of Cardiac point-of-care tests on the Meritas platform. These products were being developed by the Group’s subsidiary Fiomi Diagnostics (“Fiomi”) located in Sweden. The decision to cease the development work and to close the Swedish operation came after the company held a meeting with the U.S. Food and Drug Administration (“FDA”) in order to obtain an update on the Meritas Troponin premarket submission. At that meeting the FDA suggested that the submission should be withdrawn. The FDA made it known that any new point-of-care Troponin product would be required to demonstrate performance equivalent to the most recently cleared laboratory-based device. As there was no certainty that this level of performance could ever be achieved by the point-of-care Meritas product, even with the benefit of further development efforts, management decided to cease the development work on Troponin I and the analyzer and its sister products, BNP and D-dimer. Expenses, gains and losses relating to the discontinuation of the Cardiac point-of-care tests operation have been eliminated from profit or loss from the Group’s continuing operations and are shown as a single line item (net of related taxes) on the face of the Consolidated Statement of Operations. The discontinued operation had no revenues since commencement as the products were still in their development phase. In 2016, the loss on discontinued operations included the write off of the carrying value of all capitalised development costs, goodwill, property, plant and equipment, inventories and other assets associated with the Meritas project. It also included a provision for the cost of closing the Swedish facility, mainly consisting of contractual obligations associated with terminating premises and supplier contracts, as well as redundancy costs for 41 employees. In 2018, taxes paid to the Swedish tax authorities were recovered and there was a resulting tax credit of US$590,000. In 2020, closure provisions were finalized and an excess provision of US$127,000 was released to the Consolidated Statement of Operations. A tax receivable amount of US438,000 was expensed due to a change of estimate. The operating loss for the Cardiac point-of-care tests operation in Sweden and the (loss)/profit on re-measurement of its assets and liabilities are summarised as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 (Loss)/Profit on re-measurement of assets and liabilities: Closure provision 127 (8 ) (22 ) Foreign currency translation reserve (64 ) 85 — Tax (expense)/credit (438 ) — 590 Total (loss)/profit (375 ) 77 568 (Loss)/Profit for the year from discontinued operations (375 ) 77 568 Basic earnings per ordinary share – discontinued operations Basic (loss)/earnings per ordinary share for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$375,000 (2019: profit US$77,000) (2018: profit US$568,000) for the financial year by the weighted average number of ‘A’ ordinary shares in issue. As at December 31, 2020, this amounted to 83,606,810 shares (2019: 83,606,810 shares) (2018: 83,612,908 shares), see note 12 for further details. Diluted earnings per ordinary share – discontinued operations Diluted (loss)/earnings per ordinary share for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$375,000 (2019: profit US$77,000) (2018: profit US$568,000) for the financial year by the diluted weighted average number of ordinary shares in issue of 105,024,732 (2019: 101,870,064) (2018: 103,508,820), see note 12 for further details. Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted loss per ADS in accordance with IFRS is equal to basic earnings per ADS. Earnings per ADS In June 2005, Trinity Biotech adjusted its ADS ratio from 1 ADS: 1 ordinary share to 1 ADS: 4 ordinary shares. Earnings per ADS for all periods presented have been restated to reflect this exchange ratio. Basic (loss)/earnings per ADS for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$375,000 (2019: profit US$77,000) (2018: profit US$568,000) for the financial year by the weighted average number of ADS in issue of 20,901,703 (2019: 20,901,703) (2018: 20,903,227), see note 12 for further details. Diluted (loss)/earnings per ADS for discontinued operations is computed by dividing the loss after taxation on discontinued operations of US$375,000 (2019: profit US$77,000) (2018: profit US$568,000) for the financial year, by the diluted weighted average number of ADS in issue of 26,256,183 (2019: 25,467,516) (2018: 25,877,205), see note 12 for further details. December 31, December 31, December 31, Basic (loss)/earnings per ADS (US Dollars) – discontinued operations (0.02 ) 0.00 0.03 Diluted (loss)/earnings per ADS (US Dollars) – discontinued operations (0.02 ) 0.00 0.02 Basic (loss)/earnings/ per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.01 Diluted (loss)/earnings per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.01 Cash flows The cash flows attributable to discontinued operations are as follows: December 31, December 31, December 31, US$000 US$000 US$000 Cash flows from operating activities (22 ) (5 ) 527 There were no cash flows from investing or financing activities attributable to discontinued operations for the years ended December 31, 2020, 2019 or 2018.

LOSS BEFORE TAX

LOSS BEFORE TAX	12 Months Ended
	Dec. 31, 2020
Disclosure of loss profit before tax [Abstract]
LOSS BEFORE TAX	11. LOSS BEFORE TAX The following amounts were charged / (credited) to the statement of operations: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Directors’ emoluments (including non- executive directors): Remuneration 2,020 1,238 1,261 Pension 41 42 44 Share based payments 678 624 1,204 Auditor’s remuneration Audit fees 533 523 506 Tax fees 146 172 15 Other non-audit fees 25 - - Depreciation* 1,674 2,526 1,296 Amortisation (Note 14) 1,403 2,368 2,825 (Profit)/Loss on the disposal of property, plant and equipment 30 17 15 Net foreign exchange differences 583 (179 ) 344 * Note that US$40,000 (2019: US$4,000) (2018: US$79,000) of depreciation was capitalised to research and development projects during 2020 in line with the Group’s capitalisation policy for Intangible projects.

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Dec. 31, 2020
Earnings per share [abstract]
LOSS PER SHARE	12. LOSS PER SHARE Basic earnings per ordinary share Basic earnings per ordinary share for the group is computed by dividing the loss after taxation of US$6,388,000 (2019: loss of $28,914,000) (2018: loss of US$22,090,000) for the financial year by the weighted average number of ‘A’ ordinary shares in issue. Basic earnings per ordinary share for continuing operations is computed by dividing the loss after taxation for continued operations of US$6,013,000 (2019: loss of US$28,991,000) (2018: loss of US$22,658,000) for the financial year by the weighted average number of ‘A’ ordinary shares in issue. As at December 31, 2020, this amounted to 83,606,810 shares (2019: 83,606,810 shares) (2018: 83,612,908 shares). December 31, December 31, December 31, ‘A’ ordinary shares 83,606,810 83,606,810 83,612,908 Basic earnings per share denominator 83,606,810 83,606,810 83,612,908 Reconciliation to weighted average earnings per share denominator: Number of ‘A’ ordinary shares at January 1 (Note 21) 96,162,410 96,162,410 96,162,410 Weighted average number of shares issued during the year* - - - Weighted average number of treasury shares (12,555,600 ) (12,555,600 ) (12,549,502 ) Basic earnings per share denominator 83,606,810 83,606,810 83,612,908 *The weighted average number of shares issued during the year is calculated by taking the number of shares issued multiplied by the number of days in the year each share is in issue, divided by 365 days. Diluted earnings per ordinary share Diluted earnings per ordinary share for the group is computed by dividing the adjusted loss after tax of US$533,000 (2019: loss of US$24,512,000) (2018: loss of US$18,437,000) for the financial year by the diluted weighted average number of ordinary shares in issue of 105,024,732 (2019: 101,870,064) (2018: 103,508,820). Diluted earnings per ordinary share for continuing operations is computed by dividing the adjusted loss after tax on continuing operations of US$158,000 (2019: loss of US$24,590,000) (2018: loss of US$19,005,000) for the financial year by the diluted weighted average number of ordinary shares in issue of 105,024,732 (2019: 101,870,064) (2018: 103,508,820). The adjusted loss after tax on continuing operations is computed by adding back the interest expense, accretion interest and movements in the fair value of the derivatives on the exchangeable notes to the loss after taxation for continuing operations. Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted loss per ordinary share in accordance with IFRS would be equal to basic earnings per ordinary share. The basic weighted average number of ordinary shares for the Group may be reconciled to the number used in the diluted earnings per ordinary share calculation as follows: December 31, 2020 December 31, 2019 December 31, 2018 Basic earnings per share denominator (see above) 83,606,810 83,606,810 83,612,908 Issuable on exercise of options and warrants 3,154,668 - 22,359 Issuable on conversion of exchangeable notes 18,263,254 18,263,254 19,873,553 Diluted earnings per share denominator 105,024,732 101,870,064 103,508,820 The loss after tax for the year may be reconciled to the amount used in the diluted earnings per ordinary share calculation as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Loss after tax for the year (6,388 ) (28,914 ) (22,090 ) Non-cash financial expense/(income) (Note 8) 1,216 (233 ) (1,388 ) Cash interest expense (Note 8) 3,996 3,996 4,352 Non-cash interest on exchangeable notes (Note 8) 643 639 689 Adjusted loss after tax (533 ) (24,512 ) (18,437 ) Earnings per ADS In June 2005, Trinity Biotech adjusted its ADS ratio from 1 ADS: 1 ordinary share to 1 ADS: 4 ordinary shares. Earnings per ADS for all periods presented have been restated to reflect this exchange ratio. Basic earnings per ADS for the Group is computed by dividing the loss after taxation of US$6,388,000 (2019: loss of US$28,914,000) (2018: loss of US$22,090,000) for the financial year by the weighted average number of ADS in issue of 20,901,703 (2019: 20,901,703) (2018: 20,903,227). Basic earnings per ADS for continuing operations is computed by dividing the loss after taxation of US$6,013,000 (2019: loss of US$28,991,000) (2018: loss of US$22,658,000) for the financial year by the weighted average number of ADS in issue of 20,901,703 (2019: 20,901,703) (2018: 20,903,227). December 31, 2020 December 31, 2019 December 31, 2018 ADS 20,901,703 20,901,703 20,903,227 Basic earnings per share denominator 20,901,703 20,901,703 20,903,227 Reconciliation to weighted average earnings per share denominator: Number of ADS at January 1 (Note 21) 24,040,602 24,040,602 24,040,602 Weighted average number of shares issued during the year* - - - Weighted average number of treasury shares (3,138,899 ) (3,138,899 ) (3,137,375 ) Basic earnings per share denominator 20,901,703 20,901,703 20,903,227 Diluted earnings per ADS for the Group is computed by dividing the adjusted loss after taxation of US$533,000 (2019: loss of US$24,512,000) (2018: loss of US$18,437,000) for the financial year, by the diluted weighted average number of ADS in issue of 26,256,183 (2019:25,467,516) (2018: 25,877,205). Under IAS 33 Earnings per Share, diluted earnings per share cannot be anti-dilutive. Therefore, diluted loss per ADS in accordance with IFRS would be equal to basic earnings per ADS. *The weighted average number of shares issued during the year is calculated by taking the number of shares issued multiplied by the number of days in the year each share is in issue, divided by 365 days. The basic weighted average number of ADS shares for the Group may be reconciled to the number used in the diluted earnings per ADS share calculation as follows: December 31, 2020 December 31, 2019 December 31, 2018 Basic earnings per share denominator (see above) 20,901,703 20,901,703 20,903,227 Issuable on exercise of options and warrants 788,666 - 5,590 Issuable on conversion of exchangeable notes 4,565,814 4,565,814 4,968,388 Diluted earnings per share denominator 26,256,183 25,467,517 25,877,205

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY, PLANT AND EQUIPMENT	13. PROPERTY, PLANT AND EQUIPMENT Land and buildings US$‘000 Leasehold improvements US$‘000 Computers, fixtures and fittings US$‘000 Plant and equipment US$‘000 Total US$‘000 Cost At January 1, 2019 2,605 4,560 6,585 40,064 53,814 Adjustment on transition to IFRS 16 20,961 — 149 75 21,185 Additions 681 71 168 1,905 2,825 Disposals or retirements — (1,626 ) (2,610 ) (3,314 ) (7,550 ) Exchange adjustments 22 — — (54 ) (32 ) At December 31, 2019 24,269 3,005 4,292 38,676 70,242 At January 1, 2020 24,269 3,005 4,292 38,676 70,242 Additions 8 41 96 2,766 2,911 Disposals or retirements — (299 ) (66 ) (5,758 ) (6,123 ) Exchange adjustments 10 (77 ) (13 ) (1,845 ) (1,925 ) At December 31, 2020 24,287 2,670 4,309 33,839 65,105 Accumulated depreciation and impairment losses At January 1, 2019 (1,934 ) (3,243 ) (5,783 ) (37,492 ) (48,452 ) Charge for the year (1,545 ) (105 ) (200 ) (680 ) (2,530 ) Adjustment on transition to IFRS 16 (10,984 ) — (40 ) (75 ) (11,099 ) Impairment loss as at December 31, 2019 (4,024 ) (233 ) (276 ) (1,816 ) (6,349 ) Disposals or retirements — 1,544 2,618 3,331 7,493 Reallocations / reclassifications — — — (5 ) (5 ) Exchange adjustments (6 ) — (1 ) (3 ) (10 ) At December 31, 2019 (18,493 ) (2,037 ) (3,682 ) (36,740 ) (60,952 ) At January 1, 2020 (18,493 ) (2,037 ) (3,682 ) (36,740 ) (60,952 ) Charge for the year (783 ) (146 ) (181 ) (604 ) (1,714 ) Impairment loss as at December 31, 2020 (347 ) (78 ) (180 ) (1,190 ) (1,795 ) Disposals or retirements — 299 84 5,590 5,973 Exchange adjustments (6 ) 78 13 1,845 1,930 At December 31, 2020 (19,629 ) (1,884 ) (3,946 ) (31,099 ) (56,558 ) Carrying amounts At December 31, 2020 4,658 786 363 2,740 8,547 At December 31, 2019 5,776 968 610 1,936 9,290 Right-of-use assets The right-of-use assets are included in the same line item as the corresponding underlying assets would be presented if they were owned. The Group has used the modified retrospective application method for its first time application of IFRS 16, Leases Impairment US$000 Right-of-use assets cost at transition before impairment 21,185 Impairment adjustment on transition (11,099 ) Right-of-use assets value at transition after impairment 10,086 The following is a reconciliation of the financial statement line items from IAS 17 to IFRS 16 at January 1, 2019: Carrying amount at December 31, 2018 Remeasurement Impairment IFRS 16 carrying amount at January 1, 2019 US$000 US$000 US$000 US$000 Property, plant & equipment 5,362 21,185 (11,099 ) 15,448 Lease liabilities (962 ) (21,185 ) - (22,147 ) Retaining earnings (55,319 ) - 11,099 (44,220 ) Total (50,919 ) - - (50,919 ) Additional information on the right-of-use assets by class of assets is as follows: Carrying amount At December 31, 2020 Depreciation Charge Year ended December 31, 2020 Impairment Charge Year ended December 31, 2020 US$000 US$000 US$000 Buildings 4,200 (673 ) (347 ) Computer equipment 3 (4 ) - Plant and Equipment - (70 ) (154 ) 4,203 (747 ) (501 ) Carrying amount At December 31, 2019 Depreciation Year ended December 31, 2019 Impairment Year ended December 31, 2019 US$000 US$000 US$000 Buildings 5,220 (1,523 ) (3,913 ) Computer equipment 7 (39 ) (63 ) 5,227 (1,562 ) (3,976 ) Income from sub-letting right-of-use buildings amounted to US$3,000 in the year ended December 31, 2020 (2019: USD$3,000). Right-of-Use assets at 31 December 2020 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 12 1 to 13 4 1 - 2 4 Vehicle 16 1 to 3 2 - 16 - 16 I.T. and office equipment 10 1 to 2 1 - - - 1 Right-of-Use assets at 31 December 2019 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 13 1 to 14 5 1 - 2 4 Vehicle 9 1 to 2 1 - 9 - 9 I.T. and office equipment 11 1 to 2 2 - - - 1 The details of the impairment review are described in Note 14. When an impairment loss is identified in a cash generating unit, it must be first allocated to reduce the carrying amount of any goodwill allocated to the cash generating unit and then to the other assets of the unit pro rata on the basis of the carrying amount of each asset in the unit. In this manner, an impairment loss of US$1,795,000 was allocated to property, plant and equipment as at December 31, 2020. The recoverable amount of property, plant and equipment was determined to be the value in use of each cash generating unit. The details of the impairment review are described in Note 14. When an impairment loss is identified in a cash generating unit, it must be first allocated to reduce the carrying amount of any goodwill allocated to the cash generating unit and then to the other assets of the unit pro rata on the basis of the carrying amount of each asset in the unit. In this manner, an impairment loss of US$6,349,000 was allocated to property, plant and equipment as at December 31, 2019. The recoverable amount of property, plant and equipment was determined to be the value in use of each cash generating unit. Assets held under operating leases (where the Company is the lessor) The Company has a number of assets included in plant and equipment which generate operating lease revenue for the Group. The net book value of these assets as at December 31, 2020 and 2019 is US$Nil following full write down of the assets due to group impairment (refer to Note 14). Depreciation charged on these assets in 2020 amounted to US$21,000 (2019: US$7,000). Property, plant and equipment under construction There were no assets under construction included in property, plant and equipment at December 31, 2020 (2019: US$Nil).

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2020
Disclosure of goodwill and intangible assets [Abstract]
GOODWILL AND INTANGIBLE ASSETS	14. GOODWILL AND INTANGIBLE ASSETS Goodwill US$‘000 Development costs US$‘000 Patents and licences US$‘000 Other US$‘000 Total US$‘000 Cost At January 1, 2019 81,689 146,772 9,947 34,228 272,636 Additions — 9,569 4 38 9,611 Disposals or retirements — — — — — Exchange adjustments — 36 — — 36 At December 31, 2019 81,689 156,377 9,951 34,266 282,283 At January 1, 2020 81,689 156,377 9,951 34,266 282,283 Additions — 6,896 30 89 7,015 Disposals or retirements (2,507 ) (34,318 ) (1,034 ) (1,044 ) (38,903 ) Reclassification — — — — — Exchange adjustments — 22 — — 22 At December 31, 2020 79,182 128,977 8,947 33,311 250,417 Accumulated amortisation and Impairment losses At January 1, 2019 (65,548 ) (120,507 ) (9,814 ) (23,816 ) (219,685 ) Charge for the year — (1,182 ) (2 ) (1,184 ) (2,368 ) Disposals or retirements — — — — — Impairment losses (3,550 ) (11,904 ) (3 ) (1,113 ) (16,570 ) Exchange adjustments — (6 ) — — (6 ) At December 31, 2019 (69,098 ) (133,599 ) (9,819 ) (26,113 ) (238,629 ) At January 1, 2020 (69,098 ) (133,599 ) (9,819 ) (26,113 ) (238,629 ) Charge for the year — (959 ) (5 ) (439 ) (1,403 ) Disposals or retirements 2,507 34,318 1,034 1,044 38,903 Impairment losses — (15,287 ) — (135 ) (15,422 ) Exchange adjustments — (6 ) — — (6 ) At December 31, 2020 (66,591 ) (115,533 ) (8,790 ) (25,643 ) (216,557 ) Carrying amounts At December 31, 2020 12,591 13,444 157 7,668 33,860 At December 31, 2019 12,591 22,778 132 8,153 43,654 Included within development costs are costs of US$6,980,000 which were not amortised in 2020 (2019: US$3,719,000). These development costs are not being amortised as the projects to which the costs relate were not fully complete at December 31, 2020 or at December 31, 2019. As at December 31, 2020 these projects are expected to be completed during the period from January 1, 2021 to December 31, 2023 at an expected further cost of approximately US$8,798,000. The following represents the costs incurred during each period presented for each of the principal development projects: Product Name 2020 US $’000 2019 US $’000 HIV screening rapid test 2,278 2,587 Premier Instrument for Haemoglobin A1c testing 1,359 1,930 Autoimmune Smart Reader 666 1,325 Syphilis point-of-care test 618 870 Uni-Gold antigen improvement 556 691 COVID tests 467 - Mid-tier haemoglobins instrument 243 63 Tri-stat point-of-care instrument 203 361 Column enhancement 151 236 Ultra Genesys 139 237 Sjögrens tests 99 135 G-6-PDH test - 582 Uni-gold test - 376 Other projects 117 176 Total capitalised development costs 6,896 9,569 All of the development projects for which costs have been capitalised are judged to be technically feasible, commercially viable and likely to produce future economic benefits. In reaching this conclusion, many factors have been considered including the following: (a) The Group only develops products within its field of expertise. The R&D team is experienced in developing new products in this field and this experience means that only products which have a high probability of technical success are put forward for consideration as potential new products. (b) A technical feasibility study is undertaken in advance of every project. The feasibility study for each project is reviewed by the R&D team leader, and by other senior management depending on the size of the project. The feasibility study occurs in the initial research phase of the project and costs in this phase are not capitalised. (c) Nearly all of our new product developments involve the transfer of our existing product know-how to a new application. The Group does not engage in pure research. Every development project is undertaken with the intention of bringing a particular new product to market for which there is an expected demand. (d) The commercial feasibility of each new product is established prior to commencement of a project by ensuring it is projected to achieve an acceptable income after applying appropriate discount rates. Other intangible assets Other intangible assets consist primarily of acquired customer and supplier lists, trade names, website and software costs. Amortisation Amortisation is charged to the statement of operations through the selling, general and administrative expenses line. Impairment testing for intangibles including goodwill and indefinite lived assets Goodwill and other intangibles are subject to impairment testing on an annual basis. The recoverable amount of seven CGUs is determined based on a value-in-use computation. Among other macroeconomic considerations, the impact of the COVID-19 pandemic has been factored into our impairment testing. The value-in-use calculations use cash flow projections based on the 2021 projections for each CGU and a further four years projections using estimated revenue and cost average growth rates of between 0% and 12%. At the end of the five year forecast period, terminal values for each CGU, based on a long term growth rate of 2%, are used in the value-in-use calculations. The value-in-use represents the present value of the future cash flows, including the terminal value, discounted at a rate appropriate to each CGU. The pre-tax discount rates used range from 16% to 44% (2019: 20% to 27%). Sources of estimation uncertainty The cash flows have been arrived at taking into account the Group’s financial position, its recent financial results and cash flow generation and the nature of the medical diagnostic industry, where product obsolescence can be a feature. However, expected future cash flows are inherently uncertain and are therefore liable to material change over time. The key assumptions employed in arriving at the estimates of future cash flows factored into impairment testing are subjective and include projected EBITDA margins, net cash flows, discount rates used and the duration of the discounted cash flow model. Significant under-performance in any of the Group’s major CGUs may give rise to a material impairment which would have a substantial impact on the Group’s income and equity. 2020 impairment test The impairment test performed as at December 31, 2020 identified an impairment loss in three CGUs, namely Primus Corp., Biopool US Inc, and Trinity Biotech Do Brasil. The table below sets forth the impairment loss recorded for each of the CGU’s: December 31, 2020 December 31, 2019 US$’000 US$’000 Primus Corp 16,706 5,321 Trinity Biotech Do Brasil 919 1,253 Biopool US Inc. 154 210 Trinity Biotech Manufacturing Limited - 9,732 Immco Diagnostics Inc - 6,332 Clark Laboratories Inc. - 727 Mardx Diagnostics Inc. - 720 17, Total impairment loss 17,779 24,295 Primus Corporation, which recorded the largest impairment loss of any CGU in this financial year, has been particularly impacted by the pandemic and changes to its product offering. Trinity Biotech Do Brasil also incurred a significant impairment loss in 2020 as this CGU continues to be impacted by the weakness of the Brazilian Real. The table below sets forth the breakdown of the impairment loss for each class of asset: December 31, 2020 December 31, 2019 US$’000 US$’000 Goodwill and other intangible assets (see Note 14) 15,422 16,570 Property, plant and equipment (see Note 13) 1,795 6,349 Prepayments (see Note 18) 562 1,376 Total impairment loss 17,779 24,295 The value-in-use calculation is subject to significant estimation, uncertainty and accounting judgements and is particularly sensitive in the following areas; • In the event that there was a reduction of 10% in the assumed level of future growth in revenue growth rate, which would represent a reasonably likely range of outcomes, there would be an additional impairment loss recorded of US$384,000 at December 31, 2020. • In the event there was a 10% increase in the discount rate used to calculate the potential impairment of the carrying values, which would represent a reasonably likely range of outcomes, there would be an additional impairment loss recorded of US$1,504,000 at December 31, 2020. Significant Goodwill and Intangible Assets with Indefinite Useful Lives CGUs or combinations of CGUs for which the carrying amount of goodwill is significant for the purposes of impairment testing in comparison with the Group’s total carrying amount of goodwill are those where the percentage is greater than 20% of the total. The additional disclosures required for the CGU with significant goodwill are as follows: Fitzgerald Industries December 31, December 31, Carrying amount of goodwill (US$’000) 12,591 12,591 Discount rate applied (real pre-tax) 19.98 % 20.42 % Excess value-in-use over carrying amount (US$’000) 7,915 2,385 % EBITDA would need to decrease for an impairment to arise 31.98 % 12.11 % Long-term growth rate 2.0 % 2.0 % The key assumptions and methodology used in respect of this CGU are consistent with those described above. The assumptions and estimates used are specific to the individual CGU and were derived from a combination of internal and external factors based on historical experience. Intangible Assets with Indefinite Useful lives (included in other intangibles) December 31, 2020 US$‘000 December 31, 2019 US$‘000 Fitzgerald Industries International CGU Fitzgerald trade name 970 970 RDI trade name 560 560 Primus Corporation CGU Primus trade name 365 500 Immco Diagnostic CGU Immco Diagnostic trade name 2,938 2,938 Total 4,833 4,968 The trade name assets purchased as part of the acquisition of Fitzgerald in 2004, Primus and RDI in 2005 and Immco Diagnostics in 2013 were valued using the relief from royalty method and based on factors such as (1) the market and competitive trends and (2) the expected usage of the name. It was considered that these trade names will generate net cash inflows for the Group for an indefinite period. In 2020, an impairment loss of US$135,000 was allocated against the Primus trade name as the carrying value of the CGU’s net assets exceeded its discounted future cashflows.

DEFERRED TAX ASSETS AND LIABILI

DEFERRED TAX ASSETS AND LIABILITIES	12 Months Ended
	Dec. 31, 2020
Disclosure of deferred tax assets and liabilities [Abstract]
DEFERRED TAX ASSETS AND LIABILITIES	15. DEFERRED TAX ASSETS AND LIABILITIES Recognised deferred tax assets and liabilities Deferred tax assets and liabilities of the Group are attributable to the following: Assets Liabilities Net 2020 2019 2020 2019 2020 2019 Property, plant and equipment 733 1,027 (9 ) (9 ) 724 1,018 Intangible assets — — (4,072 ) (6,099 ) (4,072 ) (6,099 ) Inventories 750 642 — — 750 642 Provisions 2,159 3,622 — — 2,159 3,622 Tax value of loss carry-forwards 433 216 — — 433 216 Other items 110 745 (824 ) (1,031 ) (714 ) (286 ) Deferred tax assets/(liabilities) 4,185 6,252 (4,905 ) (7,139 ) (720 ) (887 ) The deferred tax asset in 2020 is mainly due to deductible temporary differences relating to provisions, property, plant and equipment and the elimination of unrealised intercompany inventory profit. In 2020, the deferred tax asset decreased by US$2,067,000 mainly due to a reduction in deductible temporary differences principally attributable to interest provisions. The deferred tax liability is caused by the net book value of non-current assets being greater than the tax written down value of non-current assets, temporary differences due to the acceleration of the recognition of certain charges in calculating taxable income permitted in Ireland and the US. The deferred tax liability decreased by US$2,234,000 in 2020, principally because of the impairment of intangible assets on which the deferred tax liabilities were recognised. Deferred tax assets and liabilities are only offset when the entity has a legally enforceable right to set off current tax assets against current tax liabilities and where the intention is to settle current tax liabilities and assets on a net basis or to realise the assets and settle the liabilities simultaneously. At December 31, 2020 and at December 31, 2019 no deferred tax assets and liabilities are offset as it is not certain as to whether there is a legally enforceable right to set off current tax assets against current tax liabilities and it is also uncertain as to what current tax assets may be set off against current tax liabilities and in what periods. The vast majority of temporary differences are expected to reverse after 2022. Movement in temporary differences during the year Balance January, 1 Recognised Balance December 31, US$’000 US$’000 US$’000 Property, plant and equipment 1,018 (294 ) 724 Intangible assets (6,099 ) 2,027 (4,072 ) Inventories 642 108 750 Provisions 3,622 (1,463 ) 2,159 Tax value of loss carry-forwards 216 217 433 Other items (286 ) (428 ) (714 ) (887 ) 167 (720 ) Balance January, 1 Recognised Balance December 31, US$’000 US$’000 US$’000 Property, plant and equipment 778 240 1,018 Intangible assets (7,189 ) 1,090 (6,099 ) Inventories 668 (26 ) 642 Provisions 4,311 (689 ) 3,622 Tax value of loss carry-forwards - 216 216 Other items (296 ) 10 (286 ) (1,728 ) 841 (887 ) Unrecognised deferred tax assets Deferred tax assets have not been recognised by the Group in respect of the following items: December 31, December 31, US$’000 US$’000 Capital losses 8,293 8,293 Net operating losses 85,198 80,577 US alternative minimum tax credits 1,848 1,928 Other temporary timing differences 21,878 7,399 US state credit carryforwards 802 493 118,019 98,690 There was an increase of US $19,329,000

OTHER NON-CURRENT ASSETS

OTHER NON-CURRENT ASSETS	12 Months Ended
	Dec. 31, 2020
Disclosure of non-current assets [Abstract]
OTHER NON-CURRENT ASSETS	16. OTHER NON-CURRENT ASSETS December 31, 2020 US$‘000 December 31, 2019 US$‘000 Finance lease receivables (see Note 18) 291 403 Other assets 64 82 355 485 The Group leases instruments as part of its business. For details of future minimum finance lease receivables with non-cancellable terms, please refer to Note 18.

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2020
Classes of current inventories [abstract]
INVENTORIES	17. INVENTORIES December 31, 2020 US$‘000 December 31, 2019 US$‘000 Raw materials and consumables 12,168 12,654 Work-in-progress 5,169 6,940 Finished goods 12,882 12,427 30,219 32,021 All inventories are stated at the lower of cost or net realisable value. The replacement cost of inventories does not differ from cost. Total inventories for the Group are shown net of provisions of US$9,781,000 (2019: US$6, 716,000). Cost of sales in 2020 includes inventories expensed of US$48,342,000 (2019: US$50,748,000), (2018: US$55,285,000). The movement on the inventory provision for the three year period to December 31, 2020 is as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Opening provision at January 1 6,716 6,299 7,543 Charged during the year 5,179 1,567 480 Utilised during the year (1,994 ) (1,150 ) (1,544 ) Released during the year (120 ) - (180 ) Closing provision at December 31 9,781 6,716 6,299 During 2020, US$120,000 (2019: US$Nil), (2018: US$180,000) of inventory provision relating to net realisable value was released to the statement of operations following a current year review of inventory usage.

TRADE AND OTHER RECEIVABLES

TRADE AND OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2020
Trade and other current receivables [abstract]
TRADE AND OTHER RECEIVABLES	18. TRADE AND OTHER RECEIVABLES December 31, 2020 US$‘000 December 31, 2019 US$‘000 Trade receivables, net of impairment losses 20,025 17,754 Prepayments 1,159 576 Contract assets 1,177 2,317 Value added tax 92 59 Finance lease receivables 215 281 22,668 20,987 Trade receivables are shown net of an impairment losses provision of US$3,922,000 (2019: US$5,443,000) (see Note 29). Prepayments are shown net of impairment of US$562,000 (2019: US$1,376,000) (see Note 7). Contract assets have decreased compared to the prior year as the Group shipped less product to customers with cost per test contracts in the last part of the year. Long-term contract receivable (i) Finance lease commitments – Group as lessor The Group leases instruments as part of its business. Future minimum receivables with non-cancellable terms are as follows: December 31, 2020 US$‘000 Gross Unearned Minimum Less than one year 415 200 215 Between one and five years (Note 16) 591 300 291 1,006 500 506 December 31, 2019 US$‘000 Gross Unearned Minimum Less than one year 523 242 281 Between one and five years (Note 16) 805 402 403 1,328 644 684 The Group classified future minimum lease receivables between one and five years of US$291,000 (2019: US$403,000) as Other Assets, see Note 16. Under the terms of the lease arrangements, no contingent rents are receivable. (ii) Operating lease commitments – Group as lessor The Group leases instruments under operating leases as part of its business. Future minimum rentals receivable under non-cancellable operating leases are as follows: December 31, 2020 US$‘000 Instruments Total Less than one year 2,767 2,767 Between one and five years 171 171 2,938 2,938 December 31, 2019 US$‘000 Instruments Total Less than one year 3,528 3,528 Between one and five years 27 27 3,555 3,555

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2020
Cash and cash equivalents [abstract]
CASH AND CASH EQUIVALENTS	19. CASH AND CASH EQUIVALENTS December 31, 2020 US$’000 December 31, 2019 US$’000 Cash at bank and in hand 24,209 6,275 Short-term deposits 3,118 8,956 Cash and cash equivalents 27,327 15,231

SHORT-TERM INVESTMENTS

SHORT-TERM INVESTMENTS	12 Months Ended
	Dec. 31, 2020
Disclosure of short-term investments [Abstract]
SHORT-TERM INVESTMENTS	20. SHORT-TERM INVESTMENTS All liquid investments with a maturity greater than six months are considered to be short-term investments. December 31, 2020 US$’000 December 31, 2019 US$’000 Investments (deposits) - 1,169 - 1,169

CAPITAL AND RESERVES

CAPITAL AND RESERVES	12 Months Ended
	Dec. 31, 2020
Disclosure of classes of share capital [abstract]
CAPITAL AND RESERVES	21. CAPITAL AND RESERVES Share capital Class ‘A’ Class ‘A’ In thousands of shares 2020 2019 In issue at January 1 96,162 96,162 Issued for cash - - In issue at December 31 96,162 96,162 ADS ADS In thousands of ADSs 2020 2019 Balance at January 1 24,041 24,041 Issued for cash - - Balance at December 31 24,041 24,041 Class ‘A’ Class ‘A’ In thousands of shares 2020 2019 Balance at January 1 12,556 12,556 Purchased during the year - - Balance at December 31 12,556 12,556 ADS Treasury shares ADS Treasury shares In thousands of ADSs 2020 2019 Balance at January 1 3,139 3,139 Purchased during the year - - Balance at December 31 3,139 3,139 The Group had authorised share capital of 200,700,000 ‘A’ ordinary shares of US$0.0109 each (2019: 200,700,000 ‘A’ ordinary shares of US$0.0109 each) as at December 31, 2020. The Group did not issue any shares from the exercise of employee options and did not repurchase any ‘A’ ordinary shares under its share buyback program in either 2019 or 2020. No dividends have been paid in the last five years. The last dividend paid was in respect of the 2014 financial year. Translation reserve The translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of foreign currency denominated operations of the Group since January 1, 2004. Hedging reserve The hedging reserve comprises the effective portion of the cumulative net change in the fair value of cash flow hedging instruments related to hedged transactions entered into but not yet crystallised. The hedging reserve is shown within Other Reserves in the Consolidated Statement of Financial Position. Treasury shares During 2020, the Group did not purchase any (2019: nil) (2018: 107,740) ‘A’ Ordinary shares (2019: nil ADS’s) (2018: 26,935 ADS’s) ‘Treasury shares’. The total cost of these shares in 2018 was US$139,000.

SHARE OPTIONS

SHARE OPTIONS	12 Months Ended
	Dec. 31, 2020
Disclosure of share options [Abstract]
SHARE OPTIONS	22. SHARE OPTIONS Options Under the terms of the Company’s Employee Share Option Plans, options to purchase 19,485,990 ‘A’ Ordinary Shares (4,871,497 ADS’s) were outstanding at December 31, 2020. Under these Plans, options are granted to officers, employees and consultants of the Group at the discretion of the Compensation Committee (designated by the Board of Directors), under the terms outlined below. Certain options have been granted to consultants of the Group and, where this is the case, the Group has measured the fair value of the services provided by these consultants by reference to the fair value of the equity instruments granted. This approach has been adopted in these cases as it is impractical for the Group to reliably estimate the fair value of such services. The terms and conditions of the grants are as follows, whereby all options are settled by physical delivery of shares: Vesting conditions The options vest following a period of service by the officer or employee. The required period of service is determined by the Board and Remuneration Committee at the date of grant of the options (usually the date of approval by the Compensation Committee) and it is generally over a three to four-year period. There are no market conditions associated with the share option vesting periods. Contractual life The term of an option is determined by the Board, Compensation Committee and Remuneration Committee provided that the term may not exceed a period of between seven to ten years from the date of grant. All options will terminate 90 days after termination of the option holder’s employment, service or consultancy with the Group (or one year after such termination because of death or disability) except where a longer period is approved by the Board of Directors. Under certain circumstances involving a change in control of the Group, the Compensation Committee may accelerate the exercisability and termination of options. The number and weighted average exercise price of share options and warrants per ordinary share is as follows (as required by IFRS 2, this information relates to all grants of share options and warrants by the Group): Options and Weighted- US$ Range US$ ‘A’ Ordinary Per ‘A’ Ordinary Share Per ‘A’ Ordinary Outstanding January 1, 2018 10,727,376 1.92 1.24 –4.36 Granted 720,000 1.07 0.67 –1.37 Exercised - - - Forfeited (539,176 ) 2.50 1.34 –4.23 Outstanding at end of year 10,908,200 1.83 0.67 –4.36 Exercisable at end of year 6,091,864 2.09 1.24 –4.36 Outstanding January 1, 2019 10,908,200 1.83 0.67 –4.36 Granted 4,370,000 0.68 0.46 –0.78 Exercised - - - Expired / Forfeited (2,974,210 ) 2.25 0.66 –4.23 Outstanding at end of year 12,303,990 1.31 0.46 –4.36 Exercisable at end of year 6,622,667 1.73 1.24 –4.36 Outstanding January 1, 2020 12,303,990 1.31 0.46 –4.36 Granted 9,100,000 0.38 0.19 –1.10 Exercised - - - Expired / Forfeited (1,918,000 ) 2.14 0.19-4.21 Outstanding at end of year 19,485,990 0.79 0.19-4.36 Exercisable at end of year 7,959,323 1.27 0.66-4.36 Options and Weighted- US$ Range US$ ‘ADS’ Equivalent Per ‘ADS’ Per ‘ADS’ Outstanding January 1, 2018 2,681,844 7.69 4.96 - 17.44 Granted 180,000 4.28 2.68 – 5.48 Exercised - - - Expired / Forfeited (134,794 ) 10.00 5.36 – 16.92 Outstanding at end of year 2,727,050 7.32 2.68–17.44 Exercisable at end of year 1,522,966 8.36 4.96 –17.44 Outstanding January 1, 2019 2,727,050 7.32 2.68–17.44 Granted 1,092,500 2.72 1.83 - 3.10 Exercised - - - Expired / Forfeited (743,552 ) 8.99 2.64 – 16.92 Outstanding at end of year 3,075,998 5.24 1.83 – 17.45 Exercisable at end of year 1,655,667 6.92 4.95 –17.45 Outstanding January 1, 2020 3,075,998 5.24 1.83 – 17.45 Granted 2,275,000 1.52 0.77-4.41 Exercised - - - Expired / Forfeited (479,500 ) 8.56 0.77-16.84 Outstanding at end of year 4,871,498 3.15 0.77-17.45 Exercisable at end of year 1,989,831 5.08 2.64-17.45 There were no share options exercised during 2020, 2019 or 2018. The opening share price per ‘A’ Ordinary share at the start of the financial year was US$0.27 or US$1.07 per ADS (2019: US$0.57 or US$2.29 per ADS) (2018: US$1.28 or US$5.10 per ADS) and the closing share price at December 31, 2020 was US$0.95 or US$3.81 per ADS (2019: US$0.26 or US$1.03 per ADS) (2018: US$0.57 or US$2.29 per ADS). The average share price for the year ended December 31, 2019 was US$0.52 per ‘A’ Ordinary share or US$2.06 per ADS. A summary of the range of prices for the Company’s stock options for the year ended December 31, 2020 follows: Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.19-US$0.99 13,260,006 0.48 4.14 2,106,673 0.69 1.44 US$1.00-US$2.05 5,664,000 1.34 1.11 5,290,667 1.35 2.44 US$2.06- US$2.99 499,984 2.52 0.05 499,984 2.52 0.13 US$3.00 -US$4.36 62,000 4.17 0.00 62,000 4.17 0.01 19,485,990 7,959,324 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0. 77 -US$3.96 3,315,002 1.92 4.17 526,668 2.76 1.44 US$4.00-US$8.20 1,416,000 5.36 1.10 1,322,667 5.40 2.44 US$8.24- US$11.96 124,996 10.08 0.05 124,996 10.08 0.13 US$12.00 -US$17.45 15,500 16.68 0.00 15,500 16.68 0.01 4,871,498 1,989,831 A summary of the range of prices for the Company’s stock options for the year ended December 31, 2019 follows: Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.46-US$0.99 4,600,000 0.69 6.42 - - - US$1.00-US$2.05 5,613,990 1.35 4.69 4,542,667 1.34 4.68 US$2.06- US$2.99 1,980,000 2.48 3.13 1,970,000 2.48 3.13 US$3.00 -US$4.36 110,000 4.19 2.07 110,000 4.19 2.07 12,303,990 6,622,667 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US1.84-US$3.96 1,150,000 2.75 6.42 0 0.00 0.00 US4.00-US$8.20 1,403,498 5.40 4.69 1,135,667 5.38 4.68 US8.24- US$11.96 495,000 9.92 3.13 492,500 9.91 3.13 US12.00 -US$17.45 27,500 16.75 2.07 27,500 16.75 2.07 3,075,998 1,655,667 The weighted-average remaining contractual life of options outstanding at December 31, 2020 was 5.32 years (2019: 5.06 years). Charge for the year under IFRS 2 The charge for the year is calculated based on the fair value of the options granted which have not yet vested. The fair value of the options is expensed over the vesting period of the option. US$792,000 was charged to the statement of operations in 2020, (2019: US$758,000), (2018: US$1,369,000) split as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Share-based payments – cost of sales 12 26 34 Share-based payments – selling, general and administrative 780 732 1,335 Total – continuing operations 792 758 1,369 Share-based payments – discontinued operations - - - Total 792 758 1,369 The total share based payments charge for the year was US$816,000 (2019: US$839,000) (2018: US$1,607,000). However, a total of US$24,000 (2019: US$80,000) (2018: US$238,000) of share based payments was capitalised in intangible development project assets during the year. The fair value of services received in return for share options granted are measured by reference to the fair value of share options granted. The estimate of the fair value of services received is measured based on a trinomial model. The following are the input assumptions used in determining the fair value of share options granted in 2020, 2019 and 2018: Key management personnel Other employees Key management personnel Other employees Key management personnel Other employees 2020 2020 2019 2019 2018 2018 Weighted average fair value at measurement date per ‘A’ share / (per ADS) US$0.20 / (US$0.80 ) US$0.27 / (US$1.08 ) US$0.14 / (US$0.56 ) US$0.25 / (US$1.02 ) - US$0.41 / (US$1.64 ) Total ‘A’ share options granted / (ADS’s equivalent) 8,480,000 / (2,120,000 ) 620,000 / (155,000 ) 4,060,000 / (1,015,000 ) 310,000 / (77,500 ) - 720,000 / (180,000 ) Weighted average share price per ‘A’ share / (per ADS) US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) US$0.46 /(US$1.84 ) US$0.64 /(US$2.53 ) - US$1.07 /(US$4.28 ) Weighted average exercise price per ‘A’ share / (per ADS) US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) US$0.69 /(US$2.74 ) US$0.64 /(US$2.53 ) - US$1.07 /(US$4.28 ) Weighted average expected volatility 66.98 % 65.89 % 51.18 % 47.31 % - 42.69 % Weighted average expected life 4.34 4.35 4.15 4.42 - 4.55 Weighted average risk free interest rate 0.44 % 0.42 % 1.84 % 2.23 % - 2.72 % The expected life of the options is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility is based on the historic volatility (calculated based on the expected life of the options). The Group has considered how future experience may affect historical volatility. The profile and activities of the Group are not expected to change in the immediate future and therefore Trinity Biotech would expect estimated volatility to be consistent with historical volatility.

TRADE AND OTHER PAYABLES

TRADE AND OTHER PAYABLES	12 Months Ended
	Dec. 31, 2020
Trade and other current payables [abstract]
TRADE AND OTHER PAYABLES	23. TRADE AND OTHER PAYABLES December 31, 2020 US$’000 December 31, 2019 US$’000 Trade payables 7,103 7,833 Payroll taxes 688 519 Employee related social insurance 344 170 Accruals and other liabilities 8,850 8,133 Deferred income 4,445 292 Government COVID-19 loans (Note 4) 2,905 - 24,335 16,947 Deferred income has increased in 2020 due to a change in the product mix and customer type, which created more uncertainty when applying IFRS 15 and in turn resulted in a higher deferral of income (for more information on the deferral of revenue, refer to Note 32, Revenue Recognition). Government COVID-19 loans comprises funding received under the U.S. government’s Cares Act, specifically its Paycheck Protection Program. Two out of six Paycheck Protection Program (“PPP”) loans received by the Company, amounting to US$1,615,000, were forgiven during the year. The four loans which remained unforgiven at year end, totaling US$2,905,000, are treated as short term liabilities at December 31, 2020. Three of these loans were 100% forgiven in early 2021 and we are in the process of seeking forgiveness for the final remaining PPP loan which amounts to US$244,000. Accruals and other liabilities includes US$194,000 (2019: US$1,307,000) relating to contracted licence payments and US$177,000, a related party current liability for the benefit of Ronan O’Caoimh (refer to Note 28 for more information).

PROVISIONS

PROVISIONS	12 Months Ended
	Dec. 31, 2020
Provisions [abstract]
PROVISIONS	24. PROVISIONS December 31, 2020 US$’000 December 31, 2019 US$’000 Product warranty provision 50 50 Other provisions 366 - 416 50 During 2020 and 2019 the Group experienced no significant product warranty claims. However, the Group believes that it is appropriate to retain a product warranty provision to cover any future claims. The provision at December 31, 2020 represents the estimated cost of product warranties, the exact amount which cannot be determined. US$50,000 represents management’s best estimate of these obligations at December 31, 2020. The increase in provisions mainly reflects outstanding obligations relating to vacated leasehold properties and other potential obligations to third parties.

EXCHANGEABLE NOTES AND OTHER BO

EXCHANGEABLE NOTES AND OTHER BORROWINGS	12 Months Ended
	Dec. 31, 2020
Borrowings [abstract]
EXCHANGEABLE NOTES AND OTHER BORROWINGS	25. EXCHANGEABLE NOTES AND OTHER BORROWINGS The carrying value of exchangeable senior notes and other borrowings is as follows: December 31, US$’000 December 31, US$’000 Exchangeable senior notes 82,664 82,021 Other borrowings 31 - Total value of embedded derivatives – liability 1,370 4 Total non-current liabilities 84,065 82,025 Exchangeable senior notes The Group issued US$115,000,000 of exchangeable senior notes in 2015, which will mature on April 1, 2045, subject to earlier repurchase, redemption or exchange. The notes are senior unsecured obligations and accrue interest at an annual rate of 4%, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2015. The notes are convertible into ordinary shares of the parent entity at the applicable exchange rate, at any time prior to the close of business on the second business day immediately preceding the maturity date, at the option of the holder, or repayable on April 1, 2045. The conversion rate is 47.112 ADSs per $1,000 principal amount of notes, equivalent to an exchange price of approximately $21.88 per ADS. The exchange rate is subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued and unpaid interest. The notes include a number of non-financial covenants, all of which were complied with at December 31, 2020. In August 2018, the Group purchased US$15,100,000 of the exchangeable notes, at a rate of 79.75 cents in the Dollar. The amount paid was US$12,042,000 plus accrued interest of US$205,000. The gain on the purchase was US$463,000 and this was shown within selling, general and administrative expenses in the statement of operations for the year ended December 31, 2018. The nominal amount of the debt after the purchase is US$99,900,000. The movement in the Exchangeable senior notes is as follows: December 31, US$’000 December 31, US$’000 Balance at 1 January 82,021 81,382 Accretion interest (Note 8) 643 639 82,664 82,021 Embedded derivatives The notes include a number of put and call options, and these embedded derivatives are measured at fair value through the Consolidated Statement of Operations. The first date on which holders can exercise their put option is April 1, 2022. If the put option is exercised, the issuer has to repurchase the notes at par. The exchangeable notes are treated as a host debt instrument with embedded derivatives attached. On initial recognition, the host debt instrument is recognised at the residual value of the total net proceeds of the bond issue less fair value of the embedded derivatives. Subsequently, the host debt instrument is measured at amortised cost using the effective interest rate method. The embedded derivatives are summarised as follows: December 31, US$’000 December 31, US$’000 Non-current assets Exchangeable note bond call option 150 - Non-current liabilities Exchangeable note equity conversion option 1,370 4 Exchangeable note bond put option - - 1,370 4 Total value of embedded derivatives – net liability 1,220 4 Financial expense in the consolidated statement of operations for the year includes US$1,216,000 (2019 financial income: US$233,000) arising from the revaluation of embedded derivatives at fair value at December 31, 2020. This liability will accrete back to its nominal value of US$99,900,000 at the end of the full term of the debt maturity in 2045 using an effective interest rate methodology. Financial expense in the consolidated statement of operations for the year includes US$643,000 (2019: US$639,000) of accretion interest. Other borrowings Other borrowings relates to an interest-free loan received under the Canada Emergency Business Account (“CEBA”). The CEBA loans were provided by the Canadian Government to mitigate the financial impact of the Covid-19 outbreak. This interest-free loan is repayable by December 31, 2022.

LEASE LIABILITIES

LEASE LIABILITIES	12 Months Ended
	Dec. 31, 2020
Disclosure of finance lease liabilities [Abstract]
LEASE LIABILITIES	26. LEASE LIABILITIES The Group has leases for some of its manufacturing plants, all warehouses, offices, motor vehicles and some IT equipment. With the exception of short-term leases and leases of low-value underlying assets, each lease is reflected on the balance sheet as a right-of-use asset (net of any depreciation and/or impairment) and a lease liability. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 13). Each lease generally imposes a restriction that, unless there is a contractual right for the Group to sublet the asset to another party, the right-of-use asset can only be used by the Group. Leases are either non-cancellable or may only be cancelled by incurring a substantive termination fee. Some leases contain an option to purchase the underlying leased asset outright at the end of the lease, or to extend the lease for a further term. The Group is prohibited from selling or pledging the underlying leased assets as security. For leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. Further, the Group must insure items of property, plant and equipment and incur maintenance fees on such items in accordance with the lease contracts. Lease liabilities Lease liabilities are payable as follows: December 31, 2020 US$’000 December 31, 2019 US$’000 Current liabilities Lease liabilities related to Right of Use assets 2,054 2,156 Sale and leaseback liabilities 99 248 2,153 2,404 Non-Current liabilities Lease liabilities related to Right of Use assets 16,407 17,474 Sale and leaseback liabilities 181 271 16,588 17,745 December 31, 2020 US$’000 December 31, 2020 US$’000 Lease liabilities related to Right of Use assets Sale and leaseback liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 2,877 823 2,054 111 12 99 In more than one year, but not more than two 2,644 730 1,914 111 7 104 In more than two years but not more than five 6,621 1,765 4,856 79 2 77 more than five years 11,389 1,752 9,637 - - - 23,531 5,070 18,461 301 21 280 December 31, 2019 US$’000 December 31, 2019 US$’000 Lease liabilities related to Right of Use assets Sale and leaseback liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 3,017 861 2,156 267 19 248 In more than one year, but not more than two 2,787 775 2,012 107 12 95 In more than two years but not more than five 6,700 1,861 4,840 185 9 176 more than five years 12,748 2,126 10,622 - - - 25,252 5,263 19,630 559 40 519 The reconciliation of operating lease commitments at December 31, 2018 to the additional lease liabilities recognized on the initial application of IFRS 16 at January 1, 2019 is as follows: US$000 Operating Lease commitments at December, 31, 2018 (Note 27) 27,342 Relief option for short term leases (130 ) Relief option for low value assets - Effect of assumed probable lease extension in adoption of IFRS 16 573 Other (149 ) Gross lease liabilities at January 1, 2019 27,636 Discounting (6,451 ) Additional Lease liabilities as a result of the initial application of IFRS 16 at January 1, 2019 21,185 The lease liabilities were discounted at the incremental borrowing rate as at January 1, 2019. The weighted average discount rate was 5.0%. Lease payments not recognised as a liability No short term lease expenses were incurred for the year ended December 31, 2020. In 2019 the Group elected not to recognise a lease liability for short term leases (leases with an expected term of 12 months or less) or for leases of low value assets. Payments made under such leases are expensed on a straight-line basis. In addition, certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred. The expense relating to payments not included in the measurement of the lease liability is as follows: December 31, 2020 December 31, 2019 US$000 US$000 Short term leases - 130 Leases of low value assets - - Variable lease payments - - - 130 Terms and debt repayment schedule The terms and conditions of outstanding interest bearing loans and borrowings at December 31, 2020 are as follows: Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities Euro 4.53 % 2023 106 106 Sale and leaseback liabilities USD 5.51 % 2023 174 174 Total interest-bearing loans and borrowings 280 280 The terms and conditions of outstanding interest bearing loans and borrowings at December 31, 2019 are as follows: Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities Euro 4.53 % 2023 286 286 Sale and leaseback liabilities USD 5.51 % 2023 233 233 Total interest-bearing loans and borrowings 519 519 The total paid in respect of lease liabilities in the year ended December 31, 2020 was US$3,240,000 (2019: US$3,533,000).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2020
Disclosure of commitments and contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	27. COMMITMENTS AND CONTINGENCIES (a) Capital Commitments The Group has capital commitments authorised and contracted for of US$156,000 as at December 31, 2020 (2019: US$323,000). (b) Leasing Commitments The Group’s leasing commitments are shown in Note 26. (c) Bank Security At December 31, 2020, the Group’s sale and leaseback borrowings were at fixed rates of interest and consisted Euro and USD denominated borrowings, refer to Note 29. The banks providing the financing have a charge over the equipment for which the borrowing pertains. (d) Group Company Guarantees Pursuant to the provisions of Section 357, Irish Companies Act, 2014, the Company has guaranteed the liabilities of Trinity Biotech Manufacturing Limited, Trinity Research Limited, Benen Trading Limited and Trinity Biotech Financial Services Limited subsidiary undertakings in the Republic of Ireland, for the financial year to December 31, 2020 and, as a result, these subsidiary undertakings have been exempted from the filing provisions of Section 357, Irish Companies Act, 2014. Where the Company enters into these guarantees of the indebtedness of other companies within its Group, the Company considers these to be insurance arrangements and accounts for them as such. The Company treats the guarantee contract as a contingent liability until such time as it becomes probable that the company will be required to make a payment under the guarantee. The Company does not enter into financial guarantees with third parties. (e) Contingent In the 2019 financial statements, a contingent asset of US$1,231,000 was disclosed in connection with the 2019 tax audit settlement payable by Darnick Company. This balance was settled in the year ended December 31, 2020 and has been credited to the Statement of Operations within Selling, General and Administrative Expenses. The underlying amount was denominated in Euro. Due to a depreciation in the US Dollar since 2019, the US Dollar equivalent amount increased from US$1,231,000 to US$1,316,000. The settlement amount received by the Company was US$177,000 more than the balance owed and this overpayment is recorded as a related party current liability for the benefit of Ronan O’Caoimh as at December 31, 2020. The amount was settled by the Group in January 2021. There are no contingent assets as of December 31, 2020. (f) Government Grant Contingencies The Group has received training and employment grant income from Irish development agencies. Subject to existence of certain conditions specified in the grant agreements, this income may become repayable. No such conditions existed as at December 31, 2020. However, if the income were to become repayable, the maximum amounts repayable as at December 31, 2020 would amount to US$3,130,000 (2019: US$2,834,000). The Company also received funds from the U.S. government as part of its Paycheck Protection Program in 2020. A total of US$4,520,000 was received under this program. As at December 31, 2020, US$1,615,000 of the loans had been forgiven, as referenced in Note 4. The four loans which remained unforgiven at year end, totaling US$2,905,000, are treated as short term liabilities at December 31, 2020. Three of these loans were 100% forgiven in early 2021 and we are in the process of seeking forgiveness for the final remaining PPP loan which amounts to US$244,000. The maximum amounts repayable as at December 31, 2020 would amount to US$2,905,000 and this contingent liability has been recorded on the balance sheet at December 31, 2020. (g) Other Contingencies The Company has other contingencies primarily relating to claims and legal proceedings, onerous contracts, product warranties and employee related provisions. The status of each significant claim and legal proceeding in which the Company is involved is reviewed by management on a periodic basis and the Group’s potential financial exposure is assessed. If the potential loss from any claim or legal proceeding is considered probable, and the amount can be reliably estimated, a liability is recognised for the estimated loss. Because of the uncertainties inherent in such matters, the related provisions are based on the best information available at the time; the issues taken into account by management and factored into the assessment of legal contingencies include, as applicable, the status of settlement negotiations, interpretations of contractual obligations, prior experience with similar contingencies/claims, and advice obtained from legal counsel and other third parties. The Group expects the majority of these provisions will be utilised within one to three years of the balance sheet date; however due to the nature of the legal provisions there is a level of uncertainty in the timing of settlement as the Group generally cannot determine the extent and duration of the legal process.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2020
Disclosure of transactions between related parties [abstract]
RELATED PARTY TRANSACTIONS	28. RELATED PARTY TRANSACTIONS The Group has related party relationships with its subsidiaries, and with its directors and executive officers. Leasing arrangements with related parties The Group has entered into various arrangements with JRJ Investments (“JRJ”), a partnership owned by Mr O’Caoimh and Dr Walsh, directors of Trinity Biotech, and directly with Mr O’Caoimh, to provide for current and potential future needs to extend its premises at IDA Business Park, Bray, Co. Wicklow, Ireland. The Group has entered into an agreement for a 25-year lease with JRJ for offices that adjacent to its then premises at IDA Business Park, Bray, Co. Wicklow, Ireland. The annual rent of €381,000 (US$466,000) is payable from January 1, 2004. Upward-only rent reviews are carried out every five years and there have been no increases arising from these rent reviews. The Group has also entered into lease agreements with Ronan O’Caoimh for a 43,860 square foot manufacturing facility in Bray, Ireland and an adjacent warehouse of 16,000 square feet. The annual rent for the manufacturing facility is €787,000 (US$961,000) and the annual rent for the warehouse is €144,000 (US$176,000). These two leases expire in 2028 and 2026 respectively. At the time, independent valuers advised the Group that the rent in respect of each of the leases represents a fair market rent. Upward-only rent reviews are carried out every five years and there have been no increases arising from these rent reviews. Towards the end of 2020, the Group occupied some additional space adjoining the warehouse. This is a short term arrangement and no payments were made to Ronan O’Caoimh for the additional space during 2020. A sum of US$20,000 was accrued for rent payable to Mr O’Caoimh in relation to this additional space. Trinity Biotech and its directors (excepting Mr O’Caoimh and Dr Walsh who express no opinion on this point) believe at the time that the arrangements entered into represent a fair and reasonable basis on which the Group can meet its ongoing requirements for premises. Dr Walsh has no ownership interest in the additional space adjoining the warehouse owned by Mr O’Caoimh and was therefore entitled to express an opinion on this arrangement. Compensation of key management personnel of the Group At December 31, 2020, 2019 and 2018 the key management personnel of the Group were made up of four key personnel: the four executive directors; Mr Ronan O’Caoimh and Dr Jim Walsh and Mr Kevin Tansley and our Chief Financial Officer Mr John Gillard. In November 2020, the Group announced that John Gillard was to replace Kevin Tansley as Chief Financial Officer. Compensation for the year ended December 31, 2020 of these personnel is detailed below: December 31, 2020 December 31, 2019 US$’000 US$’000 Short-term employee benefits 1,274 800 Performance related bonus 584 213 Post-employment benefits 41 42 Share-based compensation benefits 626 542 2,525 1,597 The amounts disclosed in respect of directors’ emoluments in Note 11 includes non-executive directors’ fees of US$162,000 (2019: US$225,000) and share-based compensation benefits of US$51,000 (2019: US$82,000). Total directors’ remuneration is also included in “personnel expenses” (Note 3) and “loss before tax” (Note 11). In 2020, share-based compensation benefits included in Note 11 exclude capitalised amounts of US$Nil (2019: US$35,000). The performance bonuses for Mr. O’Caoimh and Mr. Tansley in respect of fiscal year 2020 have been accrued as at December 31, 2020. Directors’ interests in the Company’s shares and share option plan ‘A’ Ordinary Shares Share options At January 1, 2020 9,077,706 10,414,004 Shares of retired director — — Options of retired director — — Shares purchased during the year — — Shares sold during the year — — Granted — 8,480,000 Expired / forfeited — (1,500,000 ) At December 31, 2020 9,077,706 17,394,004 ‘A’ Ordinary Shares Share options At January 1, 2019 9,139,706 8,655,004 Shares of retired director (30,000 ) — Options of retired director — (215,000 ) Shares purchased during the year — — Shares sold during the year (32,000 ) — Granted — 4,060,000 Expired / forfeited — (2,086,000 ) At December 31, 2019 9,077,706 10,414,004 Rayville Limited, an Irish registered company, which is wholly owned by three executive directors and certain other former executives of the Group, owns all of the ‘B’ non-voting Ordinary Shares in Trinity Research Limited, one of the Group’s subsidiaries. The ‘B’ shares do not entitle the holders thereof to receive any assets of the company on a winding up. All of the ‘A’ voting ordinary shares in Trinity Research Limited are held by the Group. Trinity Research Limited may, from time to time, declare dividends to Rayville Limited and Rayville Limited may declare dividends to its shareholders out of those amounts. Any such dividends paid by Trinity Research Limited are ordinarily treated as a compensation expense by the Group in the consolidated financial statements prepared in accordance with IFRS, notwithstanding their legal form of dividends to minority interests, as this best represents the substance of the transactions. The last dividend paid by Trinity Research Limited to Rayville Limited was in June 2009 for US$2,830,000. At the time this amount was immediately lent back by Rayville Limited to Trinity Research Limited. Since then US$1,788,000 of these loans have been repaid and recognised as a compensation expense by the Group. As of December 31, 2019 and December 31, 2020, the remaining amount of the loan was US$1,042,000. As this remaining amount of the original dividend is matched by a loan from Rayville Limited to Trinity Research Limited which is repayable solely at the discretion of the Remuneration Committee of the Board and is unsecured and interest free, the Group netted the dividend paid to Rayville Limited against the corresponding loan from Rayville Limited in the 2019 and 2020 consolidated financial statements. During 2019, Trinity Research Limited repaid loans to Rayville Limited of US$159,000 in order to meet its obligations under a tax settlement arising from a tax audit. As described in Note 6, in the year ended December 31, 2019 a tax audit settlement was reached which included the payment of US$3,863,000 in relation to payments made by Trinity Research Limited to Rayville Limited and US$1,231,000 in relation to payments for CEO services made to Darnick Company. Darnick Company agreed to contribute US$1,231,000 to the above settlement and this amount was outstanding at December 31, 2019 and was treated as a contingent asset and not recognised in the consolidated statement of financial position at December 31, 2019 (refer to Note 27). This balance was settled in the year ended December 31, 2020 and has been credited to the Statement of Operations within Selling, General and Administrative Expenses. The underlying amount was denominated in Euro. Due to a depreciation in the US Dollar since 2019, the US Dollar equivalent amount increased from US$1,231,000 to US$1,316,000. The settlement amount received by the Company was US$177,000 more than the balance owed and this overpayment is recorded as a related party current liability for the benefit of Ronan O’Caoimh as at December 31, 2020. The amount was settled by the Group in January 2021.

CAPITAL AND FINANCIAL RISK MANA

CAPITAL AND FINANCIAL RISK MANAGEMENT	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
CAPITAL AND FINANCIAL RISK MANAGEMENT	29. CAPITAL AND FINANCIAL RISK MANAGEMENT Capital Management The Group’s policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The Board of Directors monitors earnings per share as a measure of performance, which the Group defines as profit after tax divided by the weighted average number of shares in issue. At December 31, 2020 the Group has no bank debt (excluding government-backed COVID-19 loans), it maintains a relationship with a number of lending banks and Trinity Biotech is listed on the NASDAQ, which allows the Group to potentially raise funds through equity financing. In 2015, the Group raised US$115,000,000 through the issuance of 30 year exchangeable senior notes. In 2018 the Group repurchased $15,100,000 of the exchangeable senior notes. The remaining exchangeable senior notes which will mature on April 1, 2045, subject to earlier repurchase, redemption or exchange, the earliest which is April 1, 2022. Fair Values The table below sets out the Group’s classification of each class of financial assets/liabilities, their fair values and under which valuation method they are valued: Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2020 Loans and receivables at amortised cost Trade receivables 18 20,025 — 20,025 20,025 Cash and cash equivalents 19 27,327 — 27,327 27,327 Finance lease receivable 16, 18 506 — 506 506 47,858 — 47,858 47,858 Liabilities at amortised cost Exchangeable note 25 — (82,664 ) (82,664 ) (82,664 ) Lease liabilities 26 (18,741 ) — (18,741 ) (18,741 ) Trade and other payables (excluding deferred income) 23 (19,890 ) — (19,890 ) (19,890 ) Provisions 24 (416 ) — (416 ) (416 ) (39,047 ) (82,664 ) (121,711 ) (121,711 ) Fair value through profit and loss (FVPL) Exchangeable note bond call option 25 — 150 150 150 Exchangeable note equity conversion option 25 — (1,370 ) (1,370 ) (1,370 ) — (1,220 ) (1,220 ) (1,220 ) 8,811 (83,884 ) (75,073 ) (75,073 ) For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data. Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2019 Loans and receivables at amortised cost Trade receivables 18 17,754 — 17,754 17,754 Cash and cash equivalents 19 15,231 — 15,231 15,231 Investments (deposits) 20 1,169 — 1,169 1,169 Finance lease receivable 16,18 684 — 684 684 34,838 — 34,838 34,838 Liabilities at amortised cost Exchangeable note 25 — (82,021 ) (82,021 ) (82,021 ) Lease liabilities 26 (20,149 ) — (20,149 ) (20,149 ) Trade and other payables (excluding deferred income) 23 (16,655 ) — (16,655 ) (16,655 ) Provisions 24 (50 ) — (50 ) (50 ) (36,854 ) (82,021 ) (118,875 ) (118,875 ) Fair value through profit and loss (FVPL) Exchangeable note equity conversion option 25 — (4 ) (4 ) (4 ) — (4 ) (4 ) (4 ) (2,016 ) (82,025 ) (84,041 ) (84,041 ) The valuation techniques used for instruments categorised as level 2 are described below: The fair values of the options associated with the exchangeable notes are calculated in consultation with third-party valuation specialists due to the complexity of their nature. There are a number of inputs utilised in the valuation of the options, including share price, historical share price volatility, risk-free rate and the expected borrowing cost spread over the risk-free rate. Financial Risk Management The Group uses a range of financial instruments (including cash, finance leases, receivables, payables and derivatives) to fund its operations. These instruments are used to manage the liquidity of the Group. Working capital management is a key additional element in the effective management of overall liquidity. The Group does not trade in financial instruments or derivatives. The main risks arising from the utilization of these financial instruments are interest rate risk, liquidity risk and credit risk. Interest rate risk Effective and repricing analysis The following table sets out all interest-earning financial assets and interest bearing financial liabilities held by the Group at December 31, indicating their effective interest rates and the period in which they re-price: As at December 31, 2020 Note Effective interest Total US$’000 6 mths or less US$’000 6 –12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 19 0.1 % 27,327 27,327 — — — — Lease receivable 16,18 4.0 % 506 120 95 142 149 — Licence payments 23 8.1 % (194 ) (194 ) — — — — Exchangeable note 25 4.8 % (82,664 ) — — — — (82,664 ) Other borrowings 25 0 % (31 ) — — (31 ) — — Lease payable on Right of Use assets 26 5.0 % (18,461 ) (1,022 ) (1,032 ) (1,914 ) (4,856 ) (9,637 ) Lease payable on sale & leaseback transactions 26 5.0 % (280 ) (49 ) (50 ) (104 ) (77 ) — Total (73, 797 ) 26,182 (987 ) (1,907 ) (4,784 ) (92,301 ) As at December 31, 2019 Note Effective interest Total US$’000 6 mths or less US$’000 6 –12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 19 1.1 % 15,231 15,231 — — — — Short-term investments 20 1.3 % 1,169 — 1,169 — — — Lease receivable 16,18 4.0 % 684 157 124 202 201 — Licence payments 23 8.1 % (1,307 ) (1,307 ) — — — — Exchangeable note 25 4.8 % (82,021 ) — — — — (82,021 ) Lease payable on Right of Use assets 26 5.0 % (19,630 ) (1,136 ) (1,020 ) (2,012 ) (4,840 ) (10,622 ) Lease payable on sale & leaseback transactions 26 5.0 % (519 ) (122 ) (125 ) (95 ) (177 ) — Total (86,393 ) 12,823 148 (1,905 ) (4,816 ) (92,643 ) In broad terms, a one-percentage point increase in interest rates would increase interest income by US$31,000 (2019: US$101,000) and would not affect the interest expense (2019: nil) resulting in an increase in net interest income of US$31,000 (2019: increase in net interest income of US$101,000). Interest rate profile of financial assets / liabilities The interest rate profile of financial assets/liabilities of the Group was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 Fixed rate instruments Fixed rate financial liabilities (licence fees) (194 ) (1,307 ) Fixed rate financial liabilities (exchangeable note) (82,664 ) (82,021 ) Fixed rate financial liabilities (borrowings) (31 ) — Fixed rate financial liabilities (lease payables) (18,741 ) (20,149 ) Financial assets (short-term deposits and short-term investments) 3,118 10,125 Financial assets (lease receivables) 506 684 (98,006 ) (92,668 ) Financial assets comprise cash and cash equivalents and short-term investments as at December 31, 2020 and December 31, 2019 (see Note 19 and 20). Fair value sensitivity analysis for fixed rate instruments The Group does not account for any fixed rate financial liabilities at fair value through profit and loss. Therefore, a change in interest rates at December 31, 2020 would not affect profit or loss. There was no significant difference between the fair value and carrying value of the Group’s trade receivables and trade and other payables at December 31, 2020 and December 31, 2019 as all fell due within 6 months. Liquidity risk The Group’s operations were cash generating in the year to December 31, 2020. Short-term flexibility is achieved through the management of the Group’s short-term deposits. The following are the contractual maturities of financial liabilities, including estimated interest payments: As at December 31, 2020 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 24,335 24,335 24,335 — — — — Lease payable on Right of Use assets 18,461 18,461 1,022 1,032 1,914 4,856 9,637 Lease payable on sale & leaseback transactions 280 280 49 50 104 77 — Other borrowings 31 31 — — 31 — — Exchangeable notes ¹ 82,664 99,900 — — — — 99,900 Exchangeable note interest 999 97,902 1,998 1,998 3,996 11,988 77,922 126,770 240,909 27,404 3,080 6,045 16,921 187,459 ¹ The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045 and does not take into account the potential exercise of put and call options in the next five years. As at December 31, 2019 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 16,947 16,947 16,947 — — — — Lease payable on Right of Use assets 19,630 19,630 1,136 1,020 2,012 4,840 10,622 Lease payable on sale & leaseback transactions 519 519 122 125 95 177 — Exchangeable notes¹ 82,021 99,900 — — — — 99,900 Exchangeable note interest 999 101,898 1,998 1,998 3,996 11,988 81,918 120,116 238,894 20,203 3,143 6,103 17,005 192,440 ¹ The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045 and does not take into account the potential exercise of put and call options in the next five years. Foreign exchange risk The majority of the Group’s activities are conducted in US Dollars. Foreign exchange risk arises from the fluctuating value of the Group’s Euro denominated expenses as a result of the movement in the exchange rate between the US Dollar and the Euro. Arising from this, where considered necessary, the Group pursues a treasury policy which periodically aims to sell US Dollars forward to match a portion of its uncovered Euro expenses at exchange rates lower than budgeted exchange rates. These forward contracts are primarily cashflow hedging instruments whose objective is to cover a portion of these Euro forecasted transactions. Forward contracts normally have maturities of less than one year after the balance sheet date. There were no forward contracts in place as at December 31, 2020. Foreign currency short term financial assets and liabilities which expose the Group to currency risk are disclosed below. The amounts shown are those reported to key management translated into US Dollars at the closing rate: EUR GBP SEK CAD BRL Other As at December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 1,229 152 9 2,859 776 — Trade and other receivable 1,105 63 — 3,191 1,357 — Trade and other payables (2,821 ) (57 ) (1 ) (449 ) (529 ) — Total exposure (487 ) 158 8 5,601 1,604 — As at December 31, 2019 EUR GBP SEK CAD BRL Other US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 394 138 10 3,265 238 — Trade and other receivable 1,247 71 — 337 1,871 — Trade and other payables (2,350 ) (27 ) (142 ) (47 ) (796 ) — Total exposure (709 ) 182 (132 ) 3,555 1,313 — The Group states its forward exchange contracts at fair value in the balance sheet. The Group classifies its forward exchange contracts as hedging forecasted transactions and thus accounts for them as cash flow hedges. There were no forward exchange contracts in place at December 31, 2020 or December 31, 2019. Sensitivity analysis A 10% strengthening of the US Dollar against the Euro at December 31, 2020 would have increased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or loss US$’000 December 31, 2020 Euro 541 December 31, 2019 Euro 2,282 A 10% weakening of the US Dollar against the Euro at December 31, 2020 would have decreased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or Loss US$000 December 31, 2020 Euro (661 ) December 31, 2019 Euro (2,790 ) Credit Risk The Group has no significant concentrations of credit risk. Exposure to credit risk is monitored on an ongoing basis. The Group maintains specific provisions for potential credit losses. To date such losses have been within management’s expectations. Due to the large number of customers and the geographical dispersion of these customers, the Group has no significant concentrations of accounts receivable. With respect to credit risk arising from the other financial assets of the Group, which comprise cash and cash equivalents and deferred consideration, the Group’s exposure to credit risk arises from default of the counter-party, with a maximum exposure equal to the carrying amount of these instruments. The Group’s management considers that all of the above financial assets that are not impaired or past due for each of the 31 December reporting dates under review are of good credit quality. The Group maintains cash and cash equivalents and enters into forward contracts, when necessary, with various financial institutions. The Group performs regular and detailed evaluations of these financial institutions to assess their relative credit standing. The carrying amount reported in the balance sheet for cash and cash equivalents and forward contracts approximate their fair value. Exposure to credit risk The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is as follows: Carrying Value Carrying Value Third party trade receivables (Note 18) 20,025 17,754 Finance lease income receivable (Note 18) 506 684 Cash and cash equivalents (Note 19) 27,327 15,231 Short-term investments (Note 20) - 1,169 47,858 34,838 The maximum exposure to credit risk for trade receivables and finance lease income receivable by geographic location is as follows: Carrying Value Carrying Value United States 10,730 8,647 Euro-zone countries 1,360 786 United Kingdom 98 121 Other European countries 13 7 Other regions 8,330 8,877 20,531 18,438 The maximum exposure to credit risk for trade receivables and finance lease income receivable by type of customer is as follows: Carrying Value Carrying Value End-user customers 11,812 9,453 Distributors 8,186 7,199 Non-governmental organisations 533 1,786 20,531 18,438 Due to the large number of customers and the geographical dispersion of these customers, the Group has no significant concentrations of accounts receivable. Impairment Losses The ageing of trade receivables at December 31, 2020 is as follows: Gross Impairment Expected Credit Loss Rate Gross Impairment Expected Credit Loss Rate 2020 2020 2020 2019 2019 2019 US$’000 US$’000 % US$’000 US$’000 % Not past due 16,754 112 0.7 % 10,924 8 0.1 % Past due 0-30 days 1,829 222 12.1 % 3,743 6 0.2 % Past due 31-120 days 1,755 60 3.4 % 2,115 27 1.3 % Greater than 120 days 3,609 3,528 97.8 % 6,415 5,402 84.2 % 23,947 3,922 — 23,197 5,443 — The movement in the allowance for impairment in respect of trade receivables during the year was as follows: 2020 2019 2018 US$’000 US$’000 US$’000 Balance at January 1 5,443 4,202 3,590 Charged to costs and expenses 166 1,276 682 Amounts written off during the year (1,687 ) (35 ) (70 ) Balance at December 31 3,922 5,443 4,202 The allowance for impairment in respect of trade receivables is used to record impairment losses unless the Group is satisfied that no recovery of the account owing is possible. At this point the amount is considered irrecoverable and is written off against the financial asset directly.

RECONCILIATION OF LIABILITIES A

RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES	12 Months Ended
	Dec. 31, 2020
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES	30. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES The changes in the Group’s liabilities arising from financing activities can be classified as follows: Note Borrowings & derivative financial instruments Lease liabilities Balance at 1 January 2020 25,26 82,025 20,149 Cash-flows: Interest paid (3,996 ) — Proceeds from government Covid-19 loan (Note 25) 31 — Repayment — (3,240 ) Non-cash: Interest charged 3,996 — Additions (related to Right of Use assets) — 224 Disposals¹ — (216 ) Exchange adjustment — 928 Accretion interest 8 643 896 Fair value 1,366 — Balance at 31 December 2020 25,26 84,065 18,741 ¹ Disposal of Lease liabilities relates to the early termination of a lease for a right-of-use building asset in Carlsbad, California. This facility was closed in June 2020. Note Borrowings & derivative financial instruments Lease liabilities Balance at 1 January 2019 25,26 81,620 962 Cash-flows: Interest paid (3,996 ) — Repayment — (3,533 ) Non-cash: Interest charged 3,996 — Adoption of IFRS 16 (Note 13) — 21,185 Additions (related to Right of Use assets) — 679 Exchange adjustment — (91 ) Accretion interest 8 639 947 Fair value (234 ) — Balance at 31 December 2019 25,26 82,025 20,149

POST BALANCE SHEET EVENTS

POST BALANCE SHEET EVENTS	12 Months Ended
	Dec. 31, 2020
Disclosure of post balance sheet events [Abstract]
POST BALANCE SHEET EVENTS	31. POST BALANCE SHEET EVENTS Forgiveness of Paycheck Protection loans In 2020, six of the Group’s subsidiaries located in USA applied for and received loans under the U.S. government’s Paycheck Protection Program (“PPP”). The loans were intended to offer support for businesses during the Covid-19 pandemic and were forgivable subject to meeting certain criteria. Two out of the six PPP loans were forgiven during 2020. The four loans which remained unforgiven at year end, totaling US$2,905,000, are treated as short term liabilities at December 31, 2020. Three of these loans were 100% forgiven in early 2021, amounting to a total of US$2,661,000. We are in the process of seeking forgiveness for the final remaining PPP loan which amounts to US$244,000. Director Indemnifications In 2021, the Company and certain of its subsidiaries entered into indemnification agreements with each of the Directors in respect of their involvement with the Company. Such arrangements are adjudged to be necessary to attract and retain highly qualified individuals. Submission of TrinScreen test to World Health Organisation In March 2021, the Group submitted its new HIV screening product, TrinScreen HIV, to the World Health Organisation for approval. This product is a strategic priority for the Group. It is expected that the addition of a HIV screening test to our product range will drive future growth in Point-of-Care revenues. Covid-19 pandemic The COVID-19 pandemic has not yet abated and the situation in 2021 remains fluid. The speed and nature of economic recovery is uncertain and depends on several factors including the rollout of vaccines, the continuation of lockdown restrictions and the existence of new variants of the disease. Management continues to monitor the pandemic situation closely and seeks to minimise the negative impacts on the business, while at the same time, optimising the opportunities that a pandemic affords to a medical diagnostic company. The continued uncertainty created by the pandemic increases the uncertainty in deciding on estimates and judgements underpinning the financial statements. For more information on the impact of the Covid-19 pandemic, refer to the Management Discussion and Analysis section in Item 5.

ACCOUNTING ESTIMATES AND JUDGEM

ACCOUNTING ESTIMATES AND JUDGEMENTS	12 Months Ended
	Dec. 31, 2020
Disclosure of accounting estimates and judgements [Abstract]
ACCOUNTING ESTIMATES AND JUDGEMENTS	32. ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of these financial statements requires the Group to make estimates and judgements that affect the reported amount of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Group evaluates these estimates, including those related to intangible assets, contingencies and litigation. The estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Key sources of estimation uncertainty Note 14 contains information about the assumptions and the risk factors relating to goodwill impairment. Note 22 outlines information regarding the valuation of share options and warrants. Note 25 outlines the valuation techniques used by the Company in determining the fair value of exchangeable notes and the associated embedded derivatives. In Note 29, detailed analysis is given about the interest rate risk, credit risk, liquidity risk and foreign exchange risk of the Group. Critical accounting judgements in applying the Group’s accounting policies Certain critical accounting judgements in applying the Group’s accounting policies are described below: Revenue Recognition No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction. We make a judgement as to the collectability of invoiced sales based on an assessment of the individual debtor taking into account past payment history, the probability of default or delinquency in payments and the probability that debtor will enter into financial difficulties or bankruptcy. Some customer contracts could be regarded as offering the customer a right of return. Due to the uncertainty of the magnitude and likelihood of product returns, there is a level of estimation involved in assessing the amount of revenue to be recognized for these type of contracts. In accordance with IFRS 15, when estimating the effect of an uncertainty on an amount of variable consideration to which the Group will be entitled, all information that is reasonably available, including historical, current and forecast, is considered. We operate a licenced reference laboratory in New York, USA that specializes in diagnostics for autoimmune diseases. The laboratory provides testing services to two types of customers. Firstly, institutional customers, such as hospitals and commercial diagnostic testing providers, and secondly insurance companies on behalf of their policyholders. The revenue recognition for services provided to insurance companies requires some judgement. In the US, there are rules requiring all insurance companies to be billed the same amount per test. However, the amount that each insurance company pays for a particular test varies according to their own internal policies and this can typically be considerably less than the amount invoiced. We recognise lab services revenue for insurance companies by taking the invoiced amount and reducing it by an estimated percentage based on historical payment data. We review the percentage reduction annually based on the latest data. As a practical expedient, and in accordance with IFRS, we apply a portfolio approach to the insurance companies as they have similar characteristics. We judge that the effect on the financial statements of using a portfolio approach for the insurance companies will not differ materially from applying IFRS 15 to the individual contracts within that portfolio. At December 31, 2020 US$4,445,000 (2019: US$292,000) of revenue was deferred in accordance with IFRS15. For further information, refer to Note 23. Research and development expenditure Under IFRS as issued by IASB, the Group writes off research and development expenditure as incurred, with the exception of expenditure on projects whose outcome has been assessed with reasonable certainty as to technical feasibility, commercial viability and recovery of costs through future revenues. Such expenditure is capitalised at cost within intangible assets and amortised over its expected useful life of 15 years, which commences when commercial production starts. For further information, refer to Note 14. Acquired in-process research and development (IPR&D) is valued at its fair value at acquisition date in accordance with IFRS 3. The Company determines this fair value by adopting the income approach valuation technique. Once the fair value has been determined, the Company will recognise the IPR&D as an intangible asset when it: (a) meets the definition of an asset and (b) is identifiable (i.e. is separable or arises from contractual or other legal rights). Factors which impact our judgement to capitalise certain research and development expenditure include the degree of regulatory approval for products and the results of any market research to determine the likely future commercial success of products being developed. We review these factors each year to determine whether our previous estimates as to feasibility, viability and recovery should be changed. At December 31, 2020 the carrying value of capitalised development costs was US$13,444,000 (2019: US$22,778,000) (see Item 18, Note 14 to the consolidated financial statements). The decrease in 2020 was mainly as a result of an impairment loss charge of US$15,287,000. This charge was partially offset by additions of US$6,896,000 and amortisation of US$959,000. Impairment of intangible assets and goodwill Definite lived intangible assets are reviewed for indicators of impairment annually while goodwill and indefinite lived assets are tested for impairment annually, individually or at the cash generating unit level. Factors considered important, as part of an impairment review, include the following: • Significant underperformance relative to expected historical or projected future operating results; • Significant changes in the manner of our use of the acquired assets or the strategy for our overall business; • Obsolescence of products; • Significant decline in our stock price for a sustained period; and • Our market capitalisation relative to net book value. When we determine that the carrying value of intangibles, non-current assets and related goodwill may not be recoverable based upon the existence of one or more of the above indicators of impairment, any impairment is measured based on our estimates of projected net discounted cash flows expected to result from that asset, including eventual disposition. Our estimated impairment could prove insufficient if our analysis overestimated the cash flows or conditions change in the future. The impairment test performed as at December 31, 2020 identified an impairment loss in three CGUs, namely Primus Corp., Biopool US Inc, and Trinity Biotech Do Brasil. For further information, refer to Note 14. Allowance for slow-moving and obsolete inventory We evaluate the realisability of our inventory on a case-by-case basis and make adjustments to our inventory provision based on our estimates of expected losses. We write-off any inventory that is approaching its “use-by” date and for which no further re-processing can be performed. We also consider recent trends in revenues for various inventory items and instances where the realisable value of inventory is likely to be less than its carrying value. At December 31, 2020 our allowance for slow moving and obsolete inventory was US$9,781,000 which represents approximately 24.45% of gross inventory value. This compares with US$6,716,000, or approximately 17.33% of gross inventory value, at December 31, 2019 and US$6,299,000, or approximately 17.18% of gross inventory value, at December 31, 2018. In the event that the estimate of the provision required for slow moving and obsolete inventory was to increase or decrease by 2% of gross inventory, which would represent a reasonably likely range of outcomes, then a change in allowance of US$800,000 at December 31, 2020 (2019: US$774,000) (2018: US$733,000) would result. For further information, refer to Note 17. Allowance for impairment of receivables Revenue is recognised to the extent that it is probable that economic benefit will flow to the Group and the revenue can be measured. No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction or the possible return of goods. We make judgements as to our ability to collect outstanding receivables and where necessary make allowances for impairment. Such impairments are made based upon a specific review of all significant outstanding receivables. In determining the allowance, we analyse our historical collection experience and current economic trends. If the historical data we use to calculate the allowance for impairment of receivables does not reflect the future ability to collect outstanding receivables, additional allowances for impairment of receivables may be needed and the future results of operations could be materially affected. At December 31, 2020, the allowance was US$3,922,000 which represents approximately 3.8% of Group revenues. This compares with US$5,443,000 at December 31, 2019 which represented approximately 6.0% of Group revenues and to US$4,202,000 at December 31, 2018 which represented approximately 4.3% of Group revenues. In the event that the estimate of impairment was to increase or decrease by 0.5% of Group revenues, which would represent a reasonably likely range of outcomes, then a change in the allowance of US$510,000 at December 31, 2020 (2019: US$452,000) (2018: US$485,000) would result. For further information, refer to Note 29. Accounting for income taxes Significant judgement is required in determining our worldwide income tax expense provision. In the ordinary course of a global business, there are many transactions and calculations where the ultimate tax outcome is uncertain. Some of these uncertainties arise as a consequence of revenue sharing and cost reimbursement arrangements among related entities, the process of identifying items of revenue and expense that qualify for preferential tax treatment and segregation of foreign and domestic income and expense to avoid double taxation. In addition, we operate within multiple taxing jurisdictions and are subject to periodic audits in these jurisdictions. Deferred tax assets and liabilities are determined for the effects of net operating losses and temporary differences between the book and tax bases of assets and liabilities, using tax rates projected to be in effect for the year in which the differences are expected to reverse. While we have considered future taxable income and ongoing prudent and feasible tax planning strategies in assessing whether deferred tax assets can be recognised, there is no assurance that these deferred tax assets may be realisable. The extent to which recognised deferred tax assets are not realisable could have a material adverse impact on our income tax provision and net income in the period in which such determination is made. Note 15 to the consolidated financial statements outlines the basis for the deferred tax assets and liabilities and includes details of the unrecognised deferred tax assets at year end. The Group derecognised deferred tax assets arising on unused tax losses except to the extent that there are sufficient taxable temporary differences relating to the same taxation authority and the same taxable entity which will result in taxable amounts against which the unused tax losses can be utilized before they expire. The derecognition of these deferred tax assets was considered appropriate due to the uncertainty over the timing of the utilization of the tax losses. Except for the derecognition of deferred tax assets there were no material changes in estimates used to calculate the income tax expense provision during 2020, 2019 or 2018. IFRS 16 IFRS 16, Leases • Determining whether or not a contract contains a lease. Company assessed if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. • Significant judgement is also required in establishing whether or not it is reasonably certain that an extension option will be exercised, considering whether or not it is reasonably certain that a termination option will not be exercised. In making this decision, management considered the facts and circumstances that create a significant economic incentive. Factors specific to the asset, the entity and the wider market were also considered. • Further, critical judgement is involved in determining whether or not variable lease payments are truly variable, or in-substance fixed. In-substance variable lease payments are treated as fixed lease payments. Key source of estimation and uncertainty is calculation of the appropriate discount rate to use. When making the determination, the company considered the rate of interest that they would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. Going Concern The directors have considered the Group’s current financial position and cash flow projections, taking into account all known events and developments including the Covid-19 pandemic. The directors believe that the Group will be able to continue its operations for at least the next 12 months from the date of this report and that it is appropriate to continue to prepare the consolidated financial statements on a going concern basis. In making this assessment, the directors have considered the potential repayment in April 2022 of part or all of the US$99.9m exchangeable notes under the terms of the indenture for such exchangeable notes. The directors have considered the various financing options expected to be available to the Group to assist it in meeting any repayment obligations under the exchangeable notes over the next 12 months, to the extent such obligations cannot be met from cash on hand, including refinancing the debt, repaying the debt with the proceeds from equity or debt offerings and the sale of assets. As with all such potential transactions, there are risks to successfully implement such transactions and the directors have considered these risks when considering the financing options and the appropriateness of adopting a going concern basis of accounting.

GROUP UNDERTAKINGS

GROUP UNDERTAKINGS	12 Months Ended
	Dec. 31, 2020
Disclosure of group undertakings [Abstract]
GROUP UNDERTAKINGS	33. GROUP UNDERTAKINGS The consolidated financial statements include the financial statements of Trinity Biotech plc and the following principal subsidiary undertakings: Name and registered office Principal activity Principal Country of Group % holding Trinity Biotech Manufacturing Limited IDA Business Park, Bray Co. Wicklow, Ireland Manufacture and sale Ireland 100% Trinity Research Limited IDA Business Park, Bray Co. Wicklow, Ireland Research and Ireland 100%* Benen Trading Limited IDA Business Park, Bray Co. Wicklow, Ireland Trading Ireland 100% Trinity Biotech Manufacturing Services Limited IDA Business Park, Bray Co. Wicklow, Ireland Dormant Ireland 100% Trinity Biotech Luxembourg Sarl 1, rue Bender, L-1229 Luxembourg Investment and Luxembourg 100% Trinity Biotech Inc Girts Road, Jamestown, NY 14702, USA Holding Company U.S.A. 100% Clark Laboratories Inc Trading as Trinity Biotech (USA) Girts Road, Jamestown NY14702, USA Manufacture and sale U.S.A. 100% Mardx Diagnostics Inc 5919 Farnsworth Court Carlsbad CA 92008, USA Manufacture and sale U.S.A. 100% Fitzgerald Industries International, Inc 2711 Centerville Road, Suite 400 Wilmington, New Castle Delaware, 19808, USA Management services U.S.A. 100% Biopool US Inc (trading as Trinity Biotech Distribution) Girts Road, Jamestown NY14702, USA Sale of diagnostic test U.S.A. 100% Primus Corporation 4231 E 75 th Kansas City, MO 64132, USA Manufacture and sale U.S.A. 100% *refers to voting shares Name and registered office Principal activity Principal Country of Group % holding Phoenix Bio-tech Corp. 1166 South Service Road West Oakville, ON L6L 5T7 Canada. Dormant Canada 100% Fiomi Diagnostics Holding AB Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden Holding Company Sweden 100% Fiomi Diagnostics AB Dag Hammarskjöldsv 52A SE-752 37 Uppsala Sweden Discontinued operation Sweden 100% Trinity Biotech Do Brasil Comercio e Importacao Ltda Rua Silva Bueno 1.660 – Cj. 101/102 Ipiranga Sao Paulo Brazil Sale of diagnostic test Brazil 100% Trinity Biotech (UK) Ltd Mills and Reeve LLP Botanic House 100 Hills Road Cambridge, CB2 1PH United Kingdom Sales & marketing UK 100% Immco Diagnostics Inc 60 Pineview Drive Buffalo NY 14228, USA Manufacture and sale of U.S.A. 100% Nova Century Scientific Inc 5022 South Service Road Burlington Ontario Canada Manufacture and sale of Canada 100% Trinity Biotech Investment Ltd PO Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Investment and Cayman Islands 100%

AUTHORISATION FOR ISSUE

AUTHORISATION FOR ISSUE	12 Months Ended
	Dec. 31, 2020
Disclosure of authorisation for issue [Abstract]
AUTHORISATION FOR ISSUE	34. AUTHORISATION FOR ISSUE These Group consolidated financial statements were authorised for issue by the Board of Directors on April 30, 2021.

BASIS OF PREPARATION AND SIGN_2

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (POLICIES)	12 Months Ended
	Dec. 31, 2020
Disclosure of basis of preparation and significant accounting policies [Abstract]
General information	i) General information Trinity Biotech develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech is a significant provider of raw materials to the life sciences and research industries globally. Trinity Biotech also operates a licenced reference laboratory that specializes in diagnostics for autoimmune diseases.
Statement of compliance	i) Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) both as issued by the International Accounting Standards Board (“IASB”) and as subsequently adopted by the European Union (“EU”) (together “IFRS”). The IFRS applied are those effective for accounting periods beginning January 1, 2020. Consolidated financial statements are required by Irish law to comply with IFRS as adopted by the EU which differ in certain respects from IFRS as issued by the IASB. These differences predominantly relate to the timing of adoption of new standards by the EU. However, in relation to the 2020 consolidated financial statements there are no differences regarding the effective date of new IFRS relevant to Trinity Biotech as issued by the IASB and as adopted by the EU. In relation to prior periods presented, none of the differences are relevant in the context of Trinity Biotech and the consolidated financial statements comply with IFRS both as issued by the IASB and as adopted by the EU.
Basis of preparation	iii) Basis of preparation The consolidated financial statements have been prepared in United States Dollars (US$), rounded to the nearest thousand, under the historical cost basis of accounting, except for derivative financial instruments, certain balances arising on acquisition of subsidiary entities and share-based payments which are initially recorded at fair value. Derivative financial instruments are also subsequently revalued and carried at fair value. The preparation of financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and amounts reported in the financial statements and accompanying notes. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Judgements made by management that have a significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year are discussed in Note 32. The directors have considered the Group’s current financial position and cash flow projections, taking into account all known events and developments including the Covid-19 pandemic. The directors believe that the Group will be able to continue its operations for at least the next 12 months from the date of this report and that it is appropriate to continue to prepare the consolidated financial statements on a going concern basis. In making this assessment, the directors have considered the potential repayment in April 2022 of part or all of the US$99.9m exchangeable notes under the terms of the indenture for such exchangeable notes. The directors have considered the various financing options expected to be available to the Group to assist it in meeting any repayment obligations under the exchangeable notes over the next 12 months, to the extent such obligations cannot be met from cash on hand, including refinancing the debt, repaying the debt with the proceeds from equity or debt offerings and the sale of assets. As with all such potential transactions, there are risks to successfully implement such transactions and the directors have considered these risks when considering the financing options and the appropriateness of adopting a going concern basis of accounting. The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. The accounting policies have been applied consistently by all Group entities.
Basis of consolidation	iv) Basis of consolidation Subsidiaries Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and reporting policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights that presently are exercisable or convertible are taken into account. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Transactions eliminated on consolidation Intra-group balances and any unrealised gains or losses or income and expenses arising from intra-group transactions are eliminated in preparing the consolidated financial statements.
Property, plant and equipment	v) Property, plant and equipment Owned assets Items of property, plant and equipment are stated at cost less any accumulated depreciation and any impairment losses (see Note 1(viii)). The cost of self-constructed assets includes the cost of materials, direct labour and attributable overheads. It is not Group policy to revalue any items of property, plant and equipment. Depreciation is charged to the statement of operations on a straight-line basis to write-off the cost of the assets over their expected useful lives as follows: • Leasehold improvements 5-15 years • Buildings 50 years • Office equipment and fittings 10 years • Computer equipment 3-5 years • Plant and equipment 2-15 years Land is not depreciated. The residual values, if not insignificant, useful lives and depreciation methods of property, plant and equipment are reviewed and adjusted if appropriate on a prospective basis, at each balance sheet date. There were no changes to useful lives in the year. Leased assets - as lessee The Group has applied IFRS 16, Leases, using the modified retrospective approach and therefore comparative information has not been restated. Accounting policy applicable from 1 January 2019 For any new contracts entered into on or after 1 January 2019, the Group considers whether a contract is, or contains a lease. A lease is defined as ‘a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration’. To apply this definition the Group assesses whether the contract meets three key evaluations which are whether: • the contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Group • the Group has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract • the Group has the right to direct the use of the identified asset throughout the period of use. The Group assess whether it has the right to direct ‘how and for what purpose’ the asset is used throughout the period of use. At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made in advance of the lease commencement date (net of any incentives received). The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist. At the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group’s incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero. The Group has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included in property, plant and equipment and lease liabilities have been included in separate lines within the current liabilities and non-current liabilities sections. Leased assets - as lessor The Group’s accounting policy under IFRS 16 has not changed from the comparative period. As a lessor, the Group classifies its leases as either operating or finance leases. A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership of the underlying asset, and classified as an operating lease if it does not. Accounting policy applicable before 1 January 2019 Leased assets – as lessee Leases under terms of which the Group assumes substantially all the risks and rewards of ownership are classified as finance leases. Property, plant and equipment acquired by way of finance lease is stated at an amount equal to the lower of its fair value and present value of the minimum lease payments at inception of the lease, less accumulated depreciation and any impairment losses. Lease payments are apportioned between finance charges and reduction of the lease liability so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are recognised in financial expenses in the statement of operations. Depreciation is calculated in order to write-off the amounts capitalised over the estimated useful lives of the assets, or the lease term if shorter, by equal annual instalments. The excess of the total rentals under a lease over the amount capitalised is treated as interest, which is charged to the statement of operations in proportion to the amount outstanding under the lease. Leased assets are reviewed for impairment (see Note 1(viii)). Leases other than finance leases are classified as “operating leases”, and the rentals thereunder are charged to the statement of operations on a straight-line basis over the period of the leases. Lease incentives are recognised in the statement of operations on a straight-line basis over the lease term . Leased assets – as lessor Leases where the Group substantially transfers the risks and benefits of ownership of the asset to the customer are classified as finance leases within finance lease receivables. The Group recognises the amount receivable from assets leased under finance leases at an amount equal to the net investment in the lease. Finance lease income is recognised as revenue in the statement of operations reflecting a constant periodic rate of return on the Group’s net investment in the lease. Assets provided to customers under leases other than finance leases are classified as operating leases and carried in property, plant and equipment at cost and are depreciated on a straight-line basis over the useful life of the asset or the lease term, if shorter. Subsequent costs The Group recognises in the carrying amount of an item of property, plant and equipment the cost of replacing part of such an item when that cost is incurred if it is probable that the future economic benefits embodied within the item will flow to the Group and the cost of the replaced item can be measured reliably. All other costs are recognised in the statement of operations as an expense as incurred.
Goodwill	vi) Goodwill In respect of business combinations that have occurred since January 1, 2004 (being the transition date to IFRS), goodwill represents the difference between the cost of the acquisition and the fair value of the net identifiable assets acquired. In respect of acquisitions prior to this date, goodwill is included on the basis of its deemed cost, which represents the amount recorded under the old basis of accounting, Irish GAAP, (“Previous GAAP”). Save for retrospective restatement of deferred tax as an adjustment to retained earnings in accordance with IAS 12, Income Taxes, To the extent that the Group’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities acquired exceeds the cost of a business combination, the identification and measurement of the related assets, liabilities and contingent liabilities are revisited accompanied by a reassessment of the cost of the transaction, and any remaining balance is immediately recognised in the statement of operations. At the acquisition date, any goodwill is allocated to each of the cash generating units expected to benefit from the combination’s synergies. Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 1(viii)).
Intangibles, including research and development (other than goodwill)	vii) Intangibles, including research and development (other than goodwill) An intangible asset, which is an identifiable non-monetary asset without physical substance, is recognised to the extent that it is probable that the expected future economic benefits attributable to the asset will flow to the Group and that its cost can be measured reliably. The asset is deemed to be identifiable when it is separable (that is, capable of being divided from the entity and sold, transferred, licenced, rented or exchanged, either individually or together with a related contract, asset or liability) or when it arises from contractual or other legal rights, regardless of whether those rights are transferable or separable from the Group or from other rights and obligations. Intangible assets acquired as part of a business combination are capitalised separately from goodwill if the intangible asset meets the definition of an asset and the fair value can be reliably measured on initial recognition. Subsequent to initial recognition, these intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Intangible assets with definite useful lives are reviewed for indicators of impairment annually while intangible assets with indefinite useful lives and those not yet brought into use are tested for impairment annually, either individually or at the cash generating unit level. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalised if the product or process is technically and commercially feasible and the Group has sufficient resources to complete the development. The expenditure capitalised includes the cost of materials, direct labour and attributable overheads and third party costs. Subsequent expenditure on capitalised intangible assets is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. The technical feasibility of a new product is determined by a specific feasibility study undertaken at the first stage of any development project. The majority of our new product developments involve the transfer of existing product know-how to a new application. Since the technology is already proven in an existing product which is being used by customers, this facilitates the proving of the technical feasibility of that same technology in a new product. The results of the feasibility study are reviewed by a design review committee comprising senior managers. The feasibility study occurs in the initial research phase of a project and costs in this phase are not capitalised. The commercial feasibility of a new product is determined by preparing a discounted cash flow projection. This projection compares the discounted sales revenues for future periods with the relevant costs. As part of preparing the cash flow projection, the size of the relevant market is determined, feedback is sought from customers and the strength of the proposed new product is assessed against competitors’ offerings. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. All other development expenditure is expensed as incurred. Subsequent to initial recognition, the capitalised development expenditure is carried at cost less any accumulated amortisation and any accumulated impairment losses (Note 1(viii)). Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognised in the statement of operations as an expense as incurred. Expenditure on internally generated goodwill and brands is recognised in the statement of operations as an expense as incurred. Amortisation Amortisation is charged to the statement of operations on a straight-line basis over the estimated useful lives of intangible assets, unless such lives are indefinite. Intangible assets are amortised from the date they are available for use in its intended market. The estimated useful lives are as follows: • Capitalised development costs 15 years • Patents and licences 6-15 years • Other (including acquired customer and supplier lists) 6-15 years The Group uses a useful economic life of 15 years for capitalised development costs. This is a conservative estimate of the likely life of the products. The Group is confident that products have a minimum of 15 years life given the inertia that characterizes the medical diagnostics industry and the barriers to enter into the industry. The following factors have been considered in estimating the useful life of developed products: (a) once a diagnostic test becomes established, customers are reluctant to change to new technology until it is fully proven, thus resulting in relatively long product life cycles. There is also reluctance in customers to change to a new product as it can be costly both in terms of the initial changeover cost and as new technology is typically more expensive. (b) demand for the diagnostic tests is enduring and robust within a wide geographic base. The diseases that the products diagnose are widely prevalent (HIV, Diabetes and Chlamydia being just three examples) in many countries. There is a general consensus that these diseases will continue to be widely prevalent in the future. (c) there are significant barriers to new entrants in this industry. Patents and/or licences are in place for many of our products, though this is not the only barrier to entry. There is a significant cost and time to develop new products, it is necessary to obtain regulatory approval and tests are protected by proprietary know-how, manufacturing techniques and trade secrets. Certain trade names acquired are deemed to have an indefinite useful life as there is no foreseeable limit to the period over which these assets are expected to generate cash inflows for the Group. Where amortisation is charged on assets with finite lives, this expense is taken to the statement of operations through the ‘selling, general and administrative expenses’ line. Useful lives are examined on an annual basis and adjustments, where applicable, are made on a prospective basis.
Impairment	viii) Impairment The carrying amount of the Group’s assets, other than inventories, accounts receivable, cash and cash equivalents, short-term investments and deferred tax assets, are reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the asset’s recoverable amount (being the greater of fair value less costs to sell and value in use) is assessed at each balance sheet date. Fair value less costs to sell is defined as the amount obtainable from the sale of an asset or cash-generating unit in an arm’s length transaction between knowledgeable and willing parties, less the costs that would be incurred on disposal. Value in use is defined as the present value of the future cash flows expected to be derived through the continued use of an asset or cash-generating unit. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the future cash flow estimates have not yet been adjusted. The estimates of future cash flows exclude cash inflows or outflows attributable to financing activities. For an asset that does not generate largely independent cash flows, the recoverable amount is determined by reference to the cash generating unit to which the asset belongs. For goodwill, assets that have an indefinite useful life and intangible assets that are not yet available for use, the recoverable amount is estimated at each balance sheet date at the cash generating unit level. The goodwill and indefinite-lived assets were reviewed for impairment at December 31, 2019 and December 31, 2020. See Note 14. In-process research and development (IPR&D) is tested for impairment on an annual basis, in the fourth quarter, or more frequently if impairment indicators are present, using projected discounted cash flow models. If IPR&D becomes impaired or is abandoned, the carrying value of the IPR&D is written down to its revised fair value with the related impairment charge recognised in the period in which the impairment occurs. If the fair value of the asset becomes impaired as the result of unfavorable data from any ongoing or future clinical trial, changes in assumptions that negatively impact projected cash flows, or because of any other information regarding the prospects of successfully developing or commercializing our programs, we could incur significant charges in the period in which the impairment occurs. The valuation techniques utilized in performing impairment tests incorporate significant assumptions and judgments to estimate the fair value, as described above. The use of different valuation techniques or different assumptions could result in materially different fair value estimates. An impairment loss is recognised whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in the statement of operations. Impairment losses recognised in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to cash-generating units and then to reduce the carrying amount of other assets in the cash-generating units on a pro-rata basis. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. An impairment loss in respect of goodwill is not reversed. Following recognition of any impairment loss (and on recognition of an impairment loss reversal), the depreciation or amortisation charge applicable to the asset or cash generating unit is adjusted prospectively with the objective of systematically allocating the revised carrying amount, net of any residual value, over the remaining useful life.
Inventories	ix) Inventories Inventories are stated at the lower of cost and net realisable value. Cost is based on the first-in, first-out principle and includes all expenditure which has been incurred in bringing the products to their present location and condition, and includes an appropriate allocation of manufacturing overhead based on the normal level of operating capacity. Net realisable value is the estimated selling price of inventory on hand in the ordinary course of business less all further costs to completion and costs expected to be incurred in selling these products. The Group provides for inventory, based on estimates of the expected realisability. The estimated realisability is evaluated on a case-by-case basis and any inventory that is approaching its “use-by” date and for which no further re-processing can be performed is written off. Any reversal of an inventory provision is recognised in the statement of operations in the year in which the reversal occurs.
Trade and other receivables	x) Trade and other receivables Trade receivables are amounts due from customers for products sold or services provided in the ordinary course of business. Trade and other receivables are stated at their amortised cost less impairment losses incurred. Cost approximates fair value given the short term nature of these assets. The Group records the loss allowance as lifetime expected credit losses. These are the expected shortfalls in contractual cash flows, considering the potential for default at any point during the life of the financial instrument. Expected credit losses are recorded on all of trade receivables based on an assessment of each individual debtor taking into account the probability of default or delinquency in payments and the probability that debtor will enter into financial difficulties or bankruptcy.
Trade and other payables	xi) Trade and other payables Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business. Trade and other payables are stated at cost. Cost approximates fair value given the short term nature of these liabilities.
Cash and cash equivalents	xii) Cash and cash equivalents Cash and cash equivalents comprise cash balances and short-term deposits which are readily available at year-end. Deposits with maturities less than six months as at the year-end date are recognised as cash and cash equivalents and are carried at fair value when there is no expected loss in value on early termination. The Group has no short-term bank overdraft facilities. Where restrictions are imposed by third parties, such as lending institutions, on cash balances held by the Group these are treated as financial assets in the financial statements.
Short-term investments	xiii) Short-term investments Short-term investments comprise short-term bank deposits which have maturities greater than six months as at the year-end date. Short-term deposits made for varying periods depending on the immediate cash requirements of the Group and earn interest at the respective deposit rates in place. Where restrictions are imposed by third parties, such as lending institutions, on short-term deposits held by the Group these are treated as financial assets in the financial statements.
Share-based payments	xiv) Share-based payments For equity-settled share-based payments (share options), the Group measures the services received and the corresponding increase in equity at fair value at the measurement date (which is the grant date) using a trinomial model. Given that the share options granted do not vest until the completion of a specified period of service, the fair value, which is assessed at the grant date, is recognised on the basis that the services to be rendered by employees as consideration for the granting of share options will be received over the vesting period. The share options issued by the Group are not subject to market-based vesting conditions as defined in IFRS 2, Share-based Payment The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised. The Group does not operate any cash-settled share-based payment schemes or share-based payment transactions with cash alternatives as defined in IFRS 2.
Government grants and financial support	xv) Government grants and financial support The Group has received government-backed Covid-19 financial supports in the form of forgivable loans. Under IAS 20, Accounting for Government Grants Grants that compensate the Group for expenses incurred such as research and development, employment and training are recognised as income in the statement of operations on a systematic basis in the same periods in which the expenses are incurred. Grants that compensate the Group for the cost of an asset are recognised in the statement of operations as other operating income on a systematic basis over the useful life of the asset.
Revenue recognition	xvi) Revenue recognition Goods sold and services rendered The Group recognises revenue when it transfers control over a good or service to a customer. Revenue is recognised to the extent that it is probable that economic benefit will flow to the Group and the revenue can be measured. No revenue is recognised if there is uncertainty regarding recovery of the consideration due at the outset of the transaction. Revenue, including any amounts invoiced for shipping and handling costs, represents the value of goods and services supplied to external customers, net of discounts and rebates and excluding sales taxes. Revenue from products is generally recorded as of the date of shipment, consistent with typical ex-works shipment terms. Where the shipment terms do not permit revenue to be recognised as of the date of shipment, revenue is recognised when the Group has satisfied all of its performance obligations to the customer in accordance with the shipping terms. Some contracts oblige the Group to ship product to the customer ahead of the agreed payment schedule. For these shipments, a contract asset is recognised when control over the goods has transferred to the customer. The financing component is insignificant as invoicing for these shipments occurs within a short period of time after shipment has occurred and standard 30 day credit terms apply. The Group operates a licenced referenced laboratory in the US, which provides testing services to institutional customers and insurance companies. In the US, there are rules requiring all insurance companies to be billed the same amount per test. However, the amount that each insurance company pays for a particular test varies according to their own internal policies and this can typically be considerably less than the amount invoiced. We recognise lab services revenue for insurance companies by taking the invoiced amount and reducing it by an estimated percentage based on historical payment data. We review the percentage reduction annually based on the latest data. As a practical expedient, and in accordance with IFRS, we apply a portfolio approach to the insurance companies as they have similar characteristics. We judge that the effect on the financial statements of using a portfolio approach for the insurance companies will not differ materially from applying IFRS 15 to the individual contracts within that portfolio. Revenue from services rendered is recognised in the statement of operations in proportion to the stage of completion of the transaction at the balance sheet date. The Group leases instruments to customers typically as part of a bundled package. Where a contract has multiple performance obligations and its duration is greater than one year, the transaction price is allocated to the performance obligations in the contract by reference to their relative standalone selling prices. For contracts where control of the instrument is transferred to the customer, the fair value of the instrument is recognised as revenue at the commencement of the lease and is matched by the related cost of sale. Fair value is determined on the basis of standalone selling price. In the case where control of the instrument does not transfer to the customer, revenue is recognised on the basis of customer usage of the instrument. See also Item 18, Note 1(v). In obtaining these contracts, the Group incurs a number of incremental costs, such as sales bonus paid to sales staff commissions paid to distributors and royalty payments. As the amortisation period of these costs, if capitalised, would be less than one year, the Group makes use of the practical expedient in IFRS 15.94 and expenses them as they incur. A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due. The Group’s obligation to provide a refund for faulty products under the standard warranty terms is recognised as a provision, see Item 18, Note 24 for details. Other operating income Other operating income includes income for the provision of canteen services. This income has not been treated as revenue since the canteen activities are incidental to the main revenue-generating activities of the Group. Other operating income also includes government-backed Covid-19 financial supports. The accounting policy for this income is described in Note 1 (xv).
Employee benefits	xvii) Employee benefits Defined contribution plans The Group operates defined contribution schemes in various locations where its subsidiaries are based. Contributions to the defined contribution schemes are recognised in the statement of operations in the period in which the related service is received from the employee. Other long-term benefits Where employees participate in the Group’s other long-term benefit schemes (such as permanent health insurance schemes under which the scheme insures the employees), or where the Group contributes to insurance schemes for employees, the Group pays an annual fee to a service provider, and accordingly the Group expenses such payments as incurred. Termination benefits Termination benefits are recognised as an expense when the Group is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy.
Foreign currency	xviii) Foreign currency A majority of the revenue of the Group is generated in US Dollars. The Group’s management has determined that the US Dollar is the primary currency of the economic environment in which the Company and its subsidiaries (with the exception of the Group’s subsidiaries in Brazil, Canada and Sweden) principally operate. Thus the functional currency of the Company and its subsidiaries (other than the Brazilian, Canadian and Swedish subsidiaries) is the US Dollar. The functional currency of the Brazilian entity is the Brazilian Real, the functional currency of the Canadian subsidiary, Nova Century Scientific Inc, is the Canadian Dollar and the functional currency of the Swedish subsidiary is the Swedish Kroner. The presentation currency of the Company and Group is the US Dollar. Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. The resulting gains and losses are included in the statement of operations. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Results and cash flows of subsidiary undertakings, which have a functional currency other than the US Dollar, are translated into US Dollars at average exchange rates for the year, and the related balance sheets have been translated at the rates of exchange ruling on the balance sheet date. Any exchange differences arising from the translations are recognised in the currency translation reserve via the statement of changes in equity. Where Euro, Brazilian Real, Canadian Dollar or Swedish Kroner amounts have been referenced in this document, their corresponding US Dollar equivalent has also been included and these equivalents have been calculated with reference to the foreign exchange rates prevailing at December 31, 2020.
Hedging	xix) Hedging The activities of the Group expose it primarily to changes in foreign exchange rates and interest rates. The Group uses derivative financial instruments, from time to time, such as forward foreign exchange contracts to hedge these exposures. The Group enters into forward contracts to sell US Dollars forward for Euro. The principal exchange risk identified by the Group is with respect to fluctuations in the Euro as a substantial portion of its expenses are denominated in Euro but its revenues are primarily denominated in US Dollars. Trinity Biotech monitors its exposure to foreign currency movements and may use these forward contracts as cash flow hedging instruments whose objective is to cover a portion of this Euro expense. At the inception of a hedging transaction entailing the use of derivatives, the Group documents the relationship between the hedged item and the hedging instrument together with its risk management objective and the strategy underlying the proposed transaction. The Group also documents its quarterly assessment of the effectiveness of the hedge in offsetting movements in the cash flows of the hedged items. Derivative financial instruments are recognised at fair value. Where derivatives do not fulfil the criteria for hedge accounting, they are classified as held-for-trading and changes in fair values are reported in the statement of operations. The fair value of forward exchange contracts is calculated by reference to current forward exchange rates for contracts with similar maturity profiles and equates to the current market price at the balance sheet date. The portion of the gain or loss on a hedging instrument that is deemed to be an effective cash flow hedge is recognised directly in the hedging reserve in equity and the ineffective portion is recognised in the statement of operations. As the forward contracts are exercised the net cumulative gain or loss recognised in the hedging reserve is transferred to the statement of operations and reflected in the same line as the hedged item.
Exchangeable notes and derivative financial instruments	xx) Exchangeable notes and derivative financial instruments The Company’s exchangeable notes are treated as a host debt instrument with embedded derivatives attached. On initial recognition, the host debt instrument is recognised at the residual value of the total net proceeds of the bond issue less fair value of the embedded derivatives. Subsequently, the host debt instrument is measured at amortised cost using the effective interest rate method. The embedded derivatives are initially recognised at fair value and are restated at their fair value at each reporting date. The fair value changes of the embedded derivatives are recognised in the statement of operations, except for changes in fair value related to the Group’s own credit risk, which are recorded in the statement of comprehensive income. Where the exchangeable notes are redeemed early or repurchased in a way that does not alter the original conversion privileges, the consideration paid is allocated to the respective components and the amount of any gain or loss is recognised in the consolidated statement of operations.
Segment reporting	xxi) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors.
Tax (current and deferred)	xxii) Tax (current and deferred) Income tax on the profit or loss for the year comprises current and deferred tax. Income tax is recognised in the statement of operations except to the extent that it relates to items recognised directly in equity, in which case it is recognised in equity. Current tax represents the expected tax payable or recoverable on the taxable profit for the year using tax rates enacted or substantively enacted at the balance sheet date in the countries where the company and its subsidiaries operate and generate income, and taking into account any adjustments stemming from prior years. Deferred tax is provided on the basis of the balance sheet liability method on all temporary differences at the balance sheet date which is defined as the difference between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets and liabilities are not subject to discounting and are measured at the tax rates that are anticipated to apply in the period in which the asset is realised or the liability is settled based on tax rates and tax laws that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised when it is probable that future taxable profits will be available to utilize the associated losses or temporary differences. The amount of deferred tax provided is based on the expected manner of realisation or settlement of the carrying amount of assets and liabilities. Deferred tax assets and liabilities are recognised for all temporary differences (that is, differences between the carrying amount of the asset or liability and its tax base) with the exception of the following: i. Where the deferred tax liability arises from goodwill not deductible for tax purposes or the initial recognition of an asset or a liability in a transaction that is not a business combination and affects neither the accounting profit nor the taxable profit or loss at the time of the transaction; and ii. Where, in respect of temporary differences associated with investments in subsidiary undertakings, the timing of the reversal of the temporary difference is subject to control and it is probable that the temporary difference will not reverse in the foreseeable future. Where goodwill is tax deductible, a deferred tax liability is not recognised on initial recognition of goodwill. It is recognised subsequently for the taxable temporary difference which arises when the goodwill is amortised for tax with no corresponding adjustment to the carrying value of the goodwill. The carrying amounts of deferred tax assets are subject to review at each balance sheet date and are derecognised to the extent that future taxable profits are considered to be inadequate to allow all or part of any deferred tax asset to be utilised.
Provisions	xxiii) Provisions A provision is recognised in the balance sheet when the Group has a present legal or constructive obligation as a result of a past event, and it is probable that an outflow of economic benefits will be required to settle the obligation.
Cost of sales	xxiv) Cost of sales Cost of sales comprises product cost including manufacturing and payroll costs, quality control, shipping, handling, and packaging costs and the cost of services provided.
Finance income and costs	xxv) Finance income and costs Financing expenses comprise interest costs payable on leases and exchangeable notes. Interest payable on finance leases is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability. Financing expenses also includes the financing element of long term liabilities which have been discounted. Finance income includes interest income on deposits and is recognised in the statement of operations as it accrues, using the effective interest method. Finance income also includes fair value adjustments to embedded derivatives associated with exchangeable notes.
Treasury shares	xxvi) Treasury shares When the Group purchases its
Equity	xxvii) Equity Share capital represents the nominal (par) value of shares that have been issued. Share premium includes any premiums received on issue of share capital. Any transaction costs associated with the issuing of shares are deducted from share premium, net of any related income tax benefits.
Profit or loss from discontinued operations	xxviii) Profit or loss from discontinued operations A discontinued operation is a component of the Group that either has been disposed of, or is classified as held for sale. Profit or loss from discontinued operations comprises the post-tax profit or loss of discontinued operations and the post-tax gain or loss resulting from the measurement and disposal of assets classified as held for sale.
Fair values	xxix) Fair values For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data
New IFRS Standards and Interpretations not applied	xxx) New IFRS Standards and Interpretations not applied The following new standards, interpretations and standard amendments became effective for the Group as of January 1, 2020 and did not result in a material impact on the Group’s results: • IFRS 3 Business Combinations • Amendments to IFRS 9 Financial Instruments Financial Instruments: Recognition and Measurement Financial Instruments • Amendments to References to the Conceptual Framework in IFRS Standards • Amendments to IAS 1 Presentation of Financial Statements The following standard amendment was issued in May 2020 effective for annual reporting periods beginning on or after 1 June 2020 with earlier application permitted: • Amendments to IFRS 16 Leases

BASIS OF PREPARATION AND SIGN_3

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of basis of preparation and significant accounting policies [Abstract]
Schedule of Estimated Useful Lives of Owned Assets	Depreciation is charged to the statement of operations on a straight-line basis to write-off the cost of the assets over their expected useful lives as follows: • Leasehold improvements 5-15 years • Buildings 50 years • Office equipment and fittings 10 years • Computer equipment 3-5 years • Plant and equipment 2-15 years
Schedule of Estimated Useful Lives of Intangible Assets	Amortisation is charged to the statement of operations on a straight-line basis over the estimated useful lives of intangible assets, unless such lives are indefinite. Intangible assets are amortised from the date they are available for use in its intended market. The estimated useful lives are as follows: • Capitalised development costs 15 years • Patents and licences 6-15 years • Other (including acquired customer and supplier lists) 6-15 years

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of operating segments [abstract]
Schedule of Revenue by Geographical Area Based on Location of Assets	The distribution of revenue by geographical area based on location of assets was as follows: Rest of World Revenue Americas Ireland Other Eliminations Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 77,688 24,292 - - 101,980 Inter-segment revenue 59,304 1,095 - (60,399 ) - Total revenue 136,992 25,387 - (60,399 ) 101,980 Rest of World Revenue Americas Ireland Other Eliminations Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 64,045 26,390 - - 90,435 Inter-segment revenue 39,563 1,629 - (41,192 ) - Total revenue 103,608 28,019 - (41,192 ) 90,435 Rest of World Americas Ireland Other Eliminations Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$’000 US$‘000 Revenue from external customers 65,863 31,172 - - 97,035 Inter-segment revenue 38,665 2,899 - (41,564 ) - Total revenue 104,528 34,071 - (41,564 ) 97,035
Schedule of Revenue by Customers' Geographical Area	The distribution of revenue by customers’ geographical area was as follows: Revenue December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Americas 70,408 52,183 57,559 Asia / Africa 22,567 27,686 29,466 Europe (including Ireland) * 9,005 10,566 10,010 101,980 90,435 97,035 * Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues.
Schedule of Revenue by Major Product Group	The distribution of revenue by major product group was as follows: Revenue December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Clinical laboratory goods 84,280 68,127 71,618 Clinical laboratory services 8,485 10,915 10,581 Point-of-Care 9,215 11,393 14,836 101,980 90,435 97,035
Schedule of Amount Relating From Revenue	The group has recognised the following amounts relating to revenue in the consolidated statement of operations: Revenue December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Revenue from contracts with customers (a) 101,980 90,435 97,035 Revenue from other sources - - - 101,980 90,435 97,035 (a) Disaggregation of revenue from contracts with customers:
Schedule of Revenue Derives From Transfer of Goods and Services	The Group derives revenue from the transfer of goods and services over time and at a point in time in the following geographical areas: Timing of revenue recognition Americas Ireland Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 77,060 24,292 — 101,352 Over time 628 — — 628 Total 77,688 24,292 — 101,980 Timing of revenue recognition Americas Ireland Other Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 63,300 26,390 — 89,690 Over time 745 — — 745 Total 64,045 26,390 — 90,435 Timing of revenue recognition Americas Ireland Other Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 64,941 31,172 — 96,113 Over time 922 — — 922 Total 65,863 31,172 — 97,035 (b) The Group derives revenue from the transfer of goods and services over time and at a point in time based on customers’ geographical area as follows: Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 69,780 22,567 9,005 101,352 Over time 628 — — 628 Total 70,408 22,567 9,005 101,980 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 51,438 27,686 10,566 89,690 Over time 745 — — 745 Total 52,183 27,686 10,566 90,435 Timing of revenue recognition Americas Asia / Africa Europe Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$‘000 At a point in time 56,637 29,466 10,010 96,113 Over time 922 — — 922 Total 57,559 29,466 10,010 97,035
Schedule of Segment Results by Geographical Area	The distribution of segment results by geographical area was as follows: Rest of World Americas Ireland Other Total Year ended December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 14,495 4,264 (71 ) 18,688 Impairment (17,779 ) - — (17,779 ) Result after impairment (3,284 ) 4,264 (71 ) 909 Unallocated expenses * (827 ) Operating profit 82 Net financing expense (Note 8) (6,715 ) Loss before tax (6,633 ) Income tax credit (Note 9) 620 Loss for the year on continuing operations (6,013 ) Loss for the year on discontinued operations (Note 10) (375 ) Loss for the year (6,388 ) Rest of World Americas Ireland Other Total Year ended December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 5,239 (4,334 ) (108 ) 797 Impairment (14,562 ) (9,733 ) — (24,295 ) Result after impairment (9,323 ) (14,067 ) (108 ) (23,498 ) Unallocated expenses * (614 ) Operating loss (24,112 ) Net financing expense (Note 8) (5,885 ) Loss before tax (29,997 ) Income tax credit (Note 9) 1,006 Loss for the year on continuing operations (28,991 ) Profit for the year on discontinued operations (Note 10) 77 Loss for the year (28,914 ) Rest of World Americas Ireland Other Total Year ended December 31, 2018 US$‘000 US$‘000 US$‘000 US$‘000 Result before impairment and unallocated expenses 5,514 1,900 (44 ) 7,370 Impairment (19,095 ) (7,837 ) — (26,932 ) Result after impairment (13,581 ) (5,937 ) (44 ) (19,562 ) Unallocated expenses * (665 ) Operating loss (20,227 ) Net financing expense (Note 8) (2,956 ) Loss before tax (23,183 ) Income tax credit (Note 9) 525 Loss for the year on continuing operations (22,658 ) Loss for the year on discontinued operations (Note 10) 568 Loss for the year (22,090 ) * Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area.
Schedule of Segment Assets and Segment Liabilities by Geographical Area	The distribution of segment assets and segment liabilities by geographical area was as follows: Rest of World Americas Ireland Other Total As at December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 58,164 37,632 3 95,799 Unallocated assets: Income tax assets (current and deferred) 7,271 Cash and cash equivalents and short-term investments 27,327 Total assets as reported in the Group balance sheet 130,397 Segment liabilities 20,431 107,080 46 127,557 Unallocated liabilities: Income tax liabilities (current and deferred) 5,059 Total liabilities as reported in the Group balance sheet 132,616 Rest of World Americas Ireland Other Total As at December 31, 2019 US$‘000 US$‘000 US$‘000 US$‘000 Assets and liabilities Segment assets 69,224 37,212 1 106,437 Unallocated assets: Income tax assets (current and deferred) 8,234 Cash and cash equivalents and short-term investments 16,400 Total assets as reported in the Group balance sheet 131,071 Segment liabilities 14,575 104,396 200 119,171 Unallocated liabilities: Income tax liabilities (current and deferred) 7,187 Total liabilities as reported in the Group balance sheet 126,358
Schedule of Long-Lived Assets	The distribution of long-lived assets, which are property, plant and equipment, goodwill and intangible assets and other non-current assets (excluding deferred tax assets), by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 Rest of World – Ireland 19,927 14,626 Americas 22,835 38,803 42,762 53,429
Schedule of Depreciation and Amortisation by Geographical Area	The distribution of depreciation and amortisation by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Depreciation: Rest of World – Ireland 127 322 74 Americas 1,587 2,208 1,301 1,714 2,530 1,375 Rest of World – Ireland 32 642 655 Americas 1,371 1,726 2,170 1,403 2,368 2,825
Schedule of Share-Based Payment Expense by Geographical Area	The distribution of share-based payment expense by geographical area was as follows: December 31, 2020 December 31, 2019 December 31, 2018 Rest of World – Ireland 722 659 1,265 Americas 70 99 104 792 758 1,369
Schedule of Interest Income and Interest Expense by Geographical Area	The distribution of interest income and interest expense by geographical area was as follows: Interest Income Year ended December 31, 2020 Americas US$‘000 Ireland US$‘000 Rest of world Other US$‘000 Eliminations US$‘000 Total US$‘000 Interest income earned 9 27 — — 36 Inter-segment interest income — 3,656 4,853 (8,509 ) — Total 9 3,683 4,853 (8,509 ) 36 Interest Expense Year ended December 31, 2020 Americas US$‘000 Ireland US$‘000 Rest of World US$‘000 Eliminations US$‘000 Total US$’000 Interest on finance leases 290 606 — — 896 Cash interest on exchangeable notes — 3,996 — — 3,996 Non-cash interest on exchangeable notes ( Note 25) — 643 — — 643 Non-cash financial expense — 1,216 — — 1,216 Inter-segment interest expense 6,668 363 1,478 (8,509 ) — Total 6,958 6,824 1,478 (8,509 ) 6,751 Rest of world Interest Income Year ended December 31, 2019 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$‘000 Total US$‘000 Interest income earned 47 417 — — 464 Non-cash financial income — 233 — — 233 Inter-segment interest income — — 4,853 (4,853 ) — Total 47 650 4,853 (4,853 ) 697 Rest of World Interest Expense Year ended December 31, 2019 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$‘000 Total US$’000 Interest on finance leases 294 653 — — 947 Interest on tax audit settlement (Note 6) — 1,000 — — 1,000 Cash interest on exchangeable notes — 3,996 — — 3,996 Non-cash interest on exchangeable notes ( Note 25) — 639 — — 639 Inter-segment interest expense 4,853 — — (4,853 ) — Total 5,147 6,288 — (4,853 ) 6,582 Rest of world Interest Income Year ended December 31, 2018 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$’000 Total US$‘000 Interest income earned 32 704 — — 736 Non-cash financial income — 1,388 — — 1,388 Inter-segment interest income — — 4,853 (4,853 ) — Total 32 2,092 4,853 (4,853 ) 2,124 Rest of world Interest Income Year ended December 31, 2018 Americas US$‘000 Ireland US$‘000 Other US$‘000 Eliminations US$’000 Total US$‘000 Interest on finance leases 7 32 — — 39 Cash interest on exchangeable notes — 4,352 — — 4,352 Non-cash interest on exchangeable notes ( Note 25) — 689 — — 689 Inter-segment interest expense 4,853 — — (4,853 ) — Total 4,860 5,073 — (4,853 ) 5,080
Schedule of Taxation Expense by Geographical Area	The distribution of taxation (expense)/credit by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Rest of World – Ireland 293 831 (59 ) Rest of World – Other (8 ) — (3 ) Americas 335 175 587 620 1,006 525
Schedule of Capital Expenditure by Geographical Area	The distribution of capital expenditure by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 Rest of World – Ireland 5,609 20,758 Rest of World – Other - - Americas 4,317 12,863 9,926 33,621

EMPLOYMENT (Tables)

EMPLOYMENT (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Schedule of Persons Employed by the Group in the Financial Year	The average number of persons employed by the Group is as follows: December 31, 2020 December 31, 2019 December 31, 2018 Research and development 52 57 59 Administration and sales 148 159 163 Manufacturing and quality 343 363 353 543 579 575
Schedule of Employment Costs	Employment costs charged in the Consolidated Income Statement for continuing operations are analysed as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Wages and salaries 26,187 25,885 26,475 Social welfare costs 2,195 2,538 2,585 Pension costs 447 503 490 Tax settlement (Note 6) — 5,094 — Share-based payments 792 758 1,369 Restructuring Cost 388 - - Recognition of contingent asset (Note 27) (1,316 ) 28,693 34,778 30,919

OTHER OPERATING INCOME (Tables)

OTHER OPERATING INCOME (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of other operating income [Abstract]
Schedule of Other Operating Income	December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Government supports - COVID-19 1,840 - - Other income 17 88 99 Rental income from premises 3 3 3 1,860 91 102

IMPAIRMENT CHARGES (Tables)

IMPAIRMENT CHARGES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of impairment charges and inventory provisioning [Abstract]
Schedule of Impairment Charges and Inventory Provisioning	The impact of the above items on the statement of operations for the year ended December 31, 2020, December 31, 2019 and December 31, 2018 was as follows: December December December 31, 2020 31, 2019 31, 2018 US$’000 US$’000 US$’000 Selling, general & administration expenses Impairment of PP&E (Note 13) 1,795 6,349 6,112 Impairment of goodwill and other intangible assets (Note 14) 15,422 16,570 19,212 Impairment of prepayments (Note 18) 562 1,376 1,608 Total impairment loss 17,779 24,295 26,932 Income tax impact of impairment loss 0 148 (1,752 ) Total impairment loss after tax 17,779 24,443 25,180

FINANCIAL INCOME AND EXPENSES (

FINANCIAL INCOME AND EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of financial income and expenses [Abstract]
Schedule of Financial Income and Expenses	December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Financial income: Non-cash financial income - 233 1,388 Interest income 36 464 736 36 697 2,124 Financial expense: Interest on leases (896 ) (947 ) (39 ) Interest on tax audit settlement (Note 6) - (1,000 ) - Cash interest on exchangeable notes (3,996 ) (3,996 ) (4,352 ) Non-cash interest on exchangeable notes (Note 25) (643 ) (639 ) (689 ) Non-cash financial expense (1,216 ) - - (6,751 ) (6,582 ) (5,080 ) Net Financing Expense (6,715 ) (5,885 ) (2,956 )

INCOME TAX CREDIT (Tables)

INCOME TAX CREDIT (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of income tax credit [Abstract]
Schedule of Charge for Tax	The tax credit based on the loss comprises: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Current tax (credit)/expense Irish Corporation tax (480 ) (312 ) (258 ) Foreign taxes (a) 179 197 195 Adjustment in respect of prior years (152 ) (50 ) (56 ) Total current tax credit (453 ) (165 ) (119 ) Deferred tax credit Origination and reversal of temporary differences (see Note 15) 48 (625 ) (2,031 ) Origination and reversal of net operating losses (see Note 15) (215 ) (216 ) 1,625 Total deferred tax credit (167 ) (841 ) (406 ) Total income tax credit on continuing operations in statement of operations (620 ) (1,006 ) (525 ) Tax charge / (credit) on discontinued operations (see Note 10) 438 - (590 ) 00 Total tax credit (182 ) (1,006 ) (1,115 ) (a) In 2020, the foreign taxes relate primarily to Canada. (b) In 2020, there was a deferred tax charge of US$53,000 (2019: credit of US$444,000; 2018: charge of US$369,000) recognised in respect of Ireland and a deferred tax credit of US$220,000 (2019: credit of US$397,000; 2018: credit of US$775,000) recognised in respect of overseas tax jurisdictions.
Schedule of Overseas Tax Jurisdictions	Effective tax rate December 31, 2020 December 31, 2019 December 31, 2018 Loss before taxation – continuing operations (US$‘000) (6,633 ) (29,997 ) (23,183 ) As a percentage of loss before tax: Current tax % (6.83 )% (0.55 )% (0.51 )% Total (current and deferred) % (9.35 )% (3.36 )% (2.26 )%
Schedule of Statutory Tax Rate	The following table reconciles the applicable Republic of Ireland statutory tax rate to the effective total tax rate for the Group: December 31, 2020 December 31, 2019 December 31, 2018 Irish corporation tax (12.5 )% (12.5 )% (12.5 )% Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised (a) 24.13 % 13.21 % 15.76 % Effect of tax rates on overseas earnings (9.92 )% (3.05 )% (6.10 )% Effect of Irish income taxable at higher tax rate 5.92 % 0.04 % 0.05 % Adjustments in respect of prior years (10.66 )% (0.17 )% 0.94 % R&D tax credits (11.00 )% (2.69 )% (1.70 )% Other items (c) 4.68 % 1.80 % 1.29 % Effective tax rate (9.35 )% (3.36 )% (2.26 )% (a) The effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised is analyzed further in the table below (see also Note 15). No deferred tax asset was recognised because there was no reversing deferred tax liability in the same jurisdiction reversing in the same period and no future taxable income in the same jurisdiction. (b) Other items comprise items not chargeable to tax/expenses not deductible for tax purposes. In 2020, this mainly comprises the movement in the exchangeable notes’ embedded derivatives value and the accretion of notional interest on the Loan Note’s host contract, both of which are exempt from deferred taxation recognition under IAS 12, Income Taxes. In 2019, other items mainly comprise the tax audit settlement recorded in Selling, General and Administrative expenses (see also Note 6), which is not deductible for tax and the movement in the exchangeable notes’ embedded derivatives value and the accretion of notional interest.
Schedule of Unrecognised Deferred Tax Assets	Unrecognised deferred tax assets – continuing operations Effect in 2020 US$’000 Percentage effect in 2020 Effect in 2019 US$’000 Percentage effect in 2019 Increase in net operating losses arising in US 1,105 16.66 % 1,117 3.72 % Temporary differences arising in US - - 129 0.43 % (Decrease)/increase in net operating losses arising in Brazil (502 ) (7.57 )% 608 2.03 % Increase in net operating losses arising in Luxembourg 544 8.20 % - - Increase in net operating losses arising in UK 2 0.03 % - - Increase in net operating losses arising in Ireland 452 6.81 % 2,110 7.03 % 1,601 24.13 % 3,964 13.21 %
Schedule of (Loss)/Profit Before Taxes	The distribution of loss before taxes by geographical area was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Rest of World – Ireland 296 (20,318 ) (9,590 ) Rest of World – Other 3,304 4,760 4,809 Americas (10,233 ) (14,439 ) (18,402 ) (6,633 ) (29,997 ) (23,183 )
Schedule of Unutilised Net Operating Losses	At December 31, 2020, the Group had unutilised net operating losses for continuing operations as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Ireland 78,700 73,754 60,629 USA - 1,034 2,382 Luxembourg 2,175 - - UK 10 - - Brazil 4,313 5,789 4,001 85,198 80,577 67,012
Schedule of Unused Tax Losses and Unused Tax Credits	At December 31, 2020, the Group had unrecognised deferred tax assets in respect of unused tax losses and unused tax credits as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Ireland – unused tax losses 12,514 12,062 9,953 US – unused tax losses - 3,291 2,174 US – unused tax credits 2,862 493 364 Luxembourg – unused tax losses 544 - - UK – unused tax losses 2 - - Brazil – unused tax losses 1,466 1,968 1,360 18,810 Unrecognised deferred tax asset 17,388 17,814 13,851

(LOSS)_PROFIT FOR THE YEAR ON_2

(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of loss on discontinued operation [Abstract]
Schedule of Loss on Remeasurement of Assets and Liabilities	The operating loss for the Cardiac point-of-care tests operation in Sweden and the (loss)/profit on re-measurement of its assets and liabilities are summarised as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 (Loss)/Profit on re-measurement of assets and liabilities: Closure provision 127 (8 ) (22 ) Foreign currency translation reserve (64 ) 85 — Tax (expense)/credit (438 ) — 590 Total (loss)/profit (375 ) 77 568 (Loss)/Profit for the year from discontinued operations (375 ) 77 568
Schedule of Earnings Per ADS for Discontinued Operations	December 31, December 31, December 31, Basic (loss)/earnings per ADS (US Dollars) – discontinued operations (0.02 ) 0.00 0.03 Diluted (loss)/earnings per ADS (US Dollars) – discontinued operations (0.02 ) 0.00 0.02 Basic (loss)/earnings/ per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.01 Diluted (loss)/earnings per ‘A’ share (US Dollars) – discontinued operations 0.00 0.00 0.01
Schedule of Cash Flows Attributable to Discontinued Operations	The cash flows attributable to discontinued operations are as follows: December 31, December 31, December 31, US$000 US$000 US$000 Cash flows from operating activities (22 ) (5 ) 527

LOSS BEFORE TAX (Tables)

LOSS BEFORE TAX (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of loss profit before tax [Abstract]
Schedule of Loss Before Tax	The following amounts were charged / (credited) to the statement of operations: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Directors’ emoluments (including non- executive directors): Remuneration 2,020 1,238 1,261 Pension 41 42 44 Share based payments 678 624 1,204 Auditor’s remuneration Audit fees 533 523 506 Tax fees 146 172 15 Other non-audit fees 25 - - Depreciation* 1,674 2,526 1,296 Amortisation (Note 14) 1,403 2,368 2,825 (Profit)/Loss on the disposal of property, plant and equipment 30 17 15 Net foreign exchange differences 583 (179 ) 344 * Note that US$38,000 (2019: US$4,000) (2018: US$79,000) of depreciation was capitalised to research and development projects during 2020 in line with the Group’s capitalisation policy for Intangible projects.

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings per share [abstract]
Schedule of Basic Earnings Per Ordinary Share	As at December 31, 2020, this amounted to 83,606,810 shares (2019: 83,606,810) (2018: 83,612,908 shares). December 31, December 31, December 31, ‘A’ ordinary shares 83,606,810 83,606,810 83,612,908 Basic earnings per share denominator 83,606,810 83,606,810 83,612,908 Reconciliation to weighted average earnings per share denominator: Number of ‘A’ ordinary shares at January 1 (Note 21) 96,162,410 96,162,410 96,162,410 Weighted average number of shares issued during the year* - Weighted average number of treasury shares (12,555,600 ) (12,555,600 ) (12,549,502 ) Basic earnings per share denominator 83,606,810 83,606,810 83,612,908 *The weighted average number of shares issued during the year is calculated by taking the number of shares issued multiplied by the number of days in the year each share is in issue, divided by 365 days.
Schedule of Diluted Earnings Per Ordinary Share	The basic weighted average number of ordinary shares for the Group may be reconciled to the number used in the diluted earnings per ordinary share calculation as follows: December 31, 2020 December 31, 2019 December 31, 2018 Basic earnings per share denominator (see above) 83,606,810 83,606,810 83,612,908 Issuable on exercise of options and warrants 3,154,668 - 22,359 Issuable on conversion of exchangeable notes 18,263,254 18,263,254 19,873,553 Diluted earnings per share denominator 105,024,732 101,870,064 103,508,820
Schedule of Profit After Tax Diluted Earnings Per Ordinary Share Calculation	The loss after tax for the year may be reconciled to the amount used in the diluted earnings per ordinary share calculation as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Loss after tax for the year (6,388 ) (28,914 ) (22,090 ) Non-cash financial expense/(income) (Note 8) 1,216 (233 ) (1,388 ) Cash interest expense (Note 8) 3,996 3,996 4,352 Non-cash interest on exchangeable notes (Note 8) 643 639 689 Adjusted loss after tax (533 ) (24,512 ) (18,437 )
Schedule of Basic Earning per ADS	December 31, 2020 December 31, 2019 December 31, 2018 ADS 20,901,703 20,901,703 20,903,227 Basic earnings per share denominator 20,901,703 20,901,703 20,903,227 Reconciliation to weighted average earnings per share denominator: Number of ADS at January 1 (Note 21) 24,040,602 24,040,602 24,040,602 Weighted average number of shares issued during the year* - - - Weighted average number of treasury shares (3,138,899 ) (3,138,899 ) (3,137,375 ) Basic earnings per share denominator 20,901,703 20,901,703 20,903,227 *The weighted average number of shares issued during the year is calculated by taking the number of shares issued multiplied by the number of days in the year each share is in issue, divided by 365 days.
Schedule of Diluted Earning per ADS	The basic weighted average number of ADS shares for the Group may be reconciled to the number used in the diluted earnings per ADS share calculation as follows: December 31, 2020 December 31, 2019 December 31, 2018 Basic earnings per share denominator (see above) 20,901,703 20,901,703 20,903,227 Issuable on exercise of options and warrants 788,666 - 5,590 Issuable on conversion of exchangeable notes 4,565,814 4,565,814 4,968,388 Diluted earnings per share denominator 26,256,183 25,467,517 25,877,205

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Property, Plant and Equipment	Land and buildings US$‘000 Leasehold improvements US$‘000 Computers, fixtures and fittings US$‘000 Plant and equipment US$‘000 Total US$‘000 Cost At January 1, 2019 2,605 4,560 6,585 40,064 53,814 Adjustment on transition to IFRS 16 20,961 — 149 75 21,185 Additions 681 71 168 1,905 2,825 Disposals or retirements — (1,626 ) (2,610 ) (3,314 ) (7,550 ) Exchange adjustments 22 — — (54 ) (32 ) At December 31, 2019 24,269 3,005 4,292 38,676 70,242 At January 1, 2020 24,269 3,005 4,292 38,676 70,242 Additions 8 41 96 2,766 2,911 Disposals or retirements — (299 ) (66 ) (5,758 ) (6,123 ) Exchange adjustments 10 (77 ) (13 ) (1,845 ) (1,925 ) At December 31, 2020 24,287 2,670 4,309 33,839 65,105 Accumulated depreciation and impairment losses At January 1, 2019 (1,934 ) (3,243 ) (5,783 ) (37,492 ) (48,452 ) Charge for the year (1,545 ) (105 ) (200 ) (680 ) (2,530 ) Adjustment on transition to IFRS 16 (10,984 ) — (40 ) (75 ) (11,099 ) Impairment loss as at December 31, 2019 (4,024 ) (233 ) (276 ) (1,816 ) (6,349 ) Disposals or retirements — 1,544 2,618 3,331 7,493 Reallocations / reclassifications — — — (5 ) (5 ) Exchange adjustments (6 ) — (1 ) (3 ) (10 ) At December 31, 2019 (18,493 ) (2,037 ) (3,682 ) (36,740 ) (60,952 ) At January 1, 2020 (18,493 ) (2,037 ) (3,682 ) (36,740 ) (60,952 ) Charge for the year (783 ) (146 ) (181 ) (604 ) (1,714 ) Impairment loss as at December 31, 2020 (347 ) (78 ) (180 ) (1,190 ) (1,795 ) Disposals or retirements — 299 84 5,590 5,973 Exchange adjustments (6 ) 78 13 1,845 1,930 At December 31, 2020 (19,629 ) (1,884 ) (3,946 ) (31,099 ) (56,558 ) Carrying amounts At December 31, 2020 4,658 786 363 2,740 8,547 At December 31, 2019 5,776 968 610 1,936 9,290
Schedule of Right-of-use assets	US$000 Right-of-use assets cost at transition before impairment 21,185 Impairment adjustment on transition (11,099 ) Right-of-use assets value at transition after impairment 10,086
Schedule of Reconciliation from IAS 17 to IFRS 16	The following is a reconciliation of the financial statement line items from IAS 17 to IFRS 16 at January 1, 2019: Carrying amount at December 31, 2018 Remeasurement Impairment IFRS 16 carrying amount at January 1, 2019 US$000 US$000 US$000 US$000 Property, plant & equipment 5,362 21,185 (11,099 ) 15,448 Lease liabilities (962 ) (21,185 ) - (22,147 ) Retaining earnings (55,319 ) - 11,099 (44,220 ) Total (50,919 ) - - (50,919 )
Schedule of Additional Information on Right-of-use Assets	Additional information on the right-of-use assets by class of assets is as follows: Carrying amount At December 31, 2020 Depreciation Charge Year ended December 31, 2020 Impairment Charge Year ended December 31, 2020 US$000 US$000 US$000 Buildings 4,200 (673 ) (347 ) Computer equipment 3 (4 ) - Plant and Equipment - (70 ) (154 ) 4,203 (747 ) (501 ) Carrying amount At December 31, 2019 Depreciation Year ended December 31, 2019 Impairment Year ended December 31, 2019 US$000 US$000 US$000 Buildings 5,220 (1,523 ) (3,913 ) Computer equipment 7 (39 ) (63 ) 5,227 (1,562 ) (3,976 )
Schedule of Income from Sub-letting Right-of-use Buildings	Right-of-Use assets at 31 December 2020 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 12 1 to 13 4 1 - 2 4 Vehicle 16 1 to 3 2 - 16 - 16 I.T. and office equipment 10 1 to 2 1 - - - 1 Right-of-Use assets at 31 December 2019 No. of Right-of-Use leased assets Range of remaining term in years Average remaining lease term (years) No. of Leases with extension options No. of Leases with options to purchase No. of leases with variable payments linked to index No. of leases with termination options Building 13 1 to 14 5 1 - 2 4 Vehicle 9 1 to 2 1 - 9 - 9 I.T. and office equipment 11 1 to 2 2 - - - 1

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of goodwill and intangible assets [Abstract]
Schedule of Goodwill and Intangible Assets	Goodwill US$‘000 Development costs US$‘000 Patents and licences US$‘000 Other US$‘000 Total US$‘000 Cost At January 1, 2019 81,689 146,772 9,947 34,228 272,636 Additions — 9,569 4 38 9,611 Disposals or retirements — — — — — Exchange adjustments — 36 — — 36 At December 31, 2019 81,689 156,377 9,951 34,266 282,283 At January 1, 2020 81,689 156,377 9,951 34,266 282,283 Additions — 6,896 30 89 7,015 Disposals or retirements (2,507 ) (34,318 ) (1,034 ) (1,044 ) (38,903 ) Reclassification — — — — — Exchange adjustments — 22 — — 22 At December 31, 2020 79,182 128,977 8,947 33,311 250,417 Accumulated amortisation and Impairment losses At January 1, 2019 (65,548 ) (120,507 ) (9,814 ) (23,816 ) (219,685 ) Charge for the year — (1,182 ) (2 ) (1,184 ) (2,368 ) Disposals or retirements — — — — — Impairment losses (3,550 ) (11,904 ) (3 ) (1,113 ) (16,570 ) Exchange adjustments — (6 ) — — (6 ) At December 31, 2019 (69,098 ) (133,599 ) (9,819 ) (26,113 ) (238,629 ) At January 1, 2020 (69,098 ) (133,599 ) (9,819 ) (26,113 ) (238,629 ) Charge for the year — (959 ) (5 ) (439 ) (1,403 ) Disposals or retirements 2,507 34,318 1,034 1,044 38,903 Impairment losses — (15,287 ) — (135 ) (15,422 ) Exchange adjustments — (6 ) — — (6 ) At December 31, 2020 (66,591 ) (115,533 ) (8,790 ) (25,643 ) (216,557 ) Carrying amounts At December 31, 2020 12,591 13,444 157 7,668 33,860 At December 31, 2019 12,591 22,778 132 8,153 43,654
Schedule of Principal Development Projects	The following represents the costs incurred during each period presented for each of the principal development projects: Product Name 2020 US $’000 2019 US $’000 HIV screening rapid test 2,278 2,587 Premier Instrument for Haemoglobin A1c testing 1,359 1,930 Autoimmune Smart Reader 666 1,325 Syphilis point-of-care test 618 870 Uni-Gold antigen improvement 556 691 COVID tests 467 - Mid-tier haemoglobins instrument 243 63 Tri-stat point-of-care instrument 203 361 Column enhancement 151 236 Ultra Genesys 139 237 Sjögrens tests 99 135 G-6-PDH test - 582 Uni-gold test - 376 Other projects 117 176 Total capitalised development costs 6,896 9,569
Schedule of Impairment Loss Recorded on Discontinued Assets	The table below sets forth the impairment loss recorded for each of the CGU’s: December 31, 2020 December 31, 2019 US$’000 US$’000 Primus Corp 16,706 5,321 Trinity Biotech Do Brasil 919 1,253 Biopool US Inc. 154 210 Trinity Biotech Manufacturing Limited - 9,732 Immco Diagnostics Inc - 6,332 Clark Laboratories Inc. - 727 Mardx Diagnostics Inc. - 720 17, Total impairment loss 17,779 24,295
Schedule of Impairment Loss for Each Class of Asset	The table below sets forth the breakdown of the impairment loss for each class of asset: December 31, 2020 December 31, 2019 US$’000 US$’000 Goodwill and other intangible assets (see Note 14) 15,422 16,570 Property, plant and equipment (see Note 13) 1,795 6,349 Prepayments (see Note 18) 562 1,376 Total impairment loss 17,779 24,295
Schedule of Significant Goodwill	The additional disclosures required for the CGU with significant goodwill are as follows: Fitzgerald Industries December 31, December 31, Carrying amount of goodwill (US$’000) 12,591 12,591 Discount rate applied (real pre-tax) 19.98 % 20.42 % Excess value-in-use over carrying amount (US$’000) 7,915 2,385 % EBITDA would need to decrease for an impairment to arise 31.98 % 12.11 % Long-term growth rate 2.0 % 2.0 %
Schedule of Internal and External Factors Based on Historical Experience	Intangible Assets with Indefinite Useful lives (included in other intangibles) December 31, 2020 US$‘000 December 31, 2019 US$‘000 Fitzgerald Industries International CGU Fitzgerald trade name 970 970 RDI trade name 560 560 Primus Corporation CGU Primus trade name 365 500 Immco Diagnostic CGU Immco Diagnostic trade name 2,938 2,938 Total 4,833 4,968

DEFERRED TAX ASSETS AND LIABI_2

DEFERRED TAX ASSETS AND LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of deferred tax assets and liabilities [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities of the Group are attributable to the following: Assets Liabilities Net 2020 2019 2020 2019 2020 2019 Property, plant and equipment 733 1,027 (9 ) (9 ) 724 1,018 Intangible assets — — (4,072 ) (6,099 ) (4,072 ) (6,099 ) Inventories 750 642 — — 750 642 Provisions 2,159 3,622 — — 2,159 3,622 Tax value of loss carry-forwards 433 216 — — 433 216 Other items 110 745 (824 ) (1,031 ) (714 ) (286 ) Deferred tax assets/(liabilities) 4,185 6,252 (4,905 ) (7,139 ) (720 ) (887 )
Schedule of Unrecognised Deferred Tax Liabilities	Balance January, 1 Recognised Balance December 31, US$’000 US$’000 US$’000 Property, plant and equipment 1,018 (294 ) 724 Intangible assets (6,099 ) 2,027 (4,072 ) Inventories 642 108 750 Provisions 3,622 (1,463 ) 2,159 Tax value of loss carry-forwards 216 217 433 Other items (286 ) (428 ) (714 ) (887 ) 167 (720 ) Balance January, 1 Recognised Balance December 31, US$’000 US$’000 US$’000 Property, plant and equipment 778 240 1,018 Intangible assets (7,189 ) 1,090 (6,099 ) Inventories 668 (26 ) 642 Provisions 4,311 (689 ) 3,622 Tax value of loss carry-forwards - 216 216 Other items (296 ) 10 (286 ) (1,728 ) 841 (887 )
Schedule of Deferred Tax Assets Not Recognised	Deferred tax assets have not been recognised by the Group in respect of the following items: December 31, December 31, US$’000 US$’000 Capital losses 8,293 8,293 Net operating losses 85,198 80,577 US alternative minimum tax credits 1,848 1,928 Other temporary timing differences 21,878 7,399 US state credit carryforwards 802 493 118,019 98,690

OTHER NON-CURRENT ASSETS (Table

OTHER NON-CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of non-current assets [Abstract]
Schedule of Other Non-Current Assets	December 31, 2020 US$‘000 December 31, 2019 US$‘000 Finance lease receivables (see Note 18) 291 403 Other assets 64 82 355 485

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2020
Classes of current inventories [abstract]
Schedule of Inventories	December 31, 2020 US$‘000 December 31, 2019 US$‘000 Raw materials and consumables 12,168 12,654 Work-in-progress 5,169 6,940 Finished goods 12,882 12,427 30,219 32,021
Schedule of Movement on Inventory Provision	The movement on the inventory provision for the three year period to December 31, 2020 is as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Opening provision at January 1 6,716 6,299 7,543 Charged during the year 5,179 1,567 480 Utilised during the year (1,994 ) (1,150 ) (1,544 ) Released during the year (120 ) - (180 ) Closing provision at December 31 9,781 6,716 6,299

TRADE AND OTHER RECEIVABLES (Ta

TRADE AND OTHER RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2020
Trade and other receivables [abstract]
Schedule of Trade and Other Receivables	December 31, 2020 US$‘000 December 31, 2019 US$‘000 Trade receivables, net of impairment losses 20,025 17,754 Prepayments 1,159 576 Contract assets 1,177 2,317 Value added tax 92 59 Finance lease receivables 215 281 22,668 20,987
Schedule of Future Minimum Finance Lease Receivables	The Group leases instruments as part of its business. Future minimum receivables with non-cancellable terms are as follows: December 31, 2020 US$‘000 Gross Unearned Minimum Less than one year 415 200 215 Between one and five years (Note 16) 591 300 291 1,006 500 506 December 31, 2019 US$‘000 Gross Unearned Minimum Less than one year 523 242 281 Between one and five years (Note 16) 805 402 403 1,328 644 684
Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases	Future minimum rentals receivable under non-cancellable operating leases are as follows: December 31, 2020 US$‘000 Instruments Total Less than one year 2,767 2,767 Between one and five years 171 171 2,938 2,938 December 31, 2019 US$‘000 Instruments Total Less than one year 3,528 3,528 Between one and five years 27 27 3,555 3,555

CASH AND CASH EQUIVALENTS (Tabl

CASH AND CASH EQUIVALENTS (Tables)	12 Months Ended
	Dec. 31, 2020
Cash and cash equivalents [abstract]
Schedule of Cash and Cash Equivalents	December 31, 2020 US$’000 December 31, 2019 US$’000 Cash at bank and in hand 24,209 6,275 Short-term deposits 3,118 8,956 Cash and cash equivalents 27,327 15,231

SHORT-TERM INVESTMENTS (Tables)

SHORT-TERM INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of short-term investments [Abstract]
Schedule of Short-Term Investments	December 31, 2020 US$’000 December 31, 2019 US$’000 Investments (deposits) - 1,169 - 1,169

CAPITAL AND RESERVES (Tables)

CAPITAL AND RESERVES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of classes of share capital [abstract]
Schedule of Share Capital	Share capital Class ‘A’ Class ‘A’ In thousands of shares 2020 2019 In issue at January 1 96,162 96,162 Issued for cash - - In issue at December 31 96,162 96,162 ADS ADS In thousands of ADSs 2020 2019 Balance at January 1 24,041 24,041 Issued for cash - - Balance at December 31 24,041 24,041 Class ‘A’ Class ‘A’ In thousands of shares 2020 2019 Balance at January 1 12,556 12,556 Purchased during the year - - Balance at December 31 12,556 12,556 ADS Treasury shares ADS Treasury shares In thousands of ADSs 2020 2019 Balance at January 1 3,139 3,139 Purchased during the year - - Balance at December 31 3,139 3,139

SHARE OPTIONS (Tables)

SHARE OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of share options [Abstract]
Schedule of Grants of Share Options and Warrants	Options and Weighted- US$ Range US$ ‘A’ Ordinary Per ‘A’ Ordinary Share Per ‘A’ Ordinary Outstanding January 1, 2018 10,727,376 1.92 1.24 –4.36 Granted 720,000 1.07 0.67 –1.37 Exercised - - - Forfeited (539,176 ) 2.50 1.34 –4.23 Outstanding at end of year 10,908,200 1.83 0.67 –4.36 Exercisable at end of year 6,091,864 2.09 1.24 –4.36 Outstanding January 1, 2019 10,908,200 1.83 0.67 –4.36 Granted 4,370,000 0.68 0.46 –0.78 Exercised - - - Expired / Forfeited (2,974,210 ) 2.25 0.66 –4.23 Outstanding at end of year 12,303,990 1.31 0.46 –4.36 Exercisable at end of year 6,622,667 1.73 1.24 –4.36 Outstanding January 1, 2020 12,303,990 1.31 0.46 –4.36 Granted 9,100,000 0.38 0.19 –1.10 Exercised - - - Expired / Forfeited (1,918,000 ) 2.14 0.19-4.21 Outstanding at end of year 19,485,990 0.79 0.19-4.36 Exercisable at end of year 7,959,323 1.27 0.66-4.36 Options and Weighted- US$ Range US$ ‘ADS’ Equivalent Per ‘ADS’ Per ‘ADS’ Outstanding January 1, 2018 2,681,844 7.69 4.96 - 17.44 Granted 180,000 4.28 2.68 – 5.48 Exercised - - - Expired / Forfeited (134,794 ) 10.00 5.36 – 16.92 Outstanding at end of year 2,727,050 7.32 2.68–17.44 Exercisable at end of year 1,522,966 8.36 4.96 –17.44 Outstanding January 1, 2019 2,727,050 7.32 2.68–17.44 Granted 1,092,500 2.72 1.83 - 3.10 Exercised - - - Expired / Forfeited (743,552 ) 8.99 2.64 – 16.92 Outstanding at end of year 3,075,998 5.24 1.83 – 17.45 Exercisable at end of year 1,655,667 6.92 4.95 –17.45 Outstanding January 1, 2020 3,075,998 5.24 1.83 – 17.45 Granted 2,275,000 1.52 0.77-4.41 Exercised - - - Expired / Forfeited (479,500 ) 8.56 0.77-16.84 Outstanding at end of year 4,871,498 3.15 0.77-17.45 Exercisable at end of year 1,989,831 5.08 2.64-17.45
Summary of Range of Prices of Stock Options	A summary of the range of prices for the Company’s stock options for the year ended December 31, 2020 follows: Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.19-US$0.99 13,260,006 0.48 4.14 2,106,673 0.69 1.44 US$1.00-US$2.05 5,664,000 1.34 1.11 5,290,667 1.35 2.44 US$2.06- US$2.99 499,984 2.52 0.05 499,984 2.52 0.13 US$3.00 -US$4.36 62,000 4.17 0.00 62,000 4.17 0.01 19,485,990 7,959,324 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.77-US$3.96 3,315,002 1.92 4.17 526,668 2.76 1.44 US$4.00-US$8.20 1,416,000 5.36 1.10 1,322,667 5.40 2.44 US$8.24- US$11.96 124,996 10.08 0.05 124,996 10.08 0.13 US$12.00 -US$17.45 15,500 16.68 0.00 15,500 16.68 0.01 4,871,498 1,989,831 A summary of the range of prices for the Company’s stock options for the year ended December 31, 2019 follows: Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US$0.46-US$0.99 4,600,000 0.69 6.42 - - - US$1.00-US$2.05 5,613,990 1.35 4.69 4,542,667 1.34 4.68 US$2.06- US$2.99 1,980,000 2.48 3.13 1,970,000 2.48 3.13 US$3.00 -US$4.36 110,000 4.19 2.07 110,000 4.19 2.07 12,303,990 6,622,667 Outstanding Exercisable Exercise price range No. of Weighted– Weighted- No. of Weighted– Weighted- US1.84-US$3.96 1,150,000 2.75 6.42 0 0.00 0.00 US4.00-US$8.20 1,403,498 5.40 4.69 1,135,667 5.38 4.68 US8.24- US$11.96 495,000 9.92 3.13 492,500 9.91 3.13 US12.00 -US$17.45 27,500 16.75 2.07 27,500 16.75 2.07 3,075,998 1,655,667
Schedule of Fair Value of the Options Vesting Period	The fair value of the options is expensed over the vesting period of the option. US$792,000 was charged to the statement of operations in 2020, (2019: US$758,000), (2018: US$1,369,000) split as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 December 31, 2018 US$‘000 Share-based payments – cost of sales 12 26 34 Share-based payments – selling, general and administrative 780 732 1,335 Total – continuing operations 792 758 1,369 Share-based payments – discontinued operations - - - Total 792 758 1,369
Schedule of Assumption Determining Fair Value of Share Options	The fair value of services received in return for share options granted are measured by reference to the fair value of share options granted. The estimate of the fair value of services received is measured based on a trinomial model. The following are the input assumptions used in determining the fair value of share options granted in 2020, 2019 and 2018: Key management personnel Other employees Key management personnel Other employees Key management personnel Other employees 2020 2020 2019 2019 2018 2018 Weighted average fair value at measurement date per ‘A’ share / (per ADS) US$0.20 / (US$0.80 ) US$0.27 / (US$1.08 ) US$0.14 / (US$0.56 ) US$0.25 / (US$1.02 ) - US$0.41 / (US$1.64 ) Total ‘A’ share options granted / (ADS’s equivalent) 8,480,000 / (2,120,000 ) 620,000 / (155,000 ) 4,060,000 / (1,015,000 ) 310,000 / (77,500 ) - 720,000 / (180,000 ) Weighted average share price per ‘A’ share / (per ADS) US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) US$0.46 /(US$1.84 ) US$0.64 /(US$2.53 ) - US$1.07 /(US$4.28 ) Weighted average exercise price per ‘A’ share / (per ADS) US$0.38 / (US$1.52 ) US$0.48 / (US$1.96 ) US$0.69 /(US$2.74 ) US$0.64 /(US$2.53 ) - US$1.07 /(US$4.28 ) Weighted average expected volatility 66.98 % 65.89 % 51.18 % 47.31 % - 42.69 % Weighted average expected life 4.34 4.35 4.15 4.42 - 4.55 Weighted average risk free interest rate 0.44 % 0.42 % 1.84 % 2.23 % - 2.72 %

TRADE AND OTHER PAYABLES (Table

TRADE AND OTHER PAYABLES (Tables)	12 Months Ended
	Dec. 31, 2020
Trade and other current payables [abstract]
Schedule of Trade and Other Payables	December 31, 2020 US$’000 December 31, 2019 US$’000 Trade payables 7,103 7,833 Payroll taxes 688 519 Employee related social insurance 344 170 Accruals and other liabilities 8,850 8,133 Deferred income 4,445 292 Government COVID-19 loans (Note 4) 2,905 - 24,335 16,947

PROVISIONS (Tables)

PROVISIONS (Tables)	12 Months Ended
	Dec. 31, 2020
Provisions [abstract]
Schedule of Provisions	December 31, 2020 US$’000 December 31, 2019 US$’000 Product warranty provision 50 50 Other provisions 366 - 416 50

EXCHANGEABLE NOTES AND OTHER _2

EXCHANGEABLE NOTES AND OTHER BORROWINGS (Tables)	12 Months Ended
	Dec. 31, 2020
Borrowings [abstract]
Schedule of Carrying Value of Exchangeable Senior Notes	The carrying value of exchangeable senior notes and other borrowings is as follows: December 31, US$’000 December 31, US$’000 Exchangeable senior notes 82,664 82,021 Other borrowings 31 - Total value of embedded derivatives – liability 1,370 4 Total non-current liabilities 84,065 82,025 The movement in the Exchangeable senior notes is as follows: December 31, US$’000 December 31, US$’000 Balance at 1 January 82,021 81,382 Accretion interest (Note 8) 643 639 82,664 82,021
Schedule of Exchangeable Notes	The embedded derivatives are summarised as follows: December 31, US$’000 December 31, US$’000 Non-current assets Exchangeable note bond call option 150 - Non-current liabilities Exchangeable note equity conversion option 1,370 4 Exchangeable note bond put option - - 1,370 4 Total value of embedded derivatives – net liability 1,220 4

LEASE LIABILITIES (Tables)

LEASE LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of finance lease liabilities [Abstract]
Schedule of Carrying Values of Finance Lease Liabilities	Lease liabilities are payable as follows: December 31, 2020 US$’000 December 31, 2019 US$’000 Current liabilities Lease liabilities related to Right of Use assets 2,054 2,156 Sale and leaseback liabilities 99 248 2,153 2,404 Non-Current liabilities Lease liabilities related to Right of Use assets 16,407 17,474 Sale and leaseback liabilities 181 271 16,588 17,745
Schedule of Finance Lease Liabilities Payable	December 31, 2020 US$’000 December 31, 2020 US$’000 Lease liabilities related to Right of Use assets Sale and leaseback liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 2,877 823 2,054 111 12 99 In more than one year, but not more than two 2,644 730 1,914 111 7 104 In more than two years but not more than five 6,621 1,765 4,856 79 2 77 more than five years 11,389 1,752 9,637 - - - 23,531 5,070 18,461 301 21 280 December 31, 2019 US$’000 December 31, 2019 US$’000 Lease liabilities related to Right of Use assets Sale and leaseback liabilities Minimum lease payments Interest Principal Minimum lease payments Interest Principal Less than one year 3,017 861 2,156 267 19 248 In more than one year, but not more than two 2,787 775 2,012 107 12 95 In more than two years but not more than five 6,700 1,861 4,840 185 9 176 more than five years 12,748 2,126 10,622 - - - 25,252 5,263 19,630 559 40 519
Schedule of Reconciliation of Operating Lease Commitments	The reconciliation of operating lease commitments at December 31, 2018 to the additional lease liabilities recognized on the initial application of IFRS 16 at January 1, 2019 is as follows: US$000 Operating Lease commitments at December, 31, 2018 (Note 27) 27,342 Relief option for short term leases (130 ) Relief option for low value assets - Effect of assumed probable lease extension in adoption of IFRS 16 573 Other (149 ) Gross lease liabilities at January 1, 2019 27,636 Discounting (6,451 ) Additional Lease liabilities as a result of the initial application of IFRS 16 at January 1, 2019 21,185
Schedule of Lease Payments Not Recognised as Liability	The expense relating to payments not included in the measurement of the lease liability is as follows: December 31, 2020 December 31, 2019 US$000 US$000 Short term leases - 130 Leases of low value assets - - Variable lease payments - - - 130
Schedule of Outstanding Interest Bearing Loans and Borrowings	The terms and conditions of outstanding interest bearing loans and borrowings at December 31, 2020 are as follows: Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities Euro 4.53 % 2023 106 106 Sale and leaseback liabilities USD 5.51 % 2023 174 174 Total interest-bearing loans and borrowings 280 280 The terms and conditions of outstanding interest bearing loans and borrowings at December 31, 2019 are as follows: Facility Currency Nominal interest Year of maturity Fair Value Carrying Value Sale and leaseback liabilities Euro 4.53 % 2023 286 286 Sale and leaseback liabilities USD 5.51 % 2023 233 233 Total interest-bearing loans and borrowings 519 519

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of transactions between related parties [abstract]
Schedule of Compensation	Compensation for the year ended December 31, 2020 of these personnel is detailed below: December 31, 2020 December 31, 2019 US$’000 US$’000 Short-term employee benefits 1,274 800 Performance related bonus 584 213 Post-employment benefits 41 42 Share-based compensation benefits 626 542 2,525 1,597
Schedule of Company's Shares and Share Option Plan	Directors’ interests in the Company’s shares and share option plan ‘A’ Ordinary Shares Share options At January 1, 2020 9,077,706 10,414,004 Shares of retired director — — Options of retired director — — Shares purchased during the year — — Shares sold during the year — — Granted — 8,480,000 Expired / forfeited — (1,500,000 ) At December 31, 2020 9,077,706 17,394,004 ‘A’ Ordinary Shares Share options At January 1, 2019 9,139,706 8,655,004 Shares of retired director (30,000 ) — Options of retired director — (215,000 ) Shares purchased during the year — — Shares sold during the year (32,000 ) — Granted — 4,060,000 Expired / forfeited — (2,086,000 ) At December 31, 2019 9,077,706 10,414,004

CAPITAL AND FINANCIAL RISK MA_2

CAPITAL AND FINANCIAL RISK MANAGEMENT (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
Schedule of Fair Values of Financial Assets/Liabilities	The table below sets out the Group’s classification of each class of financial assets/liabilities, their fair values and under which valuation method they are valued: Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2020 Loans and receivables at amortised cost Trade receivables 18 20,025 — 20,025 20,025 Cash and cash equivalents 19 27,327 — 27,327 27,327 Finance lease receivable 16, 18 506 — 506 506 47,858 — 47,858 47,858 Liabilities at amortised cost Exchangeable note 25 — (82,664 ) (82,664 ) (82,664 ) Lease liabilities 26 (18,741 ) — (18,741 ) (18,741 ) Trade and other payables (excluding deferred income) 23 (19,890 ) — (19,890 ) (19,890 ) Provisions 24 (416 ) — (416 ) (416 ) (39,047 ) (82,664 ) (121,711 ) (121,711 ) Fair value through profit and loss (FVPL) Exchangeable note bond call option 25 — 150 150 150 Exchangeable note equity conversion option 25 — (1,370 ) (1,370 ) (1,370 ) — (1,220 ) (1,220 ) (1,220 ) 8,811 (83,884 ) (75,073 ) (75,073 ) For financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities Level 2: valuation techniques for which the lowest level of inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly Level 3: valuation techniques for which the lowest level of inputs that have a significant effect on the recorded fair value are not based on observable market data. Level 1 Level 2 Total carrying amount Fair Value Note US$’000 US$’000 US$’000 US$’000 December 31, 2019 Loans and receivables at amortised cost Trade receivables 18 17,754 — 17,754 17,754 Cash and cash equivalents 19 15,231 — 15,231 15,231 Investments (deposits) 20 1,169 — 1,169 1,169 Finance lease receivable 16,18 684 — 684 684 34,838 — 34,838 34,838 Liabilities at amortised cost Exchangeable note 25 — (82,021 ) (82,021 ) (82,021 ) Lease liabilities 26 (20,149 ) — (20,149 ) (20,149 ) Trade and other payables (excluding deferred income) 23 (16,655 ) — (16,655 ) (16,655 ) Provisions 24 (50 ) — (50 ) (50 ) (36,854 ) (82,021 ) (118,875 ) (118,875 ) Fair value through profit and loss (FVPL) Exchangeable note equity conversion option 25 — (4 ) (4 ) (4 ) — (4 ) (4 ) (4 ) (2,016 ) (82,025 ) (84,041 ) (84,041 )
Schedule of Interest Rate Risk Effective and Repricing Analysis	The following table sets out all interest-earning financial assets and interest bearing financial liabilities held by the Group at December 31, indicating their effective interest rates and the period in which they re-price: As at December 31, 2020 Note Effective interest Total US$’000 6 mths or less US$’000 6 –12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 19 0.1 % 27,327 27,327 — — — — Lease receivable 16,18 4.0 % 506 120 95 142 149 — Licence payments 23 8.1 % (194 ) (194 ) — — — — Exchangeable note 25 4.8 % (82,664 ) — — — — (82,664 ) Other borrowings 25 0 % (31 ) — — (31 ) — — Lease payable on Right of Use assets 26 5.0 % (18,461 ) (1,022 ) (1,032 ) (1,914 ) (4,856 ) (9,637 ) Lease payable on sale & leaseback transactions 26 5.0 % (280 ) (49 ) (50 ) (104 ) (77 ) — Total (73, 797 ) 26,182 (987 ) (1,907 ) (4,784 ) (92,301 ) As at December 31, 2019 Note Effective interest Total US$’000 6 mths or less US$’000 6 –12 mths US$’000 1-2 years US$’000 2-5 years US$’000 > 5 years US$’000 Cash and cash equivalents 19 1.1 % 15,231 15,231 — — — — Short-term investments 20 1.3 % 1,169 — 1,169 — — — Lease receivable 16,18 4.0 % 684 157 124 202 201 — Licence payments 23 8.1 % (1,307 ) (1,307 ) — — — — Exchangeable note 25 4.8 % (82,021 ) — — — — (82,021 ) Lease payable on Right of Use assets 26 5.0 % (19,630 ) (1,136 ) (1,020 ) (2,012 ) (4,840 ) (10,622 ) Lease payable on sale & leaseback transactions 26 5.0 % (519 ) (122 ) (125 ) (95 ) (177 ) — Total (86,393 ) 12,823 148 (1,905 ) (4,816 ) (92,643 )
Schedule of Interest Rate Profile of Financial Assets/Liabilities	The interest rate profile of financial assets/liabilities of the Group was as follows: December 31, 2020 US$‘000 December 31, 2019 US$‘000 Fixed rate instruments Fixed rate financial liabilities (licence fees) (194 ) (1,307 ) Fixed rate financial liabilities (exchangeable note) (82,664 ) (82,021 ) Fixed rate financial liabilities (borrowings) (31 ) — Fixed rate financial liabilities (lease payables) (18,741 ) (20,149 ) Financial assets (short-term deposits and short-term investments) 3,118 10,125 Financial assets (lease receivables) 506 684 (98,006 ) (92,668 )
Schedule of Liquidity Risk Estimated Interest Payments of Maturities	The following are the contractual maturities of financial liabilities, including estimated interest payments: As at December 31, 2020 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 24,335 24,335 24,335 — — — — Lease payable on Right of Use assets 18,461 18,461 1,022 1,032 1,914 4,856 9,637 Lease payable on sale & leaseback transactions 280 280 49 50 104 77 — Other borrowings 31 31 — — 31 — — Exchangeable notes ¹ 82,664 99,900 — — — — 99,900 Exchangeable note interest 999 97,902 1,998 1,998 3,996 11,988 77,922 126,770 240,909 27,404 3,080 6,045 16,921 187,459 ¹ The maturity of the Exchangeable Notes is based on the contractual maturity date of April 1, 2045 and does not take into account the potential exercise of put and call options in the next five years. As at December 31, 2019 US$’000 Carrying US$’000 Contractual US$’000 6 mths or US$’000 6 mths – 12 mths US$’000 1-2 years US$’000 2-5 years US$’000 >5 years US$’000 Financial liabilities Trade & other payables 16,947 16,947 16,947 — — — — Lease payable on Right of Use assets 19,630 19,630 1,136 1,020 2,012 4,840 10,622 Lease payable on sale & leaseback transactions 519 519 122 125 95 177 — Exchangeable notes¹ 82,021 99,900 — — — — 99,900 Exchangeable note interest 999 101,898 1,998 1,998 3,996 11,988 81,918 120,116 238,894 20,203 3,143 6,103 17,005 192,440
Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities	The amounts shown are those reported to key management translated into US Dollars at the closing rate: EUR GBP SEK CAD BRL Other As at December 31, 2020 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 1,229 152 9 2,859 776 — Trade and other receivable 1,105 63 — 3,191 1,357 — Trade and other payables (2,821 ) (57 ) (1 ) (449 ) (529 ) — Total exposure (487 ) 158 8 5,601 1,604 — As at December 31, 2019 EUR GBP SEK CAD BRL Other US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 US$‘000 Cash 394 138 10 3,265 238 — Trade and other receivable 1,247 71 — 337 1,871 — Trade and other payables (2,350 ) (27 ) (142 ) (47 ) (796 ) — Total exposure (709 ) 182 (132 ) 3,555 1,313 —
Schedule of Sensitivity Analysis	A 10% strengthening of the US Dollar against the Euro at December 31, 2020 would have increased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or loss US$’000 December 31, 2020 Euro 541 December 31, 2019 Euro 2,282 A 10% weakening of the US Dollar against the Euro at December 31, 2020 would have decreased profit and other equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant. Profit or Loss US$000 December 31, 2020 Euro (661 ) December 31, 2019 Euro (2,790 )
Schedule of Maximum Credit Exposure of Financial Assets	The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is as follows: Carrying Value Carrying Value Third party trade receivables (Note 18) 20,025 17,754 Finance lease income receivable (Note 18) 506 684 Cash and cash equivalents (Note 19) 27,327 15,231 Short-term investments (Note 20) - 1,169 47,858 34,838
Schedule of Exposure of Trade Receivables by Geographic Location	The maximum exposure to credit risk for trade receivables and finance lease income receivable by geographic location is as follows: Carrying Value Carrying Value United States 10,730 8,647 Euro-zone countries 1,360 786 United Kingdom 98 121 Other European countries 13 7 Other regions 8,330 8,877 20,531 18,438
Schedule of Exposure of Trade Receivables by Customer	The maximum exposure to credit risk for trade receivables and finance lease income receivable by type of customer is as follows: Carrying Value Carrying Value End-user customers 11,812 9,453 Distributors 8,186 7,199 Non-governmental organisations 533 1,786 20,531 18,438
Schedule of Ageing of Trade Receivables	The ageing of trade receivables at December 31, 2020 is as follows: Gross Impairment Expected Credit Loss Rate Gross Impairment Expected Credit Loss Rate 2020 2020 2020 2019 2019 2019 US$’000 US$’000 % US$’000 US$’000 % Not past due 16,754 112 0.7 % 10,924 8 0.1 % Past due 0-30 days 1,829 222 12.1 % 3,743 6 0.2 % Past due 31-120 days 1,755 60 3.4 % 2,115 27 1.3 % Greater than 120 days 3,609 3,528 97.8 % 6,415 5,402 84.2 % 23,947 3,922 — 23,197 5,443 —
Schedule of Movement in Allowance for Impairment of Trade Receivables	The movement in the allowance for impairment in respect of trade receivables during the year was as follows: 2020 2019 2018 US$’000 US$’000 US$’000 Balance at January 1 5,443 4,202 3,590 Charged to costs and expenses 166 1,276 682 Amounts written off during the year (1,687 ) (35 ) (70 ) Balance at December 31 3,922 5,443 4,202

RECONCILIATION OF LIABILITIES_2

RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Schedule of Liabilities Arising from Financing Activities	The changes in the Group’s liabilities arising from financing activities can be classified as follows: Note Borrowings & derivative financial instruments Lease liabilities Balance at 1 January 2020 25,26 82,025 20,149 Cash-flows: Interest paid (3,996 ) — Proceeds from government Covid-19 loan (Note 25) 31 — Repayment — (3,240 ) Non-cash: Interest charged 3,996 — Additions (related to Right of Use assets) — 224 Disposals¹ — (216 ) Exchange adjustment — 928 Accretion interest 8 643 896 Fair value 1,366 — Balance at 31 December 2020 25,26 84,065 18,741 ¹ Disposal of Lease liabilities relates to the early termination of a lease for a right-of-use building asset in Carlsbad, California. This facility was closed in June 2020. Note Borrowings & derivative financial instruments Lease liabilities Balance at 1 January 2019 25,26 81,620 962 Cash-flows: Interest paid (3,996 ) — Repayment — (3,533 ) Non-cash: Interest charged 3,996 — Adoption of IFRS 16 (Note 13) — 21,185 Additions (related to Right of Use assets) — 679 Exchange adjustment — (91 ) Accretion interest 8 639 947 Fair value (234 ) — Balance at 31 December 2019 25,26 82,025 20,149

BASIS OF PREPARATION AND SIGN_4

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2022	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Reduces assets property, plant and equipment		$ 11,099
Repayment of exchangeable notes				$ 12,042
Director [Member]
Statement Line Items [Line Items]
Repayment of exchangeable notes	$ 99,900

BASIS OF PREPARATION AND SIGN_5

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of Owned Assets) (Details)	12 Months Ended
	Dec. 31, 2020
Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of owned assets (In years)	5-15 years
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of owned assets (In years)	50 years
Office equipment and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of owned assets (In years)	10 years
Computers, fixtures and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of owned assets (In years)	3-5 years
Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of owned assets (In years)	2-15 years

BASIS OF PREPARATION AND SIGN_6

BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES (Schedule of Amortisation) (Details)	12 Months Ended
	Dec. 31, 2020
Capitalised development costs [Member]
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of intangible assets (In years)	15 years
Patents and licences [Member]
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of intangible assets (In years)	6-15 years
Intangible assets [Member]
Disclosure of intangible assets with indefinite useful life [line items]
Estimated useful lives of intangible assets (In years)	6-15 years

SEGMENT INFORMATION (Schedule o

SEGMENT INFORMATION (Schedule of Revenue by Geographical Area Based on Location of Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	$ 101,980	$ 90,435	$ 97,035
Inter-segment revenue
Total revenue	101,980	90,435	97,035
USA [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	77,688	64,045	65,863
Inter-segment revenue	59,304	39,563	38,665
Total revenue	136,992	103,608	104,528
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	24,292	26,390	31,172
Inter-segment revenue	1,095	1,629	2,899
Total revenue	25,387	28,019	34,071
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers
Inter-segment revenue
Total revenue
Eliminations [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers
Inter-segment revenue	(60,399)	(41,192)	(41,564)
Total revenue	$ (60,399)	$ (41,192)	$ (41,564)

SEGMENT INFORMATION (Schedule_2

SEGMENT INFORMATION (Schedule of Revenue by Customers Geographical Area) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers		$ 101,980	$ 90,435	$ 97,035
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers		70,408	52,183	57,559
Asia / Africa [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers		22,567	27,686	29,466
Europe (including Ireland) [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from external customers	[1]	$ 9,005	$ 10,566	$ 10,010
[1]	Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues.

SEGMENT INFORMATION (Schedule_3

SEGMENT INFORMATION (Schedule of Revenue by Major Product Group) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of products and services [line items]
Revenues	$ 101,980	$ 90,435	$ 97,035
Clinical laboratory goods [Member]
Disclosure of products and services [line items]
Revenues	84,280	68,127	71,618
Clinical laboratory services [Member]
Disclosure of products and services [line items]
Revenues	8,485	10,915	10,581
Point-of-Care [Member]
Disclosure of products and services [line items]
Revenues	$ 9,215	$ 11,393	$ 14,836

SEGMENT INFORMATION (Schedule_4

SEGMENT INFORMATION (Schedule of Amount Relating From Revenue) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of operating segments [abstract]
Revenue from contracts with customers	$ 101,980	$ 90,435	$ 97,035
Revenue from other sources
Total revenue	$ 101,980	$ 90,435	$ 97,035

SEGMENT INFORMATION (Schedule_5

SEGMENT INFORMATION (Schedule of Revenue Derives From Transfer of Goods and Services) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Timing of revenue recognition
At a point in time	$ 101,352	$ 89,690	$ 96,113
Over time	628	745	922
Total	101,980	90,435	97,035
Customer [Member]
Timing of revenue recognition
At a point in time	101,352	89,690	96,113
Over time	628	745	922
Total	101,980	90,435	97,035
Americas [Member]
Timing of revenue recognition
At a point in time	77,060	63,300	64,941
Over time	628	745	922
Total	77,688	64,045	65,863
Americas [Member] | Customer [Member]
Timing of revenue recognition
At a point in time	69,780	51,438	56,637
Over time	628	745	922
Total	70,408	52,183	57,559
Ireland [Member]
Timing of revenue recognition
At a point in time	24,292	26,390	31,172
Over time
Total	24,292	26,390	31,172
Other Countries [Member]
Timing of revenue recognition
At a point in time
Over time
Total
Asia / Africa [Member] | Customer [Member]
Timing of revenue recognition
At a point in time	22,567	27,686	29,466
Over time
Total	22,567	27,686	29,466
Europe [Member] | Customer [Member]
Timing of revenue recognition
At a point in time	9,005	10,566	10,010
Over time
Total	$ 9,005	$ 10,566	$ 10,010

SEGMENT INFORMATION (Schedule_6

SEGMENT INFORMATION (Schedule of Segment Results by Geographical Area) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		$ 18,688	$ 797	$ 7,370
Impairment		(17,779)	(24,295)	(26,932)
Result after impairment		909	(23,498)	(19,562)
Unallocated expenses	[1]	(827)	(614)	(665)
Operating profit		82	(24,112)	(20,227)
Net financing expense (Note 8)		(6,715)	(5,885)	(2,956)
Loss before tax		(6,633)	(29,997)	(23,183)
Income tax credit (Note 9)		620	1,006	525
Loss for the year on continuing operations		(6,013)	(28,991)	(22,658)
Profit/loss for the year on discontinued operations (Note 10)		(375)	77	568
Loss for the year		(6,388)	(28,914)	(22,090)
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		14,495	5,239	5,514
Impairment		(17,779)	(14,562)	(19,095)
Result after impairment		(3,284)	(9,323)	(13,581)
Loss before tax		(10,233)	(14,439)	(18,402)
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		4,264	(4,334)	1,900
Impairment			(9,733)	(7,837)
Result after impairment		4,264	(14,067)	(5,937)
Loss before tax		296	(20,318)	(9,590)
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Result before impairment and unallocated expenses		(71)	(108)	(44)
Impairment
Result after impairment		(71)	(108)	(44)
Loss before tax		$ 0	$ 4,760	$ 4,809
[1]	Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area.

SEGMENT INFORMATION (Schedule_7

SEGMENT INFORMATION (Schedule of Segment Assets and Segment Liabilities by Geographical Area) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets and liabilities
Segment assets	$ 95,799	$ 106,437
Unallocated assets:
Income tax assets (current and deferred)	7,271	8,234
Cash and cash equivalents and short-term investments	27,327	15,231
Total assets as reported in the Group balance sheet	130,397	131,071
Segment liabilities	127,557	119,171
Unallocated liabilities:
Income tax liabilities (current and deferred)	5,059	7,187
Total liabilities as reported in the Group balance sheet	132,616	126,358
Americas [Member]
Assets and liabilities
Segment assets	58,164	69,224
Unallocated assets:
Segment liabilities	20,431	14,575
Ireland [Member]
Assets and liabilities
Segment assets	37,632	37,212
Unallocated assets:
Segment liabilities	107,080	104,396
Other Countries [Member]
Assets and liabilities
Segment assets	3	1
Unallocated assets:
Segment liabilities	$ 46	$ 200

SEGMENT INFORMATION (Schedule_8

SEGMENT INFORMATION (Schedule of Long Lived Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of disaggregation of revenue from contracts with customers [line items]
Long lived asstes	$ 42,762	$ 53,429
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Long lived asstes	19,927	14,626
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Long lived asstes	$ 22,835	$ 38,803

SEGMENT INFORMATION (Schedule_9

SEGMENT INFORMATION (Schedule of Depreciation and Amortisation by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Depreciation	$ 1,714	$ 2,530	$ 1,375
Amortisation	1,403	2,368	2,825
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Depreciation	127	322	74
Amortisation	32	642	655
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Depreciation	1,587	2,208	1,301
Amortisation	$ 1,371	$ 1,726	$ 2,170

SEGMENT INFORMATION (Schedul_10

SEGMENT INFORMATION (Schedule of Share Based Payment Expense by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Share-based payments	$ 792	$ 758	$ 1,369
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Share-based payments	722	659	1,265
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total Share-based payments	$ 70	$ 99	$ 104

SEGMENT INFORMATION (Schedul_11

SEGMENT INFORMATION (Schedule of Interest Income and Interest Expense by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Interest Income
Interest income earned	$ 36	$ 464	$ 736
Non-cash financial income		233	1,388
Inter-segment interest income
Total	36	697	2,124
Interest Expense
Interest on finance leases	896	947	39
Interest on tax audit settlement (Note 6)		1,000
Cash interest on exchangeable notes	3,996	3,996	4,352
Non-cash interest on exchangeable notes (Note 25)	643	639	689
Non-cash financial expense	1,216
Inter-segment interest expense
Total	6,751	6,582	5,080
Americas [Member]
Interest Income
Interest income earned	9	47	32
Non-cash financial income
Inter-segment interest income
Total	9	47	32
Interest Expense
Interest on finance leases	290	294	7
Interest on tax audit settlement (Note 6)
Cash interest on exchangeable notes
Non-cash interest on exchangeable notes (Note 25)
Non-cash financial expense
Inter-segment interest expense	6,668	4,853	4,853
Total	6,958	5,147	4,860
Ireland [Member]
Interest Income
Interest income earned	27	417	704
Non-cash financial income		233	1,388
Inter-segment interest income	3,656
Total	3,683	650	2,092
Interest Expense
Interest on finance leases	606	653	32
Interest on tax audit settlement (Note 6)		1,000
Cash interest on exchangeable notes	3,996	3,996	4,352
Non-cash interest on exchangeable notes (Note 25)	643	639	689
Non-cash financial expense	1,216
Inter-segment interest expense	363
Total	6,824	6,288	5,073
Rest of world Other [Member]
Interest Income
Interest income earned
Non-cash financial income
Inter-segment interest income	4,853	4,853	4,853
Total	4,853	4,853	4,853
Interest Expense
Interest on finance leases
Interest on tax audit settlement (Note 6)
Cash interest on exchangeable notes
Non-cash interest on exchangeable notes (Note 25)
Non-cash financial expense
Inter-segment interest expense	1,478
Total	1,478
Eliminations [Member]
Interest Income
Interest income earned
Non-cash financial income
Inter-segment interest income	(8,509)	(4,853)	(4,853)
Total	(8,509)	(4,853)	(4,853)
Interest Expense
Interest on finance leases
Interest on tax audit settlement (Note 6)
Cash interest on exchangeable notes
Non-cash interest on exchangeable notes (Note 25)
Non-cash financial expense
Inter-segment interest expense	(8,509)	(4,853)	(4,853)
Total	$ (8,509)	$ (4,853)	$ (4,853)

SEGMENT INFORMATION (Schedul_12

SEGMENT INFORMATION (Schedule of Taxation Expense by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	$ 620	$ 1,006	$ 525
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	293	831	(59)
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	(8)		(3)
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Taxation expense	$ 335	$ 175	$ 587

SEGMENT INFORMATION (Schedul_13

SEGMENT INFORMATION (Schedule of Capital Expenditure by Geographical Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	$ 9,926	$ 33,621
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	5,609	20,758
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Capital expenditure	$ 4,317	$ 12,863

EMPLOYMENT (Narrative) (Details

EMPLOYMENT (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Total personnel expenses, inclusive of amounts capitalised for wages and salaries, social welfare costs and pension costs	$ 33,347	$ 36,288	$ 38,002
Total share based payments, inclusive of amounts capitalised	816	839	1,607
Employees contribution	447	503	490
Pension accrual	47	$ 43	$ 45
Wages and salaries net of credit	$ 1,316

EMPLOYMENT (Schedule of Average

EMPLOYMENT (Schedule of Average Number of Persons Employed) (Details) - Number	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of defined benefit plans [line items]
Number of persons employed	543	579	575
Research and development [Member]
Disclosure of defined benefit plans [line items]
Number of persons employed	52	57	59
Administration and sales [Member]
Disclosure of defined benefit plans [line items]
Number of persons employed	148	159	163
Manufacturing and quality [Member]
Disclosure of defined benefit plans [line items]
Number of persons employed	343	363	353

EMPLOYMENT (Schedule of Employm

EMPLOYMENT (Schedule of Employment Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [abstract]
Wages and salaries	$ 26,187	$ 25,885	$ 26,475
Social welfare costs	2,195	2,538	2,585
Pension costs	447	503	490
Tax settlement (Note 6)		5,094
Share-based payments	792	758	1,369
Restructuring Cost	388
Recognition of contingent asset	(1,316)
Employment Costs	$ 28,693	$ 34,778	$ 30,919

OTHER OPERATING INCOME (Details

OTHER OPERATING INCOME (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement Line Items [Line Items]
Unforgiven loans amount		$ 2,905
Forgiveness amount		4,520
Amount received from Provider Relief Fund		225
Paycheck Protection Program Loan [Member]
Statement Line Items [Line Items]
Forgiveness amount	$ 244	$ 1,615

OTHER OPERATING INCOME (Schedul

OTHER OPERATING INCOME (Schedule of Other Operating Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of other operating income [Abstract]
Government supports - COVID-19	$ 1,840
Other income	17	88	99
Rental income from premises	3	3	3
Other operating income	$ 1,860	$ 91	$ 102

SELLING, GENERAL AND ADMINIST_3

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES - CLOSURE COSTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Analysis of income and expense [abstract]
Amount of charge for closing facility	$ (2,425)

SELLING, GENERAL AND ADMINIST_4

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES - TAX AUDIT SETTLEMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of products and services [line items]
Selling, general and administrative expenses - tax audit settlement gross	$ 5,442,000	$ 6,442,000
Patent dividend scheme amount	3,863,000	3,863,000
R&D tax credits	75,000
Interest credits	1,000,000
Penalties income	273,000
Provision	400,000
Selling, general and administrative expenses - tax audit settlement		5,042,000
Darnick Company [Member]
Disclosure of products and services [line items]
Payments for CEO Services		$ 1,231,000
Contribution amount in settlement	1,231,000
Increase in settlement amount due to depreciation	1,316,000
Repayments of borrowings	$ 177,000

IMPAIRMENT CHARGES (Schedule of

IMPAIRMENT CHARGES (Schedule of Statement of Operation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of impairment charges and inventory provisioning [Abstract]
Impairment of PP&E (Note 13)	$ 1,795	$ 6,349	$ 6,112
Impairment of goodwill and other intangible assets (Note 14)	15,422	16,570	19,212
Impairment of prepayments (Note 18)	562	1,376	1,608
Total impairment loss	17,779	24,295	26,932
Income tax impact of impairment loss	0	148	(1,752)
Total impairment loss after tax	$ 17,779	$ 24,443	$ 25,180

FINANCIAL INCOME AND EXPENSES_2

FINANCIAL INCOME AND EXPENSES (Schedule of Financial Income (Expenses), Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Financial income:
Non-cash financial income		$ 233	$ 1,388
Interest income	36	464	736
Financial income	36	697	2,124
Financial expense:
Interest on leases	(896)	(947)	(39)
Interest on tax audit settlement (Note 6)		(1,000)
Cash interest on exchangeable notes	(3,996)	(3,996)	(4,352)
Non-cash interest on exchangeable notes (Note 25)	(643)	(639)	(689)
Non-cash financial expense	(1,216)
Financial expense	(6,751)	(6,582)	(5,080)
Net Financing Expense	$ (6,715)	$ (5,885)	$ (2,956)

INCOME TAX CREDIT (Narrative) (

INCOME TAX CREDIT (Narrative) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total deferred tax (credit)/expense	[1]	$ (167)	$ (841)	$ (406)
Corporation tax rate		12.50%	12.50%	12.50%
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total deferred tax (credit)/expense		$ 53	$ 444	$ 369
USA [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Net operating loss period		20 Years
Other Countries [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total deferred tax (credit)/expense		$ 220	$ 397	$ 775
[1]	In 2020, there was a deferred tax charge of US$53,000 (2019: credit of US$444,000; 2018: charge of US$369,000) recognised in respect of Ireland and a deferred tax credit of US$220,000 (2019: credit of US$397,000; 2018: credit of US$775,000) recognised in respect of overseas tax jurisdictions.

INCOME TAX CREDIT (Schedule of

INCOME TAX CREDIT (Schedule of Charge for Tax) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current tax (credit)/ expense
Irish Corporation tax		$ (480)	$ (312)	$ (258)
Foreign taxes	[1]	179	197	195
Adjustment in respect of prior years		(152)	(50)	(56)
Total current tax credit		(453)	(165)	(119)
Deferred tax credit
Origination and reversal of temporary differences (see Note 15)	[2]	48	(625)	(2,031)
Origination and reversal of net operating losses (see Note 15)	[2]	(215)	(216)	1,625
Total deferred tax credit	[2]	(167)	(841)	(406)
Total income tax credit on continuing operations in statement of operations		(620)	(1,006)	(525)
Tax charge / (credit) on discontinued operations (see Note 10)		438		(590)
Total tax credit		$ (182)	$ (1,006)	$ (1,115)
[1]	In 2020, the foreign taxes relate primarily to Canada.
[2]	In 2020, there was a deferred tax charge of US$53,000 (2019: credit of US$444,000; 2018: charge of US$369,000) recognised in respect of Ireland and a deferred tax credit of US$220,000 (2019: credit of US$397,000; 2018: credit of US$775,000) recognised in respect of overseas tax jurisdictions.

INCOME TAX CREDIT (Schedule o_2

INCOME TAX CREDIT (Schedule of Overseas Tax Jurisdictions) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Effective tax rate
Loss before taxation - continuing operations	$ (6,633)	$ (29,997)	$ (23,183)
As a percentage of loss before tax:
Current tax %	(6.83%)	(0.55%)	(0.51%)
Total (current and deferred) %	(9.35%)	(3.36%)	(2.26%)

INCOME TAX CREDIT (Schedule o_3

INCOME TAX CREDIT (Schedule of Statutory Tax Rate) (Details)		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of income tax credit [Abstract]
Irish corporation tax		(12.50%)	(12.50%)	(12.50%)
Effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised	[1]	24.13%	13.21%	15.76%
Effect of tax rates on overseas earnings		(9.92%)	(3.05%)	(6.10%)
Effect of Irish income taxable at higher tax rate		5.92%	0.04%	0.05%
Adjustments in respect of prior years		(10.66%)	(0.17%)	0.94%
R&D tax credits		(11.00%)	(2.69%)	(1.70%)
Other items	[2]	4.68%	1.80%	1.29%
Effective tax rate		(9.35%)	(3.36%)	(2.26%)
[1]	The effect of current year net operating losses and temporary differences for which no deferred tax asset was recognised is analyzed further in the table below (see also Note 15). No deferred tax asset was recognised because there was no reversing deferred tax liability in the same jurisdiction reversing in the same period and no future taxable income in the same jurisdiction.
[2]	Other items comprise items not chargeable to tax/expenses not deductible for tax purposes. In 2020, this mainly comprises the movement in the exchangeable notes' embedded derivatives value and the accretion of notional interest on the Loan Note's host contract, both of which are exempt from deferred taxation recognition under IAS 12, Income Taxes. In 2019, other items mainly comprise the tax audit settlement recorded in Selling, General and Administrative expenses (see also Note 6), which is not deductible for tax and the movement in the exchangeable notes' embedded derivatives value and the accretion of notional interest.

INCOME TAX CREDIT (Schedule o_4

INCOME TAX CREDIT (Schedule of Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Unrecognised deferred tax assets - continuing operations
Increase in net operating losses	$ 167	$ 841
Increase (Decrease) in net operating losses	$ 1,601	$ 3,964
Increase (Decrease) in net operating losses, percentage	24.13%	13.21%
USA [Member]
Unrecognised deferred tax assets - continuing operations
Increase in net operating losses	$ 1,105	$ 1,117
Increase in net operating losses, percentage	16.66%	3.72%
Temporary differences		$ 129
Temporary differences, percentage		0.43%
Brazil [Member]
Unrecognised deferred tax assets - continuing operations
Increase (Decrease) in net operating losses	$ (502)	$ 608
Increase (Decrease) in net operating losses, percentage	(7.57%)	2.03%
Luxembourg [Member]
Unrecognised deferred tax assets - continuing operations
Increase (Decrease) in net operating losses	$ 544
Increase (Decrease) in net operating losses, percentage	8.20%
UK [Member]
Unrecognised deferred tax assets - continuing operations
Increase (Decrease) in net operating losses	$ 2
Increase (Decrease) in net operating losses, percentage	(0.03%)
Ireland [Member]
Unrecognised deferred tax assets - continuing operations
Increase (Decrease) in net operating losses	$ 452	$ 2,110
Increase (Decrease) in net operating losses, percentage	6.81%	7.03%

INCOME TAX CREDIT (Schedule o_5

INCOME TAX CREDIT (Schedule of Loss Profit Before Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Loss profit before taxes	$ (6,633)	$ (29,997)	$ (23,183)
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Loss profit before taxes	296	(20,318)	(9,590)
Other regions [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Loss profit before taxes	3,304	4,760	4,809
Americas [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Loss profit before taxes	$ (10,233)	$ (14,439)	$ (18,402)

INCOME TAX CREDIT (Schedule o_6

INCOME TAX CREDIT (Schedule of Net Operating Losses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	$ 85,198	$ 80,577	$ 67,012
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	78,700	73,754	60,629
USA [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses		1,034	2,382
Luxembourg [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	2,175
UK [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	10
Brazil [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unutilised net operating losses	$ 4,313	$ 5,789	$ 4,001

INCOME TAX CREDIT (Schedule o_7

INCOME TAX CREDIT (Schedule of Unrecognised Deferred Tax Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	$ 17,388	$ 17,814	$ 13,851
Ireland [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	12,514	12,062	9,953
USA [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset		3,291	2,174
USA Tax Credits [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	2,862	493	364
Luxembourg [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	544
UK [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	2
Brazil [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Unrecognised deferred tax asset	$ 1,466	$ 1,968	$ 1,360

(LOSS)_PROFIT FOR THE YEAR ON_3

(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Profit/(Loss) for the year from discontinued operations	$ (375)	$ 77	$ 568
Basic weighted average number of ordinary shares	83,606,810	83,606,810	83,612,908
Diluted weighted average number of ordinary shares	105,024,732	101,870,064	103,508,820
Provision	$ 127
Tax credit recovered	438		$ (590)
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Profit/(Loss) for the year from discontinued operations	$ 375	$ 77	$ 568
Basic weighted average number of ordinary shares	83,606,810	83,606,810	83,612,908
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic weighted average number of ordinary shares	20,901,703	20,901,703	20,903,227
Diluted weighted average number of ordinary shares	26,256,183	25,467,517	25,877,205

(LOSS)_PROFIT FOR THE YEAR ON_4

(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION (Schedule of Operating Profit/(Loss) for Cardiac) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
(Loss)/Profit on re-measurement of assets and liabilities:
Tax (expense)/credit	$ (182)	$ (1,006)	$ (1,115)
(Loss)/Profit for the year on discontinued operations	(375)	77	568
Sweden [Member]
(Loss)/Profit on re-measurement of assets and liabilities:
Closure provision	127	(8)	(22)
Foreign currency translation reserve	(64)	85
Tax (expense)/credit	(438)		590
Total (loss)/profit	(375)	77	568
(Loss)/Profit for the year on discontinued operations	$ (375)	$ 77	$ 568

(LOSS)_PROFIT FOR THE YEAR ON_5

(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION (Schedule of Earnings Per ADS) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic earnings/(loss) per ADS (US Dollars) - discontinued operations	$ (0.02)	$ 0	$ 0.03
Diluted earnings/(loss per ADS (US Dollars) - discontinued operations	(0.02)	0	0.02
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Basic earnings/(loss) per ADS (US Dollars) - discontinued operations	0	0	0.01
Diluted earnings/(loss per ADS (US Dollars) - discontinued operations	$ 0	$ 0	$ 0.01

(LOSS)_PROFIT FOR THE YEAR ON_6

(LOSS)/PROFIT FOR THE YEAR ON DISCONTINUED OPERATION (Schedule of Cash Flows Attributable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of loss on discontinued operation [Abstract]
Cash flows from operating activities	$ (22)	$ (5)	$ 527
Cash flows from investing activities

LOSS BEFORE TAX (Narrative) (De

LOSS BEFORE TAX (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of loss profit before tax [Abstract]
Depreciation on capitalised Intangible projects	$ 40,000	$ 4,000	$ 79,000

LOSS BEFORE TAX (Schedule of Am

LOSS BEFORE TAX (Schedule of Amount Charged to Statement of Operation) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Directors' emoluments (including non- executive directors):
Remuneration		$ 2,020	$ 1,238	$ 1,261
Pension		41	42	44
Share based payments		678	624	1,204
Auditor's remuneration
Audit fees		533	523	506
Tax fees		146	172	15
Other non-audit fees		25
Depreciation	[1]	1,674	2,526	1,296
Amortisation (Note 14)		1,403	2,368	2,825
(Profit)/Loss on the disposal of property, plant and equipment		30	17	15
Net foreign exchange differences		$ 583	$ (179)	$ 344
[1]	Note that US$38,000 (2019: US$4,000) (2018: US$79,000) of depreciation was capitalised to research and development projects during 2020 in line with the Group's capitalisation policy for Intangible projects.

LOSS PER SHARE (Narrative) (Det

LOSS PER SHARE (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
(Loss)/Profit for the year	$ (6,388)	$ (28,914)	$ (22,090)
Diluted earnings per share denominator	105,024,732	101,870,064	103,508,820
Diluted earnings per ordinary share for continuing operations	$ 158	$ 24,590	$ 19,005
Adjusted (loss)/profit after tax	(533)	(24,512)	(18,437)
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Basic earnings per ordinary share for continuing operations	6,013	28,991	22,658
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic earnings per ordinary share for continuing operations	$ 6,013	$ 28,991	$ 22,658
Diluted earnings per share denominator	26,256,183	25,467,517	25,877,205
Adjusted (loss)/profit after tax	$ 533	$ 24,512	$ 18,437

LOSS PER SHARE (Schedule of Bas

LOSS PER SHARE (Schedule of Basic Earnings Per Ordinary Share) (Details) - shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Basic earnings per share denominator		83,606,810	83,606,810	83,612,908
Reconciliation to weighted average earnings per share denominator:
In issue at January 1		83,606,810	83,606,810	96,162,410
Weighted average number of shares issued during the year	[1]
Weighted average number of treasury shares		(1,255,600)	(12,555,600)	(12,549,502)
Basic earnings per share denominator		83,606,810	83,606,810	83,612,908
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Basic earnings per share denominator		83,606,810	83,606,810	83,612,908
Reconciliation to weighted average earnings per share denominator:
In issue at January 1		96,162,410	96,162,410	96,162,410
Basic earnings per share denominator		83,606,810	83,606,810	83,612,908
[1]	The weighted average number of shares issued during the year is calculated by taking the number of shares issued multiplied by the number of days in the year each share is in issue, divided by 365 days.

LOSS PER SHARE (Schedule of Dil

LOSS PER SHARE (Schedule of Diluted Earnings Per Ordinary Share) (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings per share [abstract]
Basic earnings per share denominator	83,606,810	83,606,810	83,612,908
Issuable on exercise of options and warrants	3,154,668		22,359
Issuable on conversion of exchangeable notes	18,263,254	18,263,254	19,873,553
Diluted earnings per share denominator	105,024,732	101,870,064	103,508,820

LOSS PER SHARE (Schedule of Pro

LOSS PER SHARE (Schedule of Profit After Tax Diluted Earnings Per Ordinary Share Calculation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings per share [abstract]
Loss for the year	$ (6,388)	$ (28,914)	$ (22,090)
Non-cash financial expense/(income) (Note 8)		(233)	(1,388)
Cash interest expense (Note 8)	3,996	3,996	4,352
Non-cash interest on exchangeable notes (Note 8)	643	639	689
Adjusted loss after tax	$ (533)	$ (24,512)	$ (18,437)

LOSS PER SHARE (Schedule of Ear

LOSS PER SHARE (Schedule of Earnings Per ADS) (Details) - shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020
Disclosure of classes of share capital [line items]
Ordinary shares		83,606,810	83,606,810	96,162,410
Basic earnings per share denominator		83,606,810	83,606,810	83,612,908
Reconciliation to weighted average earnings per share denominator:
In issue at January 1		83,606,810	83,606,810	96,162,410
Weighted average number of shares issued during the year	[1]
Weighted average number of treasury shares		(1,255,600)	(12,555,600)	(12,549,502)
Basic earnings per share denominator		83,606,810	83,606,810	83,612,908
American depositary share [Member]
Disclosure of classes of share capital [line items]
Ordinary shares		20,901,703	20,903,227	20,903,227	20,901,703
Basic earnings per share denominator		20,901,703	20,901,703	20,903,227
Reconciliation to weighted average earnings per share denominator:
In issue at January 1		20,901,703	20,903,227	20,903,227
Weighted average number of shares issued during the year	[1]
Weighted average number of treasury shares		(3,138,899)	(3,138,899)	(3,137,375)
Basic earnings per share denominator		20,901,703	20,901,703	20,903,227
[1]	The weighted average number of shares issued during the year is calculated by taking the number of shares issued multiplied by the number of days in the year each share is in issue, divided by 365 days.

LOSS PER SHARE (Schedule of D_2

LOSS PER SHARE (Schedule of Diluted Earnings Per ADS Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Basic earnings per share denominator	83,606,810	83,606,810	83,612,908
Issuable on exercise of options and warrants	3,154,668		22,359
Issuable on conversion of exchangeable notes	18,263,254	18,263,254	19,873,553
Diluted earnings per share denominator	105,024,732	101,870,064	103,508,820
American depositary share [Member]
Disclosure of classes of share capital [line items]
Basic earnings per share denominator	20,901,703	20,901,703	20,903,227
Issuable on exercise of options and warrants	788,666		5,590
Issuable on conversion of exchangeable notes	4,565,814	4,565,814	4,968,388
Diluted earnings per share denominator	26,256,183	25,467,517	25,877,205

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Impairment loss	$ 1,795	$ 6,349	$ 6,112
Net book value of assets held under operating lease
Depreciation charged on assets under operating lease	21	7
Property, plant and equipment under construction
Buildings [Member]
Statement Line Items [Line Items]
Income from sub-letting right-of-use	$ 3	$ 3

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT (Schedule of Composition of Property and Equipment Related to Accumulated Depreciation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	$ 9,290
Impairment loss	1,795	$ 6,349	$ 6,112
Balance at end of year	8,547	9,290
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	70,242	53,814
Adjustment on transition to IFRS 16		21,185
Additions	2,911	2,825
Disposals or retirements	(6,123)	(7,550)
Exchange adjustments	(1,925)	(32)
Balance at end of year	65,105	70,242	53,814
Cost [Member] | Land and buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	24,269	2,605
Adjustment on transition to IFRS 16		20,961
Additions	8	681
Disposals or retirements
Exchange adjustments	10	22
Balance at end of year	24,287	24,269	2,605
Cost [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	3,005	4,560
Adjustment on transition to IFRS 16
Additions	41	71
Disposals or retirements	(299)	(1,626)
Exchange adjustments	(77)
Balance at end of year	2,670	3,005	4,560
Cost [Member] | Computers, fixtures and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	4,292	6,585
Adjustment on transition to IFRS 16		149
Additions	96	168
Disposals or retirements	(66)	(2,610)
Exchange adjustments	(13)
Balance at end of year	4,309	4,292	6,585
Cost [Member] | Office equipment and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	38,676	40,064
Adjustment on transition to IFRS 16		75
Additions	2,766	1,905
Disposals or retirements	(5,758)	(3,314)
Exchange adjustments	(1,845)	(54)
Balance at end of year	33,839	38,676	40,064
Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(60,952)	(48,452)
Charge for the year	(1,714)	(2,530)
Adjustment on transition to IFRS 16		(11,099)
Impairment loss	(1,795)	(6,349)
Disposals or retirements	5,973	7,493
Reallocations / reclassifications		(5)
Exchange adjustments	1,930	(10)
Balance at end of year	(56,558)	(60,952)	(48,452)
Accumulated depreciation and impairment losses [member] | Land and buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(18,493)	(1,934)
Charge for the year	(783)	(1,545)
Adjustment on transition to IFRS 16		(10,984)
Impairment loss	(347)	(4,024)
Disposals or retirements
Reallocations / reclassifications
Exchange adjustments	(6)	(6)
Balance at end of year	(19,629)	(18,493)	(1,934)
Accumulated depreciation and impairment losses [member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(2,037)	(3,243)
Charge for the year	(146)	(105)
Adjustment on transition to IFRS 16
Impairment loss	(78)	(233)
Disposals or retirements	299	1,544
Reallocations / reclassifications
Exchange adjustments	78
Balance at end of year	(1,884)	(2,037)	(3,243)
Accumulated depreciation and impairment losses [member] | Computers, fixtures and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(3,682)	(5,783)
Charge for the year	(181)	(200)
Adjustment on transition to IFRS 16		(40)
Impairment loss	(180)	(276)
Disposals or retirements	84	2,618
Reallocations / reclassifications
Exchange adjustments	13	(1)
Balance at end of year	(3,945)	(3,682)	(5,783)
Accumulated depreciation and impairment losses [member] | Office equipment and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	(36,740)	(37,492)
Charge for the year	(604)	(680)
Adjustment on transition to IFRS 16		(75)
Impairment loss	(1,190)	(1,816)
Disposals or retirements	5,590	3,331
Reallocations / reclassifications		(5)
Exchange adjustments	1,845	(3)
Balance at end of year	(31,099)	(36,740)	$ (37,492)
Carrying amounts [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	9,290
Balance at end of year	8,547	9,290
Carrying amounts [Member] | Land and buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	5,776
Balance at end of year	4,658	5,776
Carrying amounts [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	968
Balance at end of year	786	968
Carrying amounts [Member] | Computers, fixtures and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	610
Balance at end of year	363	610
Carrying amounts [Member] | Office equipment and fittings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance at beginning year	1,936
Balance at end of year	$ 2,740	$ 1,936

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT (Schedule of Right-of-use assets) (Details $ in Thousands	Dec. 31, 2018USD ($)
Disclosure of comparative information prepared under previous GAAP [line items]
Right-of-use assets	$ 10,086
Right-of-use assets cost at transition before impairment [Member]
Disclosure of comparative information prepared under previous GAAP [line items]
Right-of-use assets	21,185
Impairment adjustment on transition [Member]
Disclosure of comparative information prepared under previous GAAP [line items]
Right-of-use assets	$ (11,099)

PROPERTY, PLANT AND EQUIPMENT_5

PROPERTY, PLANT AND EQUIPMENT (Schedule of Reconciliation from IAS 17 to IFRS 16) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of comparative information prepared under previous GAAP [line items]
Property, plant & equipment	$ 8,547	$ 9,290
Retaining earnings	$ (10,573)	(16,145)
Accumulated impairment Charge [member]
Disclosure of comparative information prepared under previous GAAP [line items]
Property, plant & equipment		(11,099)
Lease liabilities
Retaining earnings		(11,099)
Total
Right-of-use assets cost at transition before impairment [Member]
Disclosure of comparative information prepared under previous GAAP [line items]
Property, plant & equipment		5,362
Lease liabilities		(962)
Retaining earnings		(55,319)
Total		(50,919)
Remeasurement [Member]
Disclosure of comparative information prepared under previous GAAP [line items]
Property, plant & equipment		21,185
Lease liabilities		(21,185)
Retaining earnings
Total
Impairment adjustment on transition [Member]
Disclosure of comparative information prepared under previous GAAP [line items]
Property, plant & equipment		15,448
Lease liabilities		(22,147)
Retaining earnings		(44,220)
Total		$ (50,919)

PROPERTY, PLANT AND EQUIPMENT_6

PROPERTY, PLANT AND EQUIPMENT (Schedule of Additional Information on Right-of-use Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	$ 4,203	$ 5,227
Depreciation Charge [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(747)	(1,562)
Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(501)	(3,976)
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	4,200	5,220
Buildings [Member] | Depreciation Charge [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(673)	(1,523)
Buildings [Member] | Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(347)	(3,913)
Computer equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	3	7
Computer equipment [member] | Depreciation Charge [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(4)	(39)
Computer equipment [member] | Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets		$ (63)
Plant and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets
Plant and equipment [Member] | Depreciation Charge [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	(70)
Plant and equipment [Member] | Accumulated impairment Charge [member]
Disclosure of detailed information about property, plant and equipment [line items]
Right-of-use assets	$ (154)

PROPERTY, PLANT AND EQUIPMENT_7

PROPERTY, PLANT AND EQUIPMENT (Schedule of Income from Sub-letting Right-of-use Buildings) (Details) - Assets	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Buildings [Member]
Disclosure of quantitative information about right-of-use assets [line items]
No. of Right-of-Use leased assets	12	13
Average remaining lease term (years)	4 years	5 years
No. of Leases with extension options	1	1
No. of Leases with options to purchase
No. of leases with variable payments linked to index	2	2
No. of leases with termination options	4	4
Buildings [Member] | Bottom of range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	1 year	1 year
Buildings [Member] | Top of range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	14 years	14 years
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
No. of Right-of-Use leased assets	16	9
Average remaining lease term (years)	2 years	1 year
No. of Leases with extension options
No. of Leases with options to purchase	16	9
No. of leases with variable payments linked to index
No. of leases with termination options	16	9
Vehicles [Member] | Bottom of range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	1 year	1 year
Vehicles [Member] | Top of range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	3 years	2 years
I.T. and office equipment [Member]
Disclosure of quantitative information about right-of-use assets [line items]
No. of Right-of-Use leased assets	10	11
Average remaining lease term (years)	1 year	2 years
No. of Leases with extension options
No. of Leases with options to purchase
No. of leases with variable payments linked to index
No. of leases with termination options	1	1
I.T. and office equipment [Member] | Bottom of range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	1 year	1 year
I.T. and office equipment [Member] | Top of range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Range of remaining term in years	2 years	2 years

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Development costs not amortised	$ 6,980	$ 3,719
Description of project completion period	January 1, 2021 to December 31, 2023
Additional project cost	$ 8,798
Impairment through use or sale of the assets		76,740
Long term growth rate on fifth year	2.00%
Additional impairment loss due to growth in revenues	$ 384
Variation in discount rate	10.00%
Additional impairment loss	$ 1,504
Impairment loss	$ 15,422	$ 16,570	$ 19,212
Top of range [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Cash flow projections	0.00%
Pre tax discount rates	0.44	0.27
Bottom of range [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Cash flow projections	12.00%
Pre tax discount rates	0.16	0.20
Primus trade name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Impairment loss	$ 135

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS (Schedule of Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	$ 43,654
Impairment losses	15,422	$ 16,570	$ 19,212
Balance at end of year	33,860	43,654
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	282,283	272,636
Additions	7,015	9,611
Disposals or retirements	(38,903)
Reclassification
Exchange adjustments	22	36
Balance at end of year	250,417	282,283	272,636
Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	43,654
Balance at end of year	33,860	43,654
Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(238,629)	(219,685)
Charge for the year	(1,403)	(2,368)
Disposals or retirements	38,903
Impairment losses	(15,422)	(16,570)
Exchange adjustments	(6)	(6)
Balance at end of year	(216,557)	(238,629)	(219,685)
Goodwill [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	81,689	81,689
Additions
Disposals or retirements	(2,507)
Reclassification
Exchange adjustments
Balance at end of year	79,182	81,689	81,689
Goodwill [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	12,591
Balance at end of year	12,591	12,591
Goodwill [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(69,098)	(65,548)
Charge for the year
Disposals or retirements	2,507
Impairment losses		(3,550)
Exchange adjustments
Balance at end of year	(66,591)	(69,098)	(65,548)
Development cost [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	156,377	146,772
Additions	6,896	9,569
Disposals or retirements	(34,318)
Reclassification
Exchange adjustments	22	36
Balance at end of year	128,977	156,377	146,772
Development cost [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	22,778
Balance at end of year	13,444	22,778
Development cost [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(133,599)	(120,507)
Charge for the year	(959)	(1,182)
Disposals or retirements	34,318
Impairment losses	(15,287)	(11,904)
Exchange adjustments	(6)	(6)
Balance at end of year	(115,533)	(133,599)	(120,507)
Patents and licences [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	9,951	9,947
Additions	30	4
Disposals or retirements	(1,034)
Reclassification
Exchange adjustments
Balance at end of year	8,947	9,951	9,947
Patents and licences [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	132
Balance at end of year	157	132
Patents and licences [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(9,819)	(9,814)
Charge for the year	(5)	(2)
Disposals or retirements	1,034
Impairment losses		(3)
Exchange adjustments
Balance at end of year	(8,790)	(9,819)	(9,814)
Intangible assets [Member] | Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	34,266	34,228
Additions	89	38
Disposals or retirements	(1,044)
Reclassification
Exchange adjustments
Balance at end of year	33,311	34,266	34,228
Intangible assets [Member] | Carrying amounts [Member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	8,153
Balance at end of year	7,668	8,153
Intangible assets [Member] | Accumulated depreciation and impairment losses [member]
Disclosure of detailed information about intangible assets [line items]
Balance at beginning year	(26,113)	(23,816)
Charge for the year	(439)	(1,184)
Disposals or retirements	1,044
Impairment losses	(135)	(1,113)
Exchange adjustments
Balance at end of year	$ (25,643)	$ (26,113)	$ (23,816)

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS (Schedule of Principal Development Projects) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	$ 6,896	$ 9,569
HIV Screening Rapid Test [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	2,278	2,587
Premier Instrument for Haemoglobin A1c Testing [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	1,359	1,930
Autoimmune Smart Reader [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	666	1,325
Syphilis Point-of-Care Test [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	618	870
Uni-Gold Antigen Improvement [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	556	691
COVID test [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	467
Mid-tier haemoglobins instrument [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	243	63
Tri-stat Point-of-Care Instrument [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	203	361
Column Enhancement [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	151	236
Ultra Genesys [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	139	237
Sjogrens Tests [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	99	135
G-6-PDH Test [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs		582
Uni-Gold Test [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs		376
Other Projects [Member]
Disclosure of detailed information about intangible assets [line items]
Capitalised development costs	$ 117	$ 176

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS (Schedule of Impairment Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about intangible assets [line items]
Total impairment loss	$ 17,779	$ 24,295
Primus Corp [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss	16,706	5,321
Trinity Biotech Do Brasil [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss	919	1,253
Biopool US Inc [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss	154	210
Trinity Biotech Manufacturing Limited [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss		9,732
Immco Diagnostics Inc [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss		6,332
Clark Laboratories Inc [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss		727
Mardx Diagnostics Inc. [Member]
Disclosure of detailed information about intangible assets [line items]
Total impairment loss		$ 720

GOODWILL AND INTANGIBLE ASSET_6

GOODWILL AND INTANGIBLE ASSETS (Schedule of Breakdown of Impairment Loss) (Details) (USD $) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of goodwill and intangible assets [Abstract]
Goodwill and other intangible assets (see Note 14)	$ 15,422	$ 16,570
Property, plant and equipment (see Note 13)	1,795	6,349
Prepayments (see Note 18)	562	1,376
Total impairment loss	$ 17,779	$ 24,295

GOODWILL AND INTANGIBLE ASSET_7

GOODWILL AND INTANGIBLE ASSETS (Schedule of Significant Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Line Items [Line Items]
Long-term growth rate	2.00%
Fitzgerald Industries International CGU Trade Name [Member]
Statement Line Items [Line Items]
Carrying amount of goodwill	$ 12,591	$ 12,591
Discount rate applied (real pre-tax)	19.98%	20.42%
Excess value-in-use over carrying amount	$ 7,915	$ 2,385
EBITDA would need to decrease for an impairment to arise	31.98%	12.11%
Long-term growth rate	2.00%	2.00%

GOODWILL AND INTANGIBLE ASSET_8

GOODWILL AND INTANGIBLE ASSETS (Schedule of Intangible Assets with Indefinite Useful lives) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	$ 4,833	$ 4,968
Fitzgerald Industries International CGU Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	970	970
Fitzgerald Industries International CGU RDI Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	560	560
Primus Corporation CGU Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	365	500
Immco Diagnostic CGU Trade Name [Member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets with indefinite useful lives	$ 2,938	$ 2,938

DEFERRED TAX ASSETS AND LIABI_3

DEFERRED TAX ASSETS AND LIABILITIES (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Disclosure of deferred tax assets and liabilities [Abstract]
Deferred tax asset decrease due to decrease in provision	$ 2,067
Deferred tax liability decreased	2,234
Increased in unrecognised deferred tax assets	$ 19,329

DEFERRED TAX ASSETS AND LIABI_4

DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Recognised Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	$ 4,185	$ 6,252
Deferred tax liabilities	(4,905)	(7,139)
Net deferred tax assets/(liabilities)	(720)	(887)	$ (1,728)
Plant and equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	733	1,027
Deferred tax liabilities	(9)	(9)
Net deferred tax assets/(liabilities)	724	1,018	778
Intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets
Deferred tax liabilities	(4,072)	(6,099)
Net deferred tax assets/(liabilities)	(4,072)	(6,099)	(7,189)
Inventories [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	750	642
Deferred tax liabilities
Net deferred tax assets/(liabilities)	750	642	668
Provisions [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	2,159	3,622
Deferred tax liabilities
Net deferred tax assets/(liabilities)	2,159	3,622	4,311
Tax value of loss carry-forwards [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	433	216
Deferred tax liabilities
Net deferred tax assets/(liabilities)	433	216
Other items [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	110	745
Deferred tax liabilities	(824)	(1,031)
Net deferred tax assets/(liabilities)	$ (714)	$ (286)	$ (296)

DEFERRED TAX ASSETS AND LIABI_5

DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Liabilities) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	$ (887)	$ (1,728)
Recognised in income	167	841
Balance at end of year	(720)	(887)
Plant and equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	1,018	778
Recognised in income	(294)	240
Balance at end of year	724	1,018
Intangible assets [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	(6,099)	(7,189)
Recognised in income	2,027	1,090
Balance at end of year	(4,072)	(6,099)
Inventories [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	642	668
Recognised in income	108	(26)
Balance at end of year	750	642
Provisions [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	3,622	4,311
Recognised in income	(1,463)	(689)
Balance at end of year	2,159	3,622
Tax value of loss carry-forwards [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	216
Recognised in income	217	216
Balance at end of year	433	216
Other items [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Balance at beginning of year	(286)	(296)
Recognised in income	(428)	10
Balance at end of year	$ (714)	$ (286)

DEFERRED TAX ASSETS AND LIABI_6

DEFERRED TAX ASSETS AND LIABILITIES (Schedule of Unrecognised Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of deferred tax assets and liabilities [Abstract]
Capital losses	$ 8,293	$ 8,293
Net operating losses	85,198	80,577
US alternative minimum tax credits	1,848	1,928
Other temporary timing differences	21,878	7,399
US state credit carryforwards	802	493
Unrecognised deferred tax assets	$ 118,019	$ 98,690

OTHER NON-CURRENT ASSETS (Detai

OTHER NON-CURRENT ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Miscellaneous non-current assets [abstract]
Finance lease receivables (see Note 18)	$ 291	$ 403
Other assets	64	82
Total other assets	$ 355	$ 485

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Classes of current inventories [abstract]
Inventories net of provisions	$ 9,781	$ 6,716	$ 6,299
Cost of sales	$ 48,342	$ 50,748	$ 55,285

INVENTORIES (Schedule of invent

INVENTORIES (Schedule of inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Classes of current inventories [abstract]
Raw materials and consumables	$ 12,168	$ 12,654
Work-in-progress	5,169	6,940
Finished goods	12,882	12,427
Total inventories	$ 30,219	$ 32,021

INVENTORIES (Schedule of Moveme

INVENTORIES (Schedule of Movement on the Inventory Provision) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of other provisions [line items]
Opening provision at January 1
Closing provision at December 31	366
Provision for inventories [Member]
Disclosure of other provisions [line items]
Opening provision at January 1	6,716	6,299	$ 7,543
Charged during the year	5,179	1,567	480
Utilised during the year	(1,994)	(1,150)	(1,544)
Released during the year	(120)		(180)
Closing provision at December 31	$ 9,781	$ 6,716	$ 6,299

TRADE AND OTHER RECEIVABLES (Na

TRADE AND OTHER RECEIVABLES (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of maturity analysis of operating lease payments [line items]
Trade receivables, net impairment losses provision	$ 3,992	$ 5,443	$ 4,202	$ 3,590
Prepayments of impairment	562	1,376
Finance lease receivable	506	684
Between one and five years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Finance lease receivable	$ 291	$ 403

TRADE AND OTHER RECEIVABLES (Sc

TRADE AND OTHER RECEIVABLES (Schedule of Trade and Other Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Trade and other current receivables [abstract]
Trade receivables, net of impairment losses	$ 20,025	$ 17,754
Prepayments	1,159	576
Contract assets	1,177	2,317
Value added tax	92	59
Finance lease receivables	215	281
Total and other receivables	$ 22,668	$ 20,987

TRADE AND OTHER RECEIVABLES (_2

TRADE AND OTHER RECEIVABLES (Schedule of Future Minimum Finance Lease Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis of operating lease payments [line items]
Gross investment	$ 1,006	$ 1,328
Unearned income	500	644
Finance lease receivable	506	684
Less than one year [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Gross investment	415	523
Unearned income	200	242
Finance lease receivable	215	281
Between one and five years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Gross investment	591	805
Unearned income	300	402
Finance lease receivable	$ 291	$ 403

TRADE AND OTHER RECEIVABLES (_3

TRADE AND OTHER RECEIVABLES (Schedule of Future Minimum Rentals Receivable Under Non-Cancellable Operating Leases) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	$ 2,938	$ 3,555
Instruments [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	2,938	3,555
Less than one year [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	2,767	3,528
Less than one year [Member] | Instruments [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	2,767	3,528
Between one and five years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	171	27
Between one and five years [Member] | Instruments [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Future minimum rentals receivable under non-cancellable operating leases	$ 171	$ 27

CASH AND CASH EQUIVALENTS (Sche

CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents [abstract]
Cash at bank and in hand	$ 24,209	$ 6,275
Short-term deposits	3,118	8,956
Cash and cash equivalents	$ 27,327	$ 15,231

SHORT-TERM INVESTMENTS (Schedul

SHORT-TERM INVESTMENTS (Schedule of Short-Term Investments) (Details) $ in Thousands	Dec. 31, 2019USD ($)
Disclosure of short-term investments [Abstract]
Investments (deposits)	$ 1,169

CAPITAL AND RESERVES (Narrative

CAPITAL AND RESERVES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure of classes of share capital [line items]
Cost incurred issue of shares	$ 139,000
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Authorised share capital		200,700,000	200,700,000
Par value of share		$ 0.0109	$ 0.0109
Treasury shares purchased	107,740
ADS Treasury shares [Member]
Disclosure of classes of share capital [line items]
Treasury shares purchased	26,935

CAPITAL AND RESERVES (Schedule

CAPITAL AND RESERVES (Schedule of Share Capital) (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of classes of share capital [line items]
In issue at January 1	83,606,810	83,606,810
In issue at December 31		83,606,810
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
In issue at January 1	96,162,410	96,162,410
Issued for cash
In issue at December 31	96,162,000	96,162,410
American depositary share [Member]
Disclosure of classes of share capital [line items]
In issue at January 1	20,901,703	20,903,227
Issued for cash
In issue at December 31	20,901,703	20,901,703
Class A Treasury shares [Member]
Disclosure of classes of share capital [line items]
Balance at January 1	12,556,000	12,556,000
Purchased during the year
Balance at December 31	12,556,000	12,556,000
ADS Treasury shares [Member]
Disclosure of classes of share capital [line items]
Balance at January 1	3,139,000	3,139,000
Purchased during the year
Balance at December 31	3,139,000	3,139,000

SHARE OPTIONS (Narrative) (Deta

SHARE OPTIONS (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of classes of share capital [line items]
Weighted-average remaining contractual life of options outstanding	5 years 3 months 26 days	5 years 22 days
Share based payments charge	$ 816,000	$ 839,000	$ 1,607,000
share based payments capitalised in intangible development project assets	$ 24,000	$ 80,000	$ 238,000
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Opening share price	$ 0.26	$ 0.57	$ 1.28
Closing share price	0.95	0.26	0.57
Average share price		0.52
American depositary share [Member]
Disclosure of classes of share capital [line items]
Opening share price	1.03	2.29	5.10
Closing share price	3.81	1.03	2.29
Average share price		$ 2.06

SHARE OPTIONS (Schedule of Gran

SHARE OPTIONS (Schedule of Grants of Share Options and Warrants) (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Class A Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Outstanding Beginning Balance | shares	12,303,990	10,908,200	10,727,376
Granted | shares	9,100,000	4,370,000	720,000
Exercised | shares
Expired/ Forfeited | shares	(1,918,000)	(2,974,210)	(539,176)
Outstanding at end of year | shares	19,485,990	12,303,990	10,908,200
Exercisable at end of year | shares	7,959,324	6,622,667	6,091,864
Weighted Average exercise price
Outstanding Beginning Balance	$ 1.31	$ 1.83	$ 1.92
Granted	0.38	0.68	1.07
Exercised		19,685
Expired/ Forfeited	2.14	2.25	2.50
Outstanding at end of year	0.79	1.31	1.83
Exercisable at end of year	1.27	1.73	2.09
Class A Ordinary shares [Member] | Bottom of range [Member]
Weighted Average exercise price
Outstanding Beginning Balance	0.46	0.67	1.24
Granted	0.19	0.46	0.67
Exercised
Expired/ Forfeited	0.19	0.66	1.34
Outstanding at end of year	0.19	0.46	0.67
Exercisable at end of year	0.66	1.24	1.24
Class A Ordinary shares [Member] | Top of range [Member]
Weighted Average exercise price
Outstanding Beginning Balance	4.36	4.36	4.36
Granted	1.10	0.78	1.37
Exercised
Expired/ Forfeited	4.21	4.23	4.23
Outstanding at end of year	4.36	4.36	4.36
Exercisable at end of year	$ 4.36	$ 4.36	$ 4.36
American depositary share [Member]
Disclosure of classes of share capital [line items]
Outstanding Beginning Balance | shares	3,075,998	2,727,050	2,681,844
Granted | shares	2,275,000	1,092,500	180,000
Exercised | shares
Expired/ Forfeited | shares	(479,500)	(743,552)	(134,794)
Outstanding at end of year | shares	4,871,498	3,075,998	2,727,050
Exercisable at end of year | shares	1,989,831	1,655,667	1,522,966
Weighted Average exercise price
Outstanding Beginning Balance	$ 5.24	$ 7.32	$ 7.69
Granted	1.52	2.72	4.28
Exercised
Expired/ Forfeited	8.56	8.99	10
Outstanding at end of year	3.15	5.24	7.32
Exercisable at end of year	5.08	6.92	8.36
American depositary share [Member] | Bottom of range [Member]
Weighted Average exercise price
Outstanding Beginning Balance	1.83	2.68	4.96
Granted	0.77	1.83	2.68
Exercised
Expired/ Forfeited	0.77	2.64	5.36
Outstanding at end of year	0.77	1.83	2.68
Exercisable at end of year	2.64	4.95	4.96
American depositary share [Member] | Top of range [Member]
Weighted Average exercise price
Outstanding Beginning Balance	17.45	17.44	17.44
Granted	4.41	3.10	5.48
Exercised
Expired/ Forfeited	16.84	16.92	16.92
Outstanding at end of year	17.45	17.45	17.44
Exercisable at end of year	$ 17.45	$ 17.45	$ 17.44

SHARE OPTIONS (Summary of Range

SHARE OPTIONS (Summary of Range of Prices of Stock Options) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)shares$ / shares	Dec. 31, 2019USD ($)shares$ / shares	Dec. 31, 2018shares$ / shares	Dec. 31, 2017shares
Outstanding
Weighted average contractual life remaining (years)	5 years 3 months 26 days	5 years 22 days
Class A Ordinary shares [Member]
Outstanding
Number of Options	19,485,990	12,303,990	10,908,200	10,727,376
Exercisable
Number of Options	7,959,324	6,622,667	6,091,864
Weighted average exercise price | $ / shares		$ 19,685
Class A Ordinary shares [Member] | US$0.46-US$0.99 [Member]
Outstanding
Number of Options		4,600,000
Weighted average exercise price | $		$ 1
Weighted average contractual life remaining (years)		6 years 5 months 1 day
Exercisable
Number of Options
Weighted average exercise price | $ / shares
Weighted average contractual life remaining (years)		0 years
Class A Ordinary shares [Member] | US$1.00-US$2.05 [Member]
Outstanding
Number of Options	5,664,000	5,613,990
Weighted average exercise price | $	$ 1	$ 1
Weighted average contractual life remaining (years)	1 year 1 month 9 days	4 years 8 months 9 days
Exercisable
Number of Options	5,290,667	4,542,667
Weighted average exercise price | $ / shares	$ 1.35	$ 1.34
Weighted average contractual life remaining (years)	2 years 5 months 9 days	4 years 8 months 5 days
Class A Ordinary shares [Member] | US$2.06- US$2.99 [Member]
Outstanding
Number of Options	499,984	1,980,000
Weighted average exercise price | $	$ 3	$ 2
Weighted average contractual life remaining (years)	18 days	3 years 1 month 16 days
Exercisable
Number of Options	499,984	1,970,000
Weighted average exercise price | $ / shares	$ 2.52	$ 2.48
Weighted average contractual life remaining (years)	1 month 16 days	3 years 1 month 16 days
Class A Ordinary shares [Member] | US$3.00 -US$4.36 [Member]
Outstanding
Number of Options	62,000	110,000
Weighted average exercise price | $	$ 4	$ 4
Weighted average contractual life remaining (years)	0 years	2 years 26 days
Exercisable
Number of Options	62,000	110,000
Weighted average exercise price | $ / shares	$ 4.17	$ 4.19
Weighted average contractual life remaining (years)	4 days	2 years 26 days
Class A Ordinary shares [Member] | US$0.19-US$0.99 [Member]
Outstanding
Number of Options	13,260,006
Weighted average exercise price | $	$ 0
Weighted average contractual life remaining (years)	4 years 1 month 20 days
Exercisable
Number of Options	2,106,673
Weighted average exercise price | $ / shares	$ 0.69
Weighted average contractual life remaining (years)	1 year 5 months 9 days
American depositary share [Member]
Outstanding
Number of Options	4,871,498	3,075,998	2,727,050	2,681,844
Exercisable
Number of Options	1,989,831	1,655,667	1,522,966
Weighted average exercise price | $ / shares
American depositary share [Member] | US$1.84-US$3.96 [Member]
Outstanding
Number of Options	3,315,002	1,150,000
Weighted average exercise price | $	$ 2	$ 3
Weighted average contractual life remaining (years)	4 years 2 months 1 day	6 years 5 months 1 day
Exercisable
Number of Options	526,668
Weighted average exercise price | $ / shares	$ 2.76
Weighted average contractual life remaining (years)	1 year 5 months 9 days	0 years
American depositary share [Member] | US$4.00-US$8.20 [Member]
Outstanding
Number of Options	1,416,000	1,403,498
Weighted average exercise price | $	$ 5	$ 5
Weighted average contractual life remaining (years)	1 year 1 month 6 days	4 years 8 months 9 days
Exercisable
Number of Options	1,322,667	1,135,667
Weighted average exercise price | $ / shares	$ 5.40	$ 5.38
Weighted average contractual life remaining (years)	2 years 5 months 9 days	4 years 8 months 5 days
American depositary share [Member] | US$8.24- US$11.96 [Member]
Outstanding
Number of Options	124,996	495,000
Weighted average exercise price | $	$ 10	$ 10
Weighted average contractual life remaining (years)	18 days	3 years 1 month 16 days
Exercisable
Number of Options	124,996	492,500
Weighted average exercise price | $ / shares	$ 10.08	$ 9.91
Weighted average contractual life remaining (years)	1 month 16 days	3 years 1 month 16 days
American depositary share [Member] | US$12.00 -US$17.45 [Member]
Outstanding
Number of Options	15,500	27,500
Weighted average exercise price | $	$ 17	$ 17
Weighted average contractual life remaining (years)	0 years	2 years 26 days
Exercisable
Number of Options	15,500	27,500
Weighted average exercise price | $ / shares	$ 16.68	$ 16.75
Weighted average contractual life remaining (years)	4 days	2 years 26 days

SHARE OPTIONS (Schedule of Fair

SHARE OPTIONS (Schedule of Fair Value of the Options Vesting Period) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of share options [Abstract]
Share-based payments - cost of sales	$ 12	$ 26	$ 34
Share-based payments - selling, general and administrative	780	732	1,335
Total - continuing operations	792	758	1,369
Share-based payments - discontinued operations
Total Share-based payments	$ 792	$ 758	$ 1,369

SHARE OPTIONS (Schedule of Assu

SHARE OPTIONS (Schedule of Assumption Determining Fair Value of Share Options) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Key management personnel [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average expected volatility	66.98%	51.18%
Weighted average expected life	4.34	4.15
Weighted average risk free interest rate	0.44%	1.84%
Key management personnel [Member] | Bottom of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS)	$ 0	$ 0
Total 'A' share options granted / (ADS's equivalent)	8,480,000	4,060,000
Weighted average share price per 'A' share / (per ADS)	$ 0.38	$ 0.46
Weighted average exercise price per 'A' share / (per ADS)	$ 0.38	$ 0.69
Key management personnel [Member] | Top of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS)	$ 1	$ 1
Total 'A' share options granted / (ADS's equivalent)	(2,120,000)	1,015,000
Weighted average share price per 'A' share / (per ADS)	$ 1.52	$ 1.84
Weighted average exercise price per 'A' share / (per ADS)	$ 1.52	$ 2.74
Other employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average expected volatility	65.89%	47.31%	42.69%
Weighted average expected life	4.35	4.42	4.55
Weighted average risk free interest rate	0.42%	2.23%	2.72%
Other employees [Member] | Bottom of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS)	$ 0	$ 0	$ 0
Total 'A' share options granted / (ADS's equivalent)	620,000	310,000	720,000
Weighted average share price per 'A' share / (per ADS)	$ 0.48	$ 0.64	$ 1.07
Weighted average exercise price per 'A' share / (per ADS)	$ 0.48	$ 0.64	$ 1.07
Other employees [Member] | Top of range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average fair value at measurement date per 'A' share / (per ADS)	$ 1	$ 1	$ 2
Total 'A' share options granted / (ADS's equivalent)	(155,000)	77,500	180,000
Weighted average share price per 'A' share / (per ADS)	$ 1.96	$ 2.53	$ 4.28
Weighted average exercise price per 'A' share / (per ADS)	$ 1.96	$ 2.53	$ 4.28

TRADE AND OTHER PAYABLES (Narra

TRADE AND OTHER PAYABLES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2015
Disclosure of detailed information about business combination [line items]
Unforgiven Loans amount		$ 2,905,000
Accrued liabilities to contracted licence payments		194,000	$ 1,307,000
Amount of borrowings		1,042,000	$ 1,042,000	$ 1,000
Paycheck Protection Program Loan [Member]
Disclosure of detailed information about business combination [line items]
Government loans forgiven amount	$ 244,000
Paycheck Protection Program Loan [Member]
Disclosure of detailed information about business combination [line items]
Government loans forgiven amount		1,615,000
Ronan O'Caoimh [Member]
Disclosure of detailed information about business combination [line items]
Amount of borrowings		$ 177,000

TRADE AND OTHER PAYABLES (Sched

TRADE AND OTHER PAYABLES (Schedule of Trade and Other Payables) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Trade and other current payables [abstract]
Trade payables	$ 7,103	$ 7,833
Payroll taxes	688	519
Employee related social insurance	344	170
Accruals and other liabilities	8,850	8,133
Deferred income	4,445	292
Government COVID-19 loans (Note 4)	2,905
Total trade and other payables	$ 24,335	$ 16,947

PROVISIONS (Narrative) (Details

PROVISIONS (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Provisions [abstract]
Provision for reduced warranty claims	$ 50

PROVISIONS (Schedule of Provisi

PROVISIONS (Schedule of Provisions) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Provisions [abstract]
Product warranty provision	$ 50	$ 50
Other provisions	366
Provisions	$ 416	$ 50

EXCHANGEABLE NOTES AND OTHER _3

EXCHANGEABLE NOTES AND OTHER BORROWINGS (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2015
Disclosure of detailed information about borrowings [line items]
Notes maturity		2045			April 1, 2045
Accrue interest					4.00%
Conversion rate per ADS					$ 47
Principal amount		$ 1,042,000	$ 1,042,000		1,000
Exchange rate price per ADS	$ 80				22
Financial income			233,000	$ 1,388,000
Nominal value	151,000,000	99,900,000			$ 115,000,000
Financial expense		6,751,000	6,582,000	5,080,000
Purchase of exchangeable notes				$ 12,042,000
Accrued interest on notes	205,000
Gain on purchase	$ 463,000
Senior Notes [Member]
Disclosure of detailed information about borrowings [line items]
Financial expense		$ 643,000	$ 639,000

EXCHANGEABLE NOTES AND OTHER _4

EXCHANGEABLE NOTES AND OTHER BORROWINGS (Schedule of Carrying Value of Exchangeable Notes) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Borrowings [abstract]
Exchangeable senior notes	$ 82,695	$ 82,021	$ 81,382
Other borrowings	31
Total value of embedded derivatives - liability	1,370	4
Total non-current liabilities	$ 84,065	$ 82,025

EXCHANGEABLE NOTES AND OTHER _5

EXCHANGEABLE NOTES AND OTHER BORROWINGS (Schedule of Carrying Value of Exchangeable Senior Notes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Borrowings [abstract]
Balance at 1 January	$ 82,021	$ 81,382
Accretion interest (Note 8)	643	639	$ 689
Balance at 31 December	$ 82,695	$ 82,021	$ 81,382

EXCHANGEABLE NOTES AND OTHER _6

EXCHANGEABLE NOTES AND OTHER BORROWINGS (Schedule of Exchangeable Notes) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Non-current assets
Exchangeable note bond call option	$ 150
Non-current liabilities
Exchangeable note equity conversion option	1,370	4
Exchangeable note bond put option
Total non-current liabilities	1,370	4
Total value of embedded derivatives - net liability	$ 1,220	$ 4

LEASE LIABILITIES (Schedule of

LEASE LIABILITIES (Schedule of Carrying Values of Finance Lease Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current liabilities
Lease liabilities related to Right of Use assets	$ 2,054	$ 2,156
Sale and leaseback liabilities	99	248
Current liabilities	2,153	2,404
Non-Current liabilities
Lease liabilities related to Right of Use assets	16,407	17,474
Sale and leaseback liabilities	181	271
Non-current liabilities	$ 16,588	$ 17,745

LEASE LIABILITIES (Schedule o_2

LEASE LIABILITIES (Schedule of Finance Lease Liabilities Payable) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis of operating lease payments [line items]
Principal	$ 18,741	$ 20,149
Lease liabilities related Right of Use assets [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	23,531	25,252
Interest	5,070	5,263
Principal	18,461	19,630
Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	301	559
Interest	21	40
Principal	280	519
Less than one year [Member] | Lease liabilities related Right of Use assets [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	2,877	3,017
Interest	823	861
Principal	2,054	2,156
Less than one year [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	111	267
Interest	12	19
Principal	99	248
In more than one year, but not more than two [Member] | Lease liabilities related Right of Use assets [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	2,644	2,787
Interest	730	775
Principal	1,914	2,012
In more than one year, but not more than two [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	111	107
Interest	7	12
Principal	104	95
In more than two years but not more than five [Member] | Lease liabilities related Right of Use assets [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	6,621	6,700
Interest	1,765	1,861
Principal	4,856	4,840
In more than two years but not more than five [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	79	185
Interest	2	9
Principal	77	176
More than five years [Member] | Lease liabilities related Right of Use assets [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments	11,389	12,748
Interest	1,752	2,126
Principal	9,637	10,622
More than five years [Member] | Sale and leaseback liabilities [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Minimum lease payments
Interest
Principal

LEASE LIABILITIES (Schedule o_3

LEASE LIABILITIES (Schedule of Reconciliation of Operating Lease Commitments) (Details) $ in Thousands	Dec. 31, 2019USD ($)
Disclosure of finance lease liabilities [Abstract]
Operating Lease commitments at December, 31, 2018 (Note 27)	$ 27,342
Relief option for short term leases	(130)
Relief option for low value assets
Effect of assumed probable lease extension in adoption of IFRS 16	573
Other	(149)
Gross lease liabilities at January 1, 2019	27,636
Discounting	(6,451)
Additional Lease liabilities as a result of the initial application of IFRS 16 at January 1, 2019	$ 21,185
Weighted average discount rate	5.00%

LEASE LIABILITIES (Schedule o_4

LEASE LIABILITIES (Schedule of Lease Payments Not Recognised as Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of finance lease liabilities [Abstract]
Short term leases		$ 130
Leases of low value assets
Variable lease payments
Lease payments not recognised as a liability		$ 130

LEASE LIABILITIES (Schedule o_5

LEASE LIABILITIES (Schedule of Outstanding Interest Bearing Loans and Borrowings) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2015
Statement Line Items [Line Items]
Nominal interest rate			4.00%
Year of maturity	2045		April 1, 2045
Fair value	$ 18,741	$ 20,149
Carrying value	$ 280	$ 519
Sale and leaseback liabilities [Member]
Statement Line Items [Line Items]
Currency	Euro	Euro
Nominal interest rate	4.53%	4.53%
Year of maturity	2023	2023
Fair value	$ 106	$ 286
Carrying value	106	286
Total amount paid in respect of lease liabilities	$ 3,240	$ 3,533
Sale and leaseback liabilities Two [Member]
Statement Line Items [Line Items]
Currency	USD	USD
Nominal interest rate	5.51%	5.51%
Year of maturity	2023	2023
Fair value	$ 174	$ 233
Carrying value	$ 174	$ 233

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis of operating lease payments [line items]
Capital Commitments		$ 156	$ 323
Grant contingencies maximum amount payable		3,130	2,834
Forgiveness amount		4,520
Contingent liability		2,905
Unforgiven loans amount		2,905
Paycheck Protection Program Loan [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Forgiveness amount	$ 244	1,615
Darnick Company [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Contribution for tax audit settlement			$ 1,231
Increase in settlement amount due to depreciation		1,316
Repayments of borrowings		$ 177

RELATED PARTY TRANSACTIONS (Nar

RELATED PARTY TRANSACTIONS (Narrative) (Details) - USD ($)	Jun. 06, 2009	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2015
Disclosure of transactions between related parties [line items]
Non executive directors fees		$ 2,020,000	$ 1,238,000	$ 1,261,000
Share-based compensation benefits		626,000	542,000
Share-based payments (net of capitalized amounts)		792,000	758,000	$ 1,369,000
Remaining amount of loan		1,042,000	1,042,000		$ 1,000
Patent dividend scheme amount		3,863,000	3,863,000
Darnick Company [Member]
Disclosure of transactions between related parties [line items]
Repayments of borrowings		177,000
Payments for CEO Services			1,231,000
Increase in settlement amount due to depreciation		$ 1,316,000
Mr. O'Caoimh [Member]
Disclosure of transactions between related parties [line items]
Maturity date		2026
Annual rent payable		$ 961,000
Annual rent payable for ware house		176,000
Mr. O'Caoimh [Member] | Additional Space [Member]
Disclosure of transactions between related parties [line items]
Annual rent payable		20,000
Mr. O'Caoimh [Member] | Euro [Member]
Disclosure of transactions between related parties [line items]
Annual rent payable		787,000
Annual rent payable for ware house		$ 144,000
JRJ [Member]
Disclosure of transactions between related parties [line items]
Term of lease		25 Years
Annual rent payable		$ 466,000
JRJ [Member] | Euro [Member]
Disclosure of transactions between related parties [line items]
Annual rent payable		$ 381,000
Mr. O'Caoimh and Dr Walsh [Member]
Disclosure of transactions between related parties [line items]
Maturity date		2028
Darnick Company [Member]
Disclosure of transactions between related parties [line items]
Contribution for tax audit settlement			1,231,000
Repayments of borrowings		$ 177,000
Increase in settlement amount due to depreciation		1,316,000
Director [Member]
Disclosure of transactions between related parties [line items]
Non executive directors fees		162,000	225,000
Share-based compensation benefits		51,000	82,000
Share-based payments (net of capitalized amounts)			35,000
Rayville Limited [Member]
Disclosure of transactions between related parties [line items]
Payment of dividend	$ 2,830,000
Compensation expense	$ 1,788,000
Repayments of borrowings			$ 159,000

RELATED PARTY TRANSACTIONS (Sch

RELATED PARTY TRANSACTIONS (Schedule of Compensation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of transactions between related parties [abstract]
Short-term employee benefits	$ 1,274,000	$ 800,000
Performance related bonus	584,000	213,000
Post-employment benefits	41,000	42,000
Share-based compensation benefits	626,000	542,000
Total compensation	$ 2,525,000	$ 1,597,000

RELATED PARTY TRANSACTIONS (S_2

RELATED PARTY TRANSACTIONS (Schedule of Company's Shares and Share Option Plan) (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Class A Ordinary shares [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding Beginning Balance	12,303,990	10,908,200	10,727,376
Granted	9,100,000	4,370,000	720,000
Outstanding at end of year	19,485,990	12,303,990	10,908,200
Class A Ordinary shares [Member] | Directors' and Company Secretary's [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding Beginning Balance	9,077,706	9,139,706
Shares of retired director		(30,000)
Options of retired director
Shares purchased during the year
Shares sold during the year		(32,000)
Granted
Expired / forfeited
Outstanding at end of year	9,077,706	9,077,706	9,139,706
Share Option [Member] | Directors' and Company Secretary's [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding Beginning Balance	10,414,004	8,655,004
Shares of retired director
Options of retired director		(215,000)
Shares purchased during the year
Shares sold during the year
Granted	8,480,000	4,060,000
Expired / forfeited	(1,500,000)	(2,086,000)
Outstanding at end of year	17,394,004	10,414,004	8,655,004

CAPITAL AND FINANCIAL RISK MA_3

CAPITAL AND FINANCIAL RISK MANAGEMENT (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2015
Disclosure of detailed information about financial instruments [abstract]
Increase interest income	$ 31	$ 101
Issuance of exchangeable senior notes			$ 115,000
Repurchased of exchangeable senior notes		$ 15,100
Term of exchangeable senior notes			30 years
Maturity date of exchangeable senior notes			April 1, 2045

CAPITAL AND FINANCIAL RISK MA_4

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Fair Values of Financial Assets/Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Loans and receivables at amortised cost
Trade receivables	$ 3,992	$ 5,443	$ 4,202	$ 3,590
Cash and cash equivalents	27,327	15,231
Investments (deposits)		1,169
Finance lease receivable	506	684
Total maximum credit exposure	47,858	34,838
Liabilities at amortised cost
Exchangeable senior notes	(82,695)	(82,021)	$ (81,382)
Provisions	(416)	(50)
Fair value through profit and loss (FVPL)
Exchangeable note bond call option	150
Exchangeable note equity conversion option	(1,370)	(4)
Exchangeable note bond put option
Level 1 [Member]
Loans and receivables at amortised cost
Trade receivables	20,025	17,754
Cash and cash equivalents	27,327	15,231
Investments (deposits)		1,169
Finance lease receivable	506	684
Total maximum credit exposure	47,858	34,838
Liabilities at amortised cost
Exchangeable senior notes
Lease liabilities	(18,741)	(20,149)
Trade and other payables (excluding deferred income)	(19,890)	(16,655)
Provisions	(416)	(50)
Total Liabilities at amortised cost	(39,047)	(36,854)
Fair value through profit and loss (FVPL)
Exchangeable note bond call option
Exchangeable note equity conversion option
Exchangeable note bond put option
Total fair value through profit and loss (FVPL)
Total fair value of financial assets liabilities	8,811	(2,016)
Level 2 [Member]
Loans and receivables at amortised cost
Trade receivables
Cash and cash equivalents
Investments (deposits)
Finance lease receivable
Total maximum credit exposure
Liabilities at amortised cost
Exchangeable senior notes	(82,664)	(82,021)
Lease liabilities
Trade and other payables (excluding deferred income)
Provisions
Total Liabilities at amortised cost	(82,664)	(82,021)
Fair value through profit and loss (FVPL)
Exchangeable note bond call option	150
Exchangeable note equity conversion option	(1,370)	(4)
Exchangeable note bond put option
Total fair value through profit and loss (FVPL)	(1,220)	(4)
Total fair value of financial assets liabilities	(83,884)	(82,025)
Carrying Amount [Member]
Loans and receivables at amortised cost
Trade receivables	20,025	17,754
Cash and cash equivalents	27,327	15,231
Investments (deposits)		1,169
Finance lease receivable	506	684
Total maximum credit exposure	47,858	34,838
Liabilities at amortised cost
Exchangeable senior notes	(82,664)	(82,021)
Lease liabilities	(18,741)	(20,149)
Trade and other payables (excluding deferred income)	(19,890)	(16,655)
Provisions	(416)	(50)
Total Liabilities at amortised cost	(121,711)	(118,875)
Fair value through profit and loss (FVPL)
Exchangeable note bond call option	150
Exchangeable note equity conversion option	(1,370)	(4)
Exchangeable note bond put option
Total fair value through profit and loss (FVPL)	(1,220)	(4)
Total fair value of financial assets liabilities	(75,073)	(84,041)
Fair Value [Member]
Loans and receivables at amortised cost
Trade receivables	20,025	17,754
Cash and cash equivalents	27,327	15,231
Investments (deposits)		1,169
Finance lease receivable	506	684
Total maximum credit exposure	47,858	34,838
Liabilities at amortised cost
Exchangeable senior notes	(82,664)	(82,021)
Lease liabilities	(18,741)	(20,149)
Trade and other payables (excluding deferred income)	(19,890)	(16,655)
Provisions	(416)	(50)
Total Liabilities at amortised cost	(121,711)	(118,875)
Fair value through profit and loss (FVPL)
Exchangeable note bond call option	150
Exchangeable note equity conversion option	(1,370)	(4)
Exchangeable note bond put option
Total fair value through profit and loss (FVPL)	(1,220)	(4)
Total fair value of financial assets liabilities	$ (75,073)	$ (84,041)

CAPITAL AND FINANCIAL RISK MA_5

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Interest Rate Risk Effective and Repricing Analysis) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents	$ 27,327	$ 15,231
Short term investments		1,169
Lease receivable	506	684
Licence payments	(194)	(1,307)
Exchangeable senior notes	(82,695)	(82,021)	$ (81,382)
Other borrowings	(31)
Lease payable on Right of Use assets	(18,461)	(19,630)
Lease payable on sale & leaseback transactions	(280)	(519)
Total interest earning financial and interest bearing financial liabilities	$ (98,006)	$ (92,668)
Cash and cash equivalents [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	0.10%	1.10%
Short-term investments [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate		1.30%
Lease receivable [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	4.00%	4.00%
Licence payments [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	8.10%	8.10%
Exchangeable note [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	4.80%	4.80%
Other borrowings [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	0.00%
Lease payable on Right of Use assets [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	5.00%	5.00%
Lease payable on sale & leaseback transactions [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Effective interest rate	5.00%	5.00%
6 mths or less [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents	$ 27,327	$ 15,231
Short term investments
Lease receivable	120	157
Licence payments	(194)	(1,307)
Exchangeable senior notes
Other borrowings
Lease payable on Right of Use assets	(1,022)	(1,136)
Lease payable on sale & leaseback transactions	(49)	(122)
Total interest earning financial and interest bearing financial liabilities	26,182	12,823
6 mths - 12 mths [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents
Short term investments		1,169
Lease receivable	95	124
Licence payments
Exchangeable senior notes
Other borrowings
Lease payable on Right of Use assets	(1,032)	(1,020)
Lease payable on sale & leaseback transactions	(50)	(125)
Total interest earning financial and interest bearing financial liabilities	(987)	148
1-2 years [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents
Short term investments
Lease receivable	142	202
Licence payments
Exchangeable senior notes
Other borrowings	(31)
Lease payable on Right of Use assets	(1,914)	(2,012)
Lease payable on sale & leaseback transactions	(104)	(95)
Total interest earning financial and interest bearing financial liabilities	(1,907)	(1,905)
2-5 years [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents
Short term investments
Lease receivable	149	201
Licence payments
Exchangeable senior notes
Other borrowings
Lease payable on Right of Use assets	(4,856)	(4,840)
Lease payable on sale & leaseback transactions	(77)	(177)
Total interest earning financial and interest bearing financial liabilities	(4,784)	(4,816)
>5 years [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Cash and cash equivalents
Short term investments
Lease receivable
Licence payments
Exchangeable senior notes	(82,664)	(82,021)
Other borrowings
Lease payable on Right of Use assets	(9,637)	(10,622)
Lease payable on sale & leaseback transactions
Total interest earning financial and interest bearing financial liabilities	$ (92,301)	$ (92,643)

CAPITAL AND FINANCIAL RISK MA_6

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of interest Rate Profile of Financial Assets/Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Fixed rate instruments
Fixed rate financial liabilities (licence fees)	$ (194)	$ (1,307)
Fixed rate financial liabilities (exchangeable note)	(82,695)	(82,021)	$ (81,382)
Fixed rate financial liabilities (borrowings)	(31)
Fixed rate financial liabilities (lease payables)	(18,741)	(20,149)
Financial assets (short-term deposits and short-term investments)	3,118	8,956
Financial assets (lease receivables)	506	684
Total interest earning financial and interest bearing financial liabilities	$ (98,006)	$ (92,668)

CAPITAL AND FINANCIAL RISK MA_7

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Liquidity Risk Estimated Interest Payments of Maturities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Financial liabilities
Lease payable on Right of Use assets	$ (18,461)	$ (19,630)
Lease payable on sale & leaseback transactions	(280)	(519)
Other borrowings	31
Exchangeable senior notes	82,695	82,021	$ 81,382
Carrying Amount [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables	24,335	16,947
Lease payable on Right of Use assets	18,461	19,630
Lease payable on sale & leaseback transactions	280	519
Other borrowings	31
Exchangeable senior notes	82,664	82,021
Exchangeable note interest	999	999
Total maturities of financial liabilities	126,770	120,116
Contractual cash flows [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables	24,335	16,947
Lease payable on Right of Use assets	18,461	19,630
Lease payable on sale & leaseback transactions	280	519
Other borrowings	31
Exchangeable senior notes	99,900	99,900
Exchangeable note interest	97,902	101,898
Total maturities of financial liabilities	240,909	238,894
6 mths or less [Member]
Financial liabilities
Lease payable on Right of Use assets	(1,022)	(1,136)
Lease payable on sale & leaseback transactions	(49)	(122)
Other borrowings
Exchangeable senior notes
6 mths or less [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables	24,335	16,947
Lease payable on Right of Use assets	1,022	1,136
Lease payable on sale & leaseback transactions	49	122
Other borrowings
Exchangeable senior notes
Exchangeable note interest	1,998	1,998
Total maturities of financial liabilities	27,404	20,203
6 mths - 12 mths [Member]
Financial liabilities
Lease payable on Right of Use assets	(1,032)	(1,020)
Lease payable on sale & leaseback transactions	(50)	(125)
Other borrowings
Exchangeable senior notes
6 mths - 12 mths [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables
Lease payable on Right of Use assets	1,032	1,020
Lease payable on sale & leaseback transactions	50	125
Other borrowings
Exchangeable senior notes
Exchangeable note interest	1,998	1,998
Total maturities of financial liabilities	3,080	3,143
1-2 years [Member]
Financial liabilities
Lease payable on Right of Use assets	(1,914)	(2,012)
Lease payable on sale & leaseback transactions	(104)	(95)
Other borrowings	31
Exchangeable senior notes
1-2 years [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables
Lease payable on Right of Use assets	1,914	2,012
Lease payable on sale & leaseback transactions	104	95
Other borrowings	31
Exchangeable senior notes
Exchangeable note interest	3,996	3,996
Total maturities of financial liabilities	6,045	6,103
2-5 years [Member]
Financial liabilities
Lease payable on Right of Use assets	(4,856)	(4,840)
Lease payable on sale & leaseback transactions	(77)	(177)
Other borrowings
Exchangeable senior notes
2-5 years [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables
Lease payable on Right of Use assets	4,856	4,840
Lease payable on sale & leaseback transactions	77	177
Other borrowings
Exchangeable senior notes
Exchangeable note interest	11,988	11,988
Total maturities of financial liabilities	16,921	17,005
>5 years [Member]
Financial liabilities
Lease payable on Right of Use assets	(9,637)	(10,622)
Lease payable on sale & leaseback transactions
Other borrowings
Exchangeable senior notes	82,664	82,021
>5 years [Member] | Liquidity risk [Member]
Financial liabilities
Trade & other payables
Lease payable on Right of Use assets	9,637	10,622
Lease payable on sale & leaseback transactions
Other borrowings
Exchangeable senior notes	99,900	99,900
Exchangeable note interest	77,922	81,918
Total maturities of financial liabilities	$ 187,459	$ 192,440

CAPITAL AND FINANCIAL RISK MA_8

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Foreign Currency Risk Short Term Financial Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about financial instruments [line items]
Cash	$ 24,209	$ 6,275
Euro [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	1,229	394
Trade and other receivable	1,105	1,247
Trade and other payables	(2,821)	(2,350)
Total exposure	(487)	(709)
GBP [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	152	138
Trade and other receivable	63	71
Trade and other payables	(57)	(27)
Total exposure	158	182
SEK [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	9	10
Trade and other receivable
Trade and other payables	(1)	(142)
Total exposure	8	(132)
CAD [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	2,859	3,265
Trade and other receivable	3,191	337
Trade and other payables	(449)	(47)
Total exposure	5,601	3,555
BRL [Member]
Disclosure of detailed information about financial instruments [line items]
Cash	776	238
Trade and other receivable	1,357	1,871
Trade and other payables	(529)	(796)
Total exposure	1,604	1,313
Other [Member]
Disclosure of detailed information about financial instruments [line items]
Cash
Trade and other receivable
Trade and other payables
Total exposure

CAPITAL AND FINANCIAL RISK MA_9

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Sensitivity Analysis) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]
Profit or loss	$ (6,013)	$ (28,991)	$ (22,658)
Euro [Member] | 10% Strengthening US Dollar [Member]
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]
Profit or loss	541	2,282
Euro [Member] | 10% Weakening US Dollar [Member]
Disclosure of information about amounts that affected statement of comprehensive income as result of hedge accounting [line items]
Profit or loss	$ (661)	$ (2,790)

CAPITAL AND FINANCIAL RISK M_10

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Maximum Credit Exposure of Financial Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about financial instruments [abstract]
Third party trade receivables (Note 18)	$ 20,025	$ 17,754
Finance lease receivable	506	684
Cash and cash equivalents (Note 19)	27,327	15,231
Short term investments (Note 20)		1,169
Total maximum credit exposure	$ 47,858	$ 34,838

CAPITAL AND FINANCIAL RISK M_11

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Geographic Location) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 20,531	$ 18,438
USA [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	10,730	8,647
Euro-zone countries [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	1,360	786
United Kingdom [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	98	121
Other European countries [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	13	7
Other regions [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 8,330	$ 8,877

CAPITAL AND FINANCIAL RISK M_12

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Exposure of Trade Receivables by Customer) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 20,531	$ 18,438
End-user customers [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	11,812	9,453
Distributors [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	8,186	7,199
Non-government customers [Member]
Disclosure of credit risk exposure [line items]
Maximum Exposure to credit risk for trade receivables and finance lease income receivable	$ 533	$ 1,786

CAPITAL AND FINANCIAL RISK M_13

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Ageing of Trade Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	$ 3,992	$ 5,443	$ 4,202	$ 3,590
Not past due [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	0.70%	0.10%
Past due 0-30 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	12.10%	0.20%
Past due 31-120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	3.40%	1.30%
Greater than 120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Expected credit loss rate	97.80%	84.20%
Cost [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	$ 23,947	$ 23,197
Cost [Member] | Not past due [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	16,754	10,924
Cost [Member] | Past due 0-30 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	1,829	3,743
Cost [Member] | Past due 31-120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	1,755	2,115
Cost [Member] | Greater than 120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	3,609	6,415
Accumulated impairment Charge [member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	3,992	5,443
Accumulated impairment Charge [member] | Not past due [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	112	8
Accumulated impairment Charge [member] | Past due 0-30 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	222	6
Accumulated impairment Charge [member] | Past due 31-120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	60	27
Accumulated impairment Charge [member] | Greater than 120 days [Member]
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items]
Trade receivables	$ 3,528	$ 5,402

CAPITAL AND FINANCIAL RISK M_14

CAPITAL AND FINANCIAL RISK MANAGEMENT (Schedule of Movement in the Allowance for Impairment of Trade Receivables) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Balance at January 1	$ 5,443	$ 4,202	$ 3,590
Charged to costs and expenses	166	1,276	682
Amounts written off during the year	(1,687)	(35)	(70)
Balance at December 31	$ 3,992	$ 5,443	$ 4,202

RECONCILIATION OF LIABILITIES_3

RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES (Schedule of Liabilities Arising from Financing) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash-flows:
Interest paid	$ (3,996)	$ (3,996)	$ (4,503)
Borrowings & derivative financial instruments [Member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance at 1 January	82,025	81,620
Cash-flows:
Interest paid	(3,996)	(3,996)
Proceeds from government Covid-19 loan (Note 25)	31
Repayment
Non-cash:
Interest charged	3,996	3,996
Adoption of IFRS 16 (Note 13)
Additions (related to Right of Use assets)
Disposals
Exchange adjustment
Accretion interest	643	639
Fair value	1,366	(234)
Balance at 31 December	84,065	82,025	81,620
Lease liabilities [Member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Balance at 1 January	20,149	962
Cash-flows:
Interest paid
Proceeds from government Covid-19 loan (Note 25)
Repayment	(3,240)	(3,533)
Non-cash:
Interest charged
Adoption of IFRS 16 (Note 13)		21,185
Additions (related to Right of Use assets)	224	679
Disposals	(216)
Exchange adjustment	928	(91)
Accretion interest	896	947
Fair value
Balance at 31 December	$ 18,741	$ 20,149	$ 962

POST BALANCE SHEET EVENTS (Deta

POST BALANCE SHEET EVENTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement Line Items [Line Items]
Unforgiven loans amount		$ 2,905
Forgiveness amount		4,520
Three Loan [Member]
Statement Line Items [Line Items]
Forgiveness amount	$ 2,661
Paycheck Protection Program Loan [Member]
Statement Line Items [Line Items]
Forgiveness amount	$ 244	$ 1,615

ACCOUNTING ESTIMATES AND JUDG_2

ACCOUNTING ESTIMATES AND JUDGEMENTS (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2022	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Line Items [Line Items]
Deferred income		$ 4,445	$ 292
Carrying amounts		$ 33,860	$ 43,654
Percentage of gross inventory		24.45%	17.33%	17.18%
Inventories net of provisions		$ 9,781	$ 6,716	$ 6,299
Percentage of group revenues		3.80%	6.00%	4.30%
Trade receivables, net impairment losses provision		$ 3,992	$ 5,443	$ 4,202	$ 3,590
Repayment of exchangeable notes				12,042
Impairment loss additions		17,779	24,295	26,932
Amortisation expense		1,403	2,368	2,825
Impairment loss charge			76,740
Director [Member]
Statement Line Items [Line Items]
Repayment of exchangeable notes	$ 99,900
Capitalised development costs [Member]
Statement Line Items [Line Items]
Carrying amounts		13,444	22,778
Impairment loss additions		6,896
Amortisation expense		959
Impairment loss charge		15,287
2% of gross inventory [Member]
Statement Line Items [Line Items]
Change in allowance		800	774	733
0.5% of gross inventory [Member]
Statement Line Items [Line Items]
Change in allowance		$ 510	$ 452	$ 485